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FROM DEVELOPMENT TO THERAPY: A PANORAMIC APPROACH TO FURTHER
OUR UNDERSTANDING OF CANCER

Brittany J. Poelaert, Ph.D.
University of Nebraska Medical Center, 2019

Supervisor: Joyce C. Solheim, Ph.D.
Solid tumors, such as pancreatic cancer, often result in dismally low survival
outcomes for patients due to insufficient understanding of disease development and
progression. Pancreatic cancer is the fourth leading cause of cancer-related deaths in the
United States and although oncogenic drivers (such as KRAS mutation or loss of tumor
suppressor p53) and stages of disease development have been studied, further
understanding of pancreatic cancer development is greatly needed. Studies from our
laboratory have identified novel and varied functions of amyloid precursor-like protein 2
(APLP2) in the development and progression of pancreatic cancer. These functions
include promoting cancer cell migration, proliferation, and invasion. APLP2 has also been
found to bind to MHC class I molecules, thus leading to their internalization, loss of surface
expression on cancer cells, and possible functions in cancer cell immune evasion. We
furthered our investigation into elucidating the role of APLP2 in pancreatic cancer by
employing the genetically engineered KPC/KC mouse models and incorporated a
conditional APLP2 knockout (KPCA).

These genetically engineered mouse strains

enabled us to investigate how APLP2 loss, in a pancreas-specific manner, modulates
pancreatic cancer development and progression. Loss of APLP2 in the pancreas delayed
tumor development, inhibited metastasis, and prolonged survival in KPCA mice. We
derived cell lines from primary tumors collected from mice bearing wild type APLP2,
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heterozygous knockout of APLP2, or homozygous knockout of APLP2 and confirmed
modulation in APLP2 expression at the protein at mRNA levels.
An additional hurdle in successfully treating solid tumors, such as neuroblastoma
or pancreatic cancer, is the lack of efficacious, durable treatment agents that are capable
of inducing a robust antitumor immune response. Neuroblastoma is the most common
extracranial solid tumor diagnosed in children and patients with aggressive metastatic
disease or refractory/relapsed neuroblastoma face dauntingly low survival prognoses. It
has been reported, by our laboratory and others, that chemoattractant C-C motif
chemokine ligand 21 (CCL21) is effective as an intratumoral therapy, able to deter tumor
growth and induce an antitumor immune response. We hypothesized that utilizing CCL21
in a novel, slow-release alginate nanoformulation would provide prolonged release of
CCL21, leading to a steady influx of immune cells into the tumor mass, delaying tumor
growth, and halting disease progression in a manner superior to CCL21 alone. Initial
studies resulted in the characterization of alginate-nanoformulated CCL21 in vitro,
including rates of release. When injected intratumorally into mice bearing subcutaneous
neuroblastoma lesions, alginate-nanoformulated CCL21 significantly prolonged survival
and reduced the tumor growth rate compared to CCL21 alone, empty nanoparticles, or
buffer control. Notably, complete tumor clearance and subsequent protection against
tumor re-challenge was observed in 33% of nanoformulated CCL21-treated mice. Further
analysis revealed superior intratumoral retention of nanoformulated CCL21 compared to
free CCL21 at days 1 and 2 post treatment as determined via fluorescent labeling and
tracking of CCL21. A general pattern of prolonged increases in antitumor cytokines and
relatively lower levels of protumor cytokines was observed in nanoformulated CCL21treated mice when compared to CCL21-treated or buffer-treated tumors. Overall, we
report that nanoformulated CCL21 is an effective and novel treatment for neuroblastoma.

v
In addition, this novel nanoformulation has potential for future development as a slowrelease modality for other immunotherapies, as well as for the delivery of CCL21 when
used in a combinatorial therapeutic approach.

vi
ACKNOWLEDGMENTS .................................................................................................... I
LIST OF FIGURES ........................................................................................................... X
LIST OF TABLES .......................................................................................................... XIII
LIST OF ABBREVIATIONS ......................................................................................... XIV
CHAPTER 1: INTRODUCTION TO AMYLOID PRECURSOR-LIKE PROTEIN 2 (APLP2)
........................................................................................................................................ 17
1.1 APLP2: AN AMYLOID PRECURSOR PROTEIN (APP) FAMILY MEMBER........................ 18
1.1.1 APLP2 Molecular Structure ............................................................................ 19
1.1.2 Proteolytic Processing and Post Translational Modification of APLP2 ........... 23
1.1.3 Functions of APLP2 ........................................................................................ 24
1.2 ROLE OF APLP2 IN CANCER .................................................................................... 27
1.3 DISSERTATION HYPOTHESIS: PART I ........................................................................ 33
CHAPTER 2: MATERIALS AND METHODS ................................................................. 43
2.1 RNA-SEQ ............................................................................................................... 44
2.2 BIOINFORMATIC ANALYSIS ....................................................................................... 44
2.3 IMMUNOHISTOCHEMISTRY ........................................................................................ 45
2.4 MOUSE STRAINS AND GENETIC MUTATIONS ............................................................. 45
2.4.1 Mouse Strains ................................................................................................. 46
2.4.2 DNA Acquisition via Tail Digestion ................................................................. 51
2.4.3 Polymerase Chain Reaction of Genes of Interest ........................................... 51
2.4.4 DNA Agarose Gel Electrophoresis ................................................................. 52
2.5 CELL LINES, CULTURE CONDITIONS, AND DERIVING NOVEL LINES............................. 52
2.5.1 Cell Lines and Culture Conditions .................................................................. 52
2.5.2 Establishment of Tumor-Derived Cell Lines ................................................... 53
2.6 TISSUE COLLECTION, PROTEIN LYSIS, AND PROTEIN QUANTIFICATION ...................... 53
2.7 PROTEIN ELECTROPHORESIS AND WESTERN BLOTTING............................................ 54
2.8 ANTIBODIES ............................................................................................................ 55
2.9 RNA ISOLATION, CDNA SYNTHESIS, AND QRT-PCR ANALYSIS ................................ 55
2.10 STATISTICAL ANALYSIS .......................................................................................... 57
2.10.1 Kaplan-Meier Survival Distributions .............................................................. 57
2.10.2 Two-Way ANOVA and Fisher’s Exact Test .................................................. 57
2.10.3 Statistical Significance .................................................................................. 57
CHAPTER 3: ROLE OF APLP2 IN PANCREATIC CANCER DEVELOPMENT ........... 58
3.1 INTRODUCTION TO PANCREATIC CANCER AND ASSOCIATED MOUSE MODELS ............ 59
3.2 HUMAN PRIMARY TUMORS AND METASTASES EXPRESS HIGHER LEVELS OF APLP2 THAN
PANIN EPITHELIAL AND STROMAL CELLS ....................................................................... 64
3.3 APLP2 EXPRESSION IS INCREASED IN MURINE PANCREATIC TUMOR-DERIVED CELL
LINES, PRIMARY TUMOR TISSUES, AND METASTASES ..................................................... 67

vii
3.4 GENERATING A CONDITIONAL APLP2 KNOCKOUT MOUSE WITHIN THE KPC MODEL OF
PDAC .......................................................................................................................... 72
3.5 APLP2 LOSS IN TUMOR DEVELOPMENT AND TUMOR-DERIVED CELL LINES ............... 73
3.6 PANCREAS-SPECIFIC LOSS OF APLP2 PROLONGS THE SURVIVAL OF KPC MICE....... 76
3.7 LOSS OF APLP2 RESULTED IN DECREASED METASTASES TO THE VARIOUS SITES WITHIN
THE PERITONEAL CAVITY ............................................................................................... 79
CHAPTER 4: DISCUSSION, SUMMARY, AND FUTURE DIRECTIONS ...................... 83
4.1 DISCUSSION AND SUMMARY OF RESEARCH .............................................................. 84
4.2 FUTURE DIRECTIONS ............................................................................................... 87
4.2.1 Further Characterization of Tumor Development and Progression in the KPCA
Mouse Model ........................................................................................................... 88
4.2.2 Determination of Proliferation, Migration, and Invasion Properties of TumorDervied Cell Lines from KPC mice with Pancreas-Specific APLP2 Mutations. ....... 89
4.2.3 Assessing APLP2 Immune Modulation ........................................................... 90
4.2.4 Combining APLP2 Loss and Therapy ............................................................. 90
CHAPTER 5: INTRODUCTION TO C-C MOTIF CHEMOKINE LIGAND 21 (CCL21) ... 92
5.1 CCL21: A CHEMOTACTIC CYTOKINE ........................................................................ 93
5.2 CCL21 AS A COMPONENT OF THE IMMUNE SYSTEM.................................................. 97
5.2.1 Immune Cell Homing is Mediated by the CCR7/CCL19/CCL21 Chemokine Axis.
............................................................................................................................... 100
5.2.2 The CCR7/CCL19/CCL21 Signaling Axis Mediates Thymus Structure and
Function. ................................................................................................................ 107
5.2.3 Lymphoid Organogenesis is Mediated by CCR7/CCL19/CCL21. ................ 107
5.2.4 CCR7 and CCL21 Modulates Immunity. ....................................................... 110
5.3 CCL21 IN CANCER ................................................................................................ 115
5.4 CCL21 AS AN IMMUNOTHERAPY IN CANCER ........................................................... 120
5.5 DISSERTATION HYPOTHESIS: PART II ..................................................................... 124
CHAPTER 6: MATERIALS AND METHODS ............................................................... 127
6.1 CCL21 ................................................................................................................. 128
6.2 NANOPARTICLE FORMULATION AND CHARACTERIZATION ........................................ 128
6.2.1 Standard Gelation Processes ....................................................................... 128
6.2.2 Diameter, Polydispersity, and Distribution .................................................... 131
6.2.3 Transmission Electron Microscopy and Atomic Force Microscopy ............... 132
6.2.4 Encapsulation and Loading Efficiency .......................................................... 133
6.2.5 Loading and Release via Dialysis Assay and Enzyme-Linked Immunosorbent
Assay (ELISA) ....................................................................................................... 134
6.3 CELL LINE, CULTURE CONDITIONS, AND A MOUSE MODEL ....................................... 134
6.3.1 Mouse Neuroblastoma Cell Line: Neuro2a ................................................... 134
6.3.2 Mouse Strain: A/J ......................................................................................... 135
6.4 TUMOR CELL INJECTIONS, ADMINISTRATION OF TREATMENTS, AND MONITORING .... 135

viii
6.4.1 Injection of Tumor Cells ................................................................................ 135
6.4.2 Intratumoral Treatment ................................................................................. 136
6.4.3 Assessing Tumor Growth and the Survival of Tumor-Bearing Mice ............. 136
6.5 FLUORESCENT DYE TAGGING ................................................................................ 139
6.6 FLUORESCENT IMAGING......................................................................................... 139
6.7 FLUORESCENT MICROSCOPY ................................................................................. 139
6.8 ANALYSIS OF CELL VIABILITY ................................................................................. 140
6.9 FLOW CYTOMETRY ANALYSIS ................................................................................ 140
6.10 MULTIPLEX PROTEOME ARRAY ............................................................................ 146
6.11 STATISTICAL ANALYSIS ........................................................................................ 147
6.11.1 Linear Mixed Model Analysis ...................................................................... 147
6.11.2 Kaplan-Meier Survival Distributions ............................................................ 147
6.11.3 Two-Way ANOVA ....................................................................................... 147
6.11.4 Statistical Significance ................................................................................ 148
CHAPTER 7: NANOFORMULATION OF CCL21 AND ITS EFFICACY AS AN
INTRATUMORAL IMMUNOTHERAPY ........................................................................ 149
7.1 INTRODUCTION TO ALGINATE AND THE NANOFORMULATION PROCESS..................... 150
7.2 OPTIMIZATION AND CHARACTERIZATION OF THE ALGINATE NANOPARTICLES ........... 151
7.2.1 Component Ratio Optimization Allowed for the Generation of Uniform, Stable
Nanoparticles ......................................................................................................... 151
7.2.2 Addition of Pluronic F127, as a Nanoparticle Component, Prolonged Protein
Release and Improved Encapsulation Efficiency and Loading Capacity ............... 153
7.2.3 Nanoparticle Loading and CCL21 Release .................................................. 160
7.2.4 Alginate Nanoparticles Demonstrated Spherical Shape, Unimodal Size
Distributions, and Neutral Charge .......................................................................... 163
7.3 IN VIVO APPLICATION OF NANOFORMULATED CCL21 INHIBITED TUMOR GROWTH AND
INCREASED SURVIVAL ................................................................................................. 169
7.3.1 Introduction to Neuroblastoma and the Study Model .................................... 169
7.3.2 Nanoformulated CCL21’s Effect on Neuroblastoma Tumor Growth and Survival
............................................................................................................................... 169
7.4 NANOFORMULATED CCL21 INDUCED A SYSTEMIC, PROTECTIVE RESPONSE ........... 176
7.5 INTRATUMORAL RETENTION AND CLEARANCE OF NANOFORMULATED CCL21.......... 181
7.6 EFFECTS OF NANOFORMULATED CCL21 ON INFILTRATING INTRATUMORAL IMMUNE
CELLS ......................................................................................................................... 186
7.6.1 Frequencies of Intratumoral Total Leukocytes, NK Cells, and NKT Cells were
Significantly Elevated in both the Nanoformulated CCL21 and CCL21 Treatment
Groups ................................................................................................................... 186
7.6.2 Dendritic Cell and Macrophage Frequencies Were Increased Following
Treatment with Either CCL21 Modality .................................................................. 189
7.6.3 The Frequency of CD4+ and CD8+ T Cells, but not Memory B Cells, Increased
in Both Nanoformulated CCL21-Treated and Free CCL21-Treated Tumors, ........ 195

ix
7.6.4 Mice with Regressing Tumors Exhibited Specific Characteristics of Immune Cell
Infiltrates ................................................................................................................ 204
7.7 INTRATUMORAL CYTOKINE PROFILES VARIED BY TREATMENT ................................. 218
7.7.1 Nanoformulated CCL21 Treatment Increased and Prolonged Levels of Antitumor Cytokines ..................................................................................................... 218
7.7.2 Nanoformulated CCL21-Treated Tumors Exhibited Decreased Levels of ProTumor Cytokines .................................................................................................... 231
CHAPTER 8: DISCUSSION, SUMMARY, AND FUTURE DIRECTIONS .................... 233
8.1 DISCUSSION AND SUMMARY OF RESEARCH ............................................................ 234
8.2 FUTURE DIRECTIONS ............................................................................................. 239
8.2.1 Further Investigation into Nanoformulated CCL21-Mediated Immune
Responses in Neuroblastoma. ............................................................................... 240
8.2.2 Determining the Therapeutic Efficacy of Nanoformulated CCL21 Utilizing Other
Mouse Models of Neuroblastoma. ......................................................................... 242
8.2.2 Maximizing Nanoformulated CCL21 to its Fullest Potential. ......................... 244
REFERENCES ............................................................................................................. 246

x
LIST OF FIGURES
FIGURE 1.1.OVERALL STRUCTURE OF THE APP FAMILY OF PROTEINS. ................................ 20
FIGURE 1.2. APLP2 MEDIATES MHC CLASS I INTERNALIZATION.......................................... 28
FIGURE 1.3. ABERRANT EXPRESSION AND PROCESSING OF APLP2 AND APP RESULTS IN
CANCER PROGRESSION AND METASTASES. ................................................................. 30
FIGURE 1.4. HUMAN PANCREATIC PRIMARY TUMORS AND METASTASES DEMONSTRATE
ELEVATED LEVELS OF APLP2 EXPRESSION IN COMPARISON TO NORMAL PANCREAS. .... 34
FIGURE 1.5. LOSS OF APLP2 RESULTED IN DECREASED TUMOR GROWTH, SMALLER PRIMARY
TUMOR WEIGHTS, AND LESS INCIDENCE OF METASTASES, PARTICULARLY IN THE
DIAPHRAGM AND SMALL BOWEL. ................................................................................. 37
FIGURE 2.1. SCHEMATIC OF THE TARGETING VECTOR. ....................................................... 47
FIGURE 2.2. APLP2 VECTOR TARGETING AND RECOMBINATION PROCESSES AS WELL AS THE
KPCA BREEDING SCHEME. ........................................................................................ 49
FIGURE 3.1. AN OVERVIEW OF THE KPC MOUSE MODEL FOR SPONTANEOUS PANCREATIC
DUCTAL ADENOCARCINOMA (PDAC). .......................................................................... 62
FIGURE 3.2. HUMAN PRIMARY TUMOR EPITHELIAL CELLS MORE HIGHLY EXPRESS APLP2 THAN
HUMAN PANIN EPITHELIAL AND STROMAL CELLS. ........................................................ 65
FIGURE 3.3. APLP2 IS HIGHLY EXPRESSED IN THREE MURINE PDAC-DERIVED CELL LINES. . 68
FIGURE 3.4. APLP2 IS EXPRESSED IN A MOUSE MODEL OF PANCREATIC ADENOCARCINOMA.
................................................................................................................................. 70
FIGURE 3.5. EXPRESSION OF APLP2 IN PANCREATIC TISSUE SAMPLES. .............................. 74
FIGURE 3.6. PANCREAS-SPECIFIC LOSS OF APLP2 DELAYS PANCREATIC CANCER
DEVELOPMENT AND PROLONGS THE SURVIVAL OF KPC MICE. ...................................... 77
FIGURE 3.7. METASTATIC SPREAD OF PDAC WAS DECREASED UPON HOMOZYGOUS, AND
HETEROZYGOUS TO A LESSER EXTENT, LOSS OF APLP2. ............................................ 81
FIGURE 5.1. SCHEMATIC REPRESENTATION OF CHEMOKINES CCL21, CCL19, AND THEIR
RECEPTOR, CCR7. .................................................................................................... 95
FIGURE 5.2. EXPRESSION OF CCR7, CCL21, AND CCL19 IN THE IMMUNE SYSTEM............. 98
FIGURE 5.3. THE CCR7/CCL19/CCL21 CHEMOKINE AXIS FACILITATES THE RECRUITMENT AND
MIGRATION OF CELLS TO AND WITHIN THE LYMPH NODE. ............................................ 102
FIGURE 5.4. CHEMOTAXIS AND MIGRATORY SPEED IN DCS IS MEDIATED BY CCR7. ........... 104
FIGURE 5.5. THE ROLE OF THE CCR7/CCL19/CCL21CHEMOKINE AXIS IN THE THYMUS. ... 108
FIGURE 5.6. SCHEMATIC OF AN IMMUNE RESPONSE AND FORMATION OF TERTIARY LYMPHOID
STRUCTURES. .......................................................................................................... 111
FIGURE 5.7. SCHEMATIC OF THE CCL21/CCR7-MEDIATED FUNCTIONS IN THE IMMUNE SYSTEM.
............................................................................................................................... 113
FIGURE 5.8. CHEMOKINE NETWORKS AND CELLULAR ASSOCIATIONS IN CANCER. ............... 116
FIGURE 5.9. SCHEMATIC REPRESENTATION OF AN ANTI-TUMOR IMMUNE RESPONSE AND THE
CHEMOKINE NETWORK INVOLVED. ............................................................................ 121

xi
FIGURE 6.1. SCHEMATIC REPRESENTATION OF THE FORMULATION PROCESS OF PROTEIN
(CYTOCHROME C OR CCL21) – LOADED ALGINATE NANOPARTICLES VIA IONOTROPIC
GELATION. ............................................................................................................... 129
FIGURE 6.2. STRATEGY FOR EVALUATING THE THERAPEUTIC EFFICACY OF NANOFORMULATED
CCL21 IN A MURINE NEUROBLASTOMA MODEL. ......................................................... 137
FIGURE 6.3. SCHEMATIC OF THE IMMUNOPHENOTYPING STRATEGY THAT WAS USED TO
CHARACTERIZE THE FREQUENCIES OF IMMUNE CELLS WITHIN TREATED NEUROBLASTOMA
TUMORS. ................................................................................................................. 142

FIGURE 7.1. OPTIMIZATION OF NANOFORMULATION COMPONENT RATIOS. ......................... 154
FIGURE 7.2. SUSTAINED RELEASE OF PROTEIN CARGO FROM THE ALGINATE NANOPARTICLES
WAS DEMONSTRATED. .............................................................................................. 157
FIGURE 7.3. ALGINATE NANOPARTICLES RELEASE CCL21 OVER AN EXTENDED PERIOD OF TIME.
............................................................................................................................... 161
FIGURE 7.4. AFM AND TEM DEMONSTRATED UNIFORM, SPHERICAL ALGINATE NANOPARTICLE
STRUCTURES WITH MINIMAL TO NO AGGREGATION. ................................................... 165
FIGURE 7.5. ADDITIONAL AFM IMAGING. ........................................................................... 167
FIGURE 7.6. INTRATUMORAL TREATMENT WITH NANOFORMULATED CCL21 CAUSED COMPLETE
REGRESSION IN 7 OUT OF 21 NEURO2A TUMOR-BEARING MICE TREATED WITH
NANOFORMULATED CC21, AND THE AVERAGE TUMOR GROWTH WAS SLOWER FOR
NANOFORMULATED CCL21-TREATED MICE COMPARED TO CONTROLS. ...................... 170
FIGURE 7.7. AVERAGE MOUSE WEIGHT WAS NOT SIGNIFICANTLY AFFECTED UPON
INTRATUMORAL TREATMENT WITH NANOFORMULATED CCL21, BUT AVERAGE TUMOR
WEIGHT WAS SIGNIFICANTLY REDUCED (DUE TO TUMOR REGRESSION IN SOME OF THE
MICE). ..................................................................................................................... 174
FIGURE 7.8. SURVIVAL DISTRIBUTIONS OF TUMOR-BEARING MICE WERE SIGNIFICANTLY
PROLONGED BY NANOFORMULATED CCL21 TREATMENT. .......................................... 177
FIGURE 7.9. SYSTEMIC, PROTECTIVE, ANTITUMOR RESPONSES WERE OBSERVED IN A SUBSET
OF NANOFORMULATED CCL21-TREATED MICE, A PHENOMENON NOT SEEN WITH THE
OTHER TREATMENTS TESTED. .................................................................................. 179
FIGURE 7.10. FLUORESCENTLY LABELED CCL21 DELIVERED TO NEUROBLASTOMA TUMORS IN
NANOPARTICLES WAS FOUND TO BE PRESENT AT A HIGHER LEVEL AT DAY 1 AND DAY 2
FOLLOWING TREATMENT, AS COMPARED TO FLUORESCENTLY LABELED CCL21 DELIVERED
ALONE. .................................................................................................................... 183
FIGURE 7.11. ELEVATED FREQUENCIES OF CD45+ CELLS WERE OBSERVED IN TUMORS
TREATED WITH EITHER NANOFORMULATED CCL21 OR CCL21 IN COMPARISON TO THE
CONTROL. ............................................................................................................... 187
FIGURE 7.12. INTRATUMORAL INJECTION OF NANOFORMULATED CCL21 AND CCL21 ALONE
RESULTED IN INCREASED FREQUENCIES OF NK AND NKT CELLS. .............................. 190
FIGURE 7.13. RECRUITMENT OF DCS INTO THE TUMOR WAS INCREASED IN THE
NANOFORMULATED CCL21 AND CCL21 TREATMENT GROUPS. .................................. 192
FIGURE 7.14. NANOFORMULATED CCL21 AND CCL21 TREATMENT GROUPS INDUCED
CHANGES IN THE FREQUENCY, MER SURFACE EXPRESSION LEVELS, AND SUBPOPULATIONS

xii
OF MACROPHAGES OVER TIME IN A MANNER MORE VARIED THAN THE BUFFER CONTROL
GROUP. ................................................................................................................... 196

FIGURE 7.15. CD4+ T CELL POPULATIONS AND SUBPOPULATIONS ARE DIFFERENTIALLY
MODULATED FOLLOWING TREATMENT WITH EITHER NANOFORMULATED CCL21 OR CCL21
ALONE. .................................................................................................................... 200
FIGURE 7.16. TREATMENT WITH NANOFORMULATED CCL21 OR CC21 ALONE ALTERS CD8+ T
CELL POPULATIONS AND SUBPOPULATIONS FREQUENCIES WITHIN TUMORS. ............... 205
FIGURE 7.17. ELEVATED LEVELS OF MEMORY B CELLS WERE OBSERVED IN NEUROBLASTOMA
TUMORS TREATED WITH EITHER NANOFORMULATED CCL21 OR CCL21 IN COMPARISON TO
THE CONTROL. ......................................................................................................... 209
FIGURE 7.18. COMPARISONS OF IMMUNE CELL SUBSET FREQUENCIES ACROSS TREATMENT
GROUPS OVER TIME ARE SHOWN, WITH THE MICE THAT UNDERWENT COMPLETE
REGRESSION DURING THIS EXPERIMENT HIGHLIGHTED IN COLOR. .............................. 212
FIGURE 7.19. CYTOKINE LEVELS WERE ASSESSED IN TUMOR SUPERNATANTS DERIVED FROM
THE NEUROBLASTOMA TUMORS OF MICE EUTHANIZED AT DAY 2 OR AT DAY 7 POSTTREATMENT INITIATION WITH NANOFORMULATED CCL21, CCL21 ALONE, OR BUFFER
ALONE. .................................................................................................................... 219
FIGURE

7.20. IN TOTAL, THE INTRATUMORAL CYTOKINE PROFILE INDUCED BY
NANOFORMULATED CCL21 TREATMENT, AS COMPARED TO CCL21 TREATMENT, FAVORED
INCREASED ANTI-TUMOR CYTOKINE EXPRESSION. ..................................................... 224

FIGURE 7.21. THE INTRATUMORAL CYTOKINE PROFILE INDUCED BY NANOFORMULATED CCL21
TREATMENT, AS COMPARED TO CCL21 TREATMENT DECREASED THE EXPRESSION OF
PRO-TUMOR CYTOKINES IL-6 AND IL-16 BUT ELEVATED THE EXPRESSION OF TIMP-1. 228

xiii

LIST OF TABLES
TABLE 1.1. MURINE APLP2 MRNA PRIMER SEQUENCES USED FOR QRT-PCR ANALYSIS. .... 56
TABLE 6.1 MARKERS USED FOR IMMUNOPHENOTYPING. ................................................... 144
TABLE 7.1 EVALUATION OF ENCAPSULATION EFFICIENCY (EE) AND LOADING CAPACITY (LC) OF
ALGINATE NANOPARTICLES. ...................................................................................... 159
TABLE 7.2 PHYSICOCHEMICAL CHARACTERISTICS OF ALGINATE NANOPARTICLES. ............. 164

xiv
LIST OF ABBREVIATIONS

°C

Degrees Celsius

AcD

Acidic domain

APC

Antigen-presenting cells

APLP1

Amyloid precursor-like protein 1

APLP2

Amyloid precursor-like protein 2

APP

Amyloid precursor protein

Bat3

Human leukocyte antigen-B associated transcript 3

bp

Base pair

BSA

Bovine serum albumin

CBD

Collagen binding domain

CCL

C-C motif chemokine ligand

CCL19

C-C motif chemokine ligand 19

CCL21

C-C motif chemokine ligand 21

CCR

C-C motif chemokine receptor

CCR7

C-C motif chemokine receptor 7

CCRCC

Clear cell renal cell carcinoma

cDNA

Complementary DNA

CTF

C terminal fragments

CuBD

Copper binding domain

DC

Dendritic cell

DKO

Double knockout

DMEM

Dulbecco's Modified Eagle Medium

DMSO

Dimethyl sulfoxide

DNA

Deoxyribonucleic acid

xv
EDTA

Ethylenediaminetetraacetic acid

EUCOMM

European Conditional Mouse Mutagenesis Program (EUCOMM)

FRC

Fibroblastic reticular cells

GAGs

Glycosaminoglycans

GFLD

Growth factor like domain

HBD

Heparin binding domain

HEPES

4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid

HEVs

High endothelial venules

HLA

Human leukocyte antigen

HRP

Horseradish peroxidase

ICD

Intracellular Domain

IHC

Immunohistochemistry

JMR

Juxtamembrane region

KOMP

Knockout-first allele with promoter-driven cassette strategy

KPC

LSL-KrasG12D/+, LSL-Trp53R172H/+, and Pdx-1-Cre

KPC

LSL-KrasG12D/+; LSL-Trp53R172H/+; Pdx-1-Cre

KPCA

LSL-KrasG12D/+; LSL-Trp53R172H/+; LSL-Aplp2; Pdx-1-Cre

KPI

Kunitz protease inhibitor domain

LECs

Lymphatic endothelial cells

LSL

LoxP-flanked stop codon

mg

Milligram

MHC

Major histocompatibility complex

mL

Milliliter

mM

Millimolar

MMRRC

Mutant Mouse Resources and Research Center

mRNA

Messenger RNA

xvi
mTECs

Medullary thymic epithelial cells

MΦ

Macrophage

NK

Natural killer cell

NKT

Natural killer T cell

PanINs

Pancreatic intraepithelial neoplasias

PBS

Phosphate buffered saline

PCR

Polymerase chain reaction

PDAC

Pancreatic ductal adenocarcinoma

qRT-PCR

Quantitative real-time polymerase chain reaction

RNA-seq

RNA sequencing

rpm

Revolutions per minute

shRNA

Short hairpin RNA

SKO

Single knockout

T cell

T lymphocyte

TMD

Transmembrane domain

TPM

Transcripts per million

ZnBD

Zinc binding domain

µg

Microgram

µL

Microliter

µM

Micromolar

17

Chapter 1: Introduction to Amyloid Precursor-Like Protein 2 (APLP2)
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1.1 APLP2: An Amyloid Precursor Protein (APP) Family Member
The amyloid precursor protein (APP) family consists of three members: APP,
amyloid precursor-like protein 1 (APLP1), and amyloid precursor-like protein 2 (APLP2);
all of which are evolutionarily conserved (Kang J et al., 1987; Sprecher CA et al., 1993;
Wasco W et al., 1992; Wasco W et al., 1993). The APP family of proteins has largely
been studied for their roles in mammalian development, particularly within the nervous
system.

APP is the most well known family member as its proteolytic processing

generates amyloid-β plaques, which are believed to be causative agents in Alzheimer’s
disease. Extensive study pertaining to the role of APP in Alzheimer’s disease has left the
normal physiological and cancer-related functions of APLP2, APP, and APLP1 largely
understudied. The paralogues (APP, APLP1, and APLP2) demonstrate similarities across
domain architecture, proteolytic processing, and functionality; however, only APP contains
the amyloid-β sequence that is pathologically linked to Alzheimer’s disease. All three
proteins can form homo- and heterodimers that facilitate cell-to-cell interactions, but their
expression patterns vary (Soba P et al., 2005; Kaden D et al., 2008). APP and APLP2
are ubiquitously expressed and have been found to localize to intracellular compartments,
while APLP1 expression is restricted to tissues of the nervous system and demonstrates
cell surface localization (Slunt HH et al., 1994; Kim TW et al., 1995; Wasco W et al., 1992;
Wasco W et al., 1993; Lorent K et al., 1995; Soba P et al., 2005; Kaden D et al., 2008).
Despite their high degree of similarity, the APP family of proteins are transcriptionally
different and contain unique variances that suggest divergent functions in addition to their
redundant roles (Shariati SAM et al., 2013).
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1.1.1 APLP2 Molecular Structure
APLP2 and its family members are type I transmembrane proteins that have
undergone extensive structural and functionality studies over the past couple of decades.
The overall structure of each APP family member consists of a large extracellular domain,
a transmembrane domain (TMD), and a short (~50 amino acid in length) cytoplasmic tail
(Figure 1.1). The ectodomain of APLP2 is highly flexible and extended as it contains the
E1 and E2 subdomains which are independently folded and linked via an acidic domain
(AcD), the Kunitz protease inhibitor (KPI) domain, and an OX-2 domain (Kaden D. et al.,
2012). Beginning at the N-terminus, the E1 domain (blue) consists of the following
subdomains: growth factor like domain (GFLD), copper binding domain (CuBD), heparin
binding domain (HBD), and zinc binding domain (ZnBD) (Rossjohn J et al., 1999; Small
DH et al., 1994; Kong GKW et al., 2007; Barnham KJ et al., 2003). As indicated by the
darker blue color, the E1 domain is highly conserved between APP and APLP2 but
diverges in APLP1 as indicated by the lighter blue color (Dahms et al., 2010). The AcD
(indicated in yellow) is a flexible linker with a strong negative charge density and unknown
function that is located between the E1 and E2 domains. Located between the AcD and
E2 domains lies the KPI (indicated in pink). This region is rich is aspartic and glutamic
acid residues, inhibits multiple proteases (trypsin, chymotrypsin, etc.), and likely facilitates
the internalization of APLP2/APP via association with the LDL receptor-related protein
(Petersen LC et al., 1994, Sandbrink R et al., 1994; Dyrks T et al., 1988, Pandey P et al.,
2016; Kounnas MZ et al., 1995). Notably, the KPI domain is only present in APLP2 and
APP proteins, not in APLP1. Like the E1 domain, the E2 domain (indicated in teal) is
capable of binding copper, zinc, and heparin as well as facilitating the formation of homoand heterodimers (Kaden D et al., 2012; van der Kant and Goldstein, 2015). The E2
domain is also necessary for stimulation of cell growth and neurite extension (Jin LW et
al., 1994; Ninomiya H et al.,
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Figure 1.1.Overall structure of the APP family of proteins.
(A) The diagram shows the domain architecture, functional segments, and
conserved/divergent regions of the APP-family proteins. All family members demonstrated
similar domain architecture including the E1 domain, the acidic domain (AcD), the E2
domain, the juxtamembrane region (JMR), the transmembrane domain (TMD), and the
intracellular domain (ICD). Divergent regions between the homologs are evident as only
APP contains the Aβ-peptide and extension domain (ED), the Kunitz protease inhibitor
domain (KPI/OX2)- insertion is only present in APP and APLP2, and the E1 domain is less
conserved in APLP1 than in the remaining family members. Brackets were used to
indicate the following subdomains: heparin binding domain (HBD), copper binding domain
(CuBD), zinc binding domain (ZnBD), collagen binding domain (CBD), and the growth
factor like domain (GFLD). Phosphorylation and glycosylation sites are shown as P and
empty circles, respectively.
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1994). The juxtamembrane region (indicated in purple; JMR) is an additional, flexible
linker that connects the E2 domain to the TMD. A single transmembrane helix makes up
the TMD and contains cleavage sites for α, β, and γ secretases. The Aβ domain is unique
to the APP protein and is responsible for the pathological function of the amyloid peptide.
Lastly, the intracellular domain (ICD) contains a conserved YENPTY sequence that
functions in signal transduction (Borg et al., 1996; Pardossi-Piquard and Chelcer, 2012).
The sequence for APLP2 and each of its homologs were aligned via Clustal X and analysis
revealed regions of conservation, both strong and weak, in many of the key domains
across all APP family members (Coburger I et al., 2014).
Each family member is encoded by a separate, multi-exon gene. APP is located
on chromosome 21q21, APLP1 is positioned at 19.13.1, and APLP2 is found at 11q24
(Robaskis NK et al., 1987; Lenkkeri U et al., 1998; Leach R et al., 1999). As reviewed by
Anliker and Muller (2016), simple sequence analysis revealed variations between APP
family members, indicating differences in structure and function regardless of their
similarities. APLP2 undergoes splice variation to generate unique isoforms (Petersen LC
et al., 1994; Sandbrink R et al., 1994; von der Kammer H et al., 1994). The canonical
APLP2 isoform, which contains all 18 exons, has a length of 763 amino acids, and a
molecular mass of roughly 110 kDa. In comparison to canonical APLP2, the APLP2
isoforms (751, 707, and 695 amino acids) are reported to occur from removal of exons 7
and/or 14. Loss of the KPI domain results from the exclusion of exon 7 while APLP2
isoforms that contain exon 14 lack susceptibility to Ser614 modification by chondroitin
sulfate glycosaminoglycan (Petersen LC et al., 1994; Salameh MA et al., 2010;
Thinakaren G et al., 1994; Thinakaren G et al., 1995a). It has been shown that APLP2
isoforms with chondroitin sulfate glycosaminoglycan modification, specifically APLP2-751,
increase cell migration towards type IV collagen and fibronectin in wound healing (Li XF
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et al., 1999). The isoforms of APLP2 demonstrate varied loss or maintenance of functions
depending on exon junction modifications and changes in encoded residues (Figure 1.3C).

1.1.2 Proteolytic Processing and Post Translational Modification of APLP2
The APP family of proteins undergoes proteolytic cleavage by enzymes known as
secretases, which result in the formation of both secreted and cytoplasmic fragments
(Walsh DM et al., 2007, Eggert S et al., 2004; Vassar R et al., 2009). Alpha- (α-secretase)
and beta-secretase (β-secretase) cleavage sites have been identified within APP and
APLP2 on the N-terminal side near the TMD, in the trans-golgi network, and at the cell
surface (Endres K et al., 2005; Kinoshita A et al., 2003; Skovronsky DM et al., 2000; Hogl
S et al., 2011; Walsh DM et al., 2007, Jacobsen and Iverfeldt, 2009). These cleavage
events result in the formation of a ~70 kDA soluble fragment of the ectodomain and are
denoted as α or β, representing the secretase responsible for their formation. Subsequent
cleavage events further reduce the soluble fragment size to ~10-15 kDa. The small
fragment is identified as a C-terminal fragment (CTF) (Walsh DM et al., 2007). Gammasecretases cleave APP and APLP2 (full length or CTFs) within the TM domain at several
sites, thus forming the intracellular domain (ICD) fragment. This fragment is able to
undergo nuclear translocation via Fe65 family member interactions and function as a
transcriptional regulator of actin cytoskeleton components and of various proteins
including glycogen synthase kinase 3 beta (Guenette SY et al., 1996; Coburger I et al.,
2013; Kitano et. al., 2013, Xu Y et al., 2007). It has also been reported that APLP2 is able
to form a complex with Mint 3 and either Yap or Taz to modulate transcription (Orcholski
ME et al., 2011).
In addition to proteolytic processing, APLP2 isoforms often undergo posttranslational modification such as glycosylation and phosphorylation. N- and O-linked
glycosylation is suggested to occur on asparagine-287, asparagine 752, threonine-289,
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and threonine 367 (Dyrks T et al., 1988, Lyckman AW et al., 1998; Thinakaran and Sisodia
1994). As mentioned above, APLP2 isoforms lacking exon 14 are modified by an O-linked
glycan that can be extended by chondroitin sulfate glycosaminoglycans, which can
increase cell migration and expression in certain tissues. As shown in Figure 1.1, APLP2
can be phosphorylated at several serine, threonine, and tyrosine resides, thus modulating
protein function and interactions. Phosphorylation of APLP2 (threonine 736) can occur
during times of stress via JNK1α and MAPK8 (Taru and Suzuki, 2004). The overall
similarities in structure, sequence, and processing suggest highly redundant functions
within the APP family; however, studies have shown that divergent roles are attributed to
individual family members.

1.1.3 Functions of APLP2
The APP family has been linked to a vast array of functions in both neuronal and
non-neuronal tissues. APLP2 has been found to mediate a variety of cellular processes
including signaling, mitosis, migration, and adhesion (Cappai R et al., 1999; Guo J et al.,
1998; Li XF et al., 1999; Rassoulzadegan M et al., 19998; Thinakaran G et al., 1995b;
Walsh DM et al., 2007). Various murine knockout strains targeting APLP2 and its family
members (APP, APLP1) were generated to further our understanding of their functionality.
Single gene knockout (SKO) of APLP2, APLP1, or APP resulted in subtle phenotypes with
minimal to no defects (Zheng H et al., 1995; Heber S et al., 2000; von Koch CS et al.,
1997). Mild phenotypes included some loss in locomotive activity, reduced forelimb
strength, gliosis, and slight weight loss; APLP2 loss can result in hyperinsulinemia and
retinal abnormalities (Zheng H et al., 1995; von Koch CS et al., 1997; Heber S et al., 2000;
Needham BE et al., 2008; Aydin D et al., 2011; Dinet V et al., 2016; Muller UC et al.,
2017). Double knockout (DKO) strains of APP/APLP1 resulted in mice that were both
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viable and fertile, indicating that APLP2 expression alone is sufficient for survival (Heber
et al., 2000).
In contrast, DKO mice deficient in APLP2/APP or APLP2/APLP1 demonstrated
early postnatal lethality with various neurological shortfalls, pre- and postsynaptic
transmission deficits, and abnormal levels of copper, magnesium, calcium, and phosphate
(von Koch et al., 1997; White AR et al., 1999; Heber S et al., 2000; Wang P et al., 2005;
Yang G et al., 2005; Saganich MJ et al., 2006; Caldwell JH et al., 2005; Klevanski M et
al., 2014; Klevanski M et al., 2015). This suggests that, upon loss of APLP2, the APP and
APLP1 proteins can compensate for a function(s) typically performed by APLP2. Notably,
upregulation of either APP or APLP1 was not observed following deletion of APLP2, which
may indicate a novel compensatory mechanism independent of the APP family (Heber S
et al., 2000; Aydin D, et al., 2011). It has also been reported that loss of APP and APLP2
resulted in decreased proliferation, migration and adhesion in murine keratinocytes
(Siemes C et al., 2006). The soluble, extracellular cleavage fragment of APP was able
to rescue the lethality of the APP/APLP2 DKO mice; however, a rescue of normal function
was not observed as the mice showed impairment of neuromuscular junction
transmissions, deficits in neuromuscular transmitter release, and reductions in spatial
memory (Weyer SW et al., 2011). Interestingly, expression of a different soluble fragment
of APP, sAPP β, was unable to rescue either the lethality or neuromuscular deficits
exhibited by APP/APLP2 DKO mice (Li H et al., 2010). This indicates that only a few
amino acids between the α and β cleavage sites are necessary for the biological functions
of sAPP and, as such, provide an untapped area of study. Overall, there is evidence for
genetic interaction between APP and APLP2, but the questions of functional redundancy
remain unanswered.
APP and APLP2 are multimodal proteins that participate in a vast array of
processes. Elucidation of APLP2 functions have indicated that, within the nervous system,
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APLP2 is able to modulate a variety of cellular processes (proliferation, signaling,
migration, and adhesion) as well as alter neurite outgrowth, metabolism, mitosis
segregation, and transcription (Cappai R et al 1999, Guo J et al., 1998, Li X-F et al., 1999,
Rassoulzadagan M et al., 1998, Thinakaran G et al., 1995a, Thinakaran G et al., 1995b).
APLP2 can function as a cell surface receptor-like protein, even though it lacks inherent
enzymatic abilities, or as a ligand following secretion of the N-terminal fragment that
results from proteolytic processing (Muller et al., 2017). APLP2 has been shown to
function as a Go-coupled receptor in the Mullerian inhibiting substance signaling complex,
which mediates cell survival and anti-apoptotic activity through alterations in ERK1/2
activation (Yin X et al, 2007). The APP family has also been linked to roles in insulin and
glucose homeostasis and can mediate cell signaling and cell-cell adhesion (Needham BE
et al., 2008; Cao and Sudhof, 2001; Soba et al., 2005; Atwood et al., 2000; Brunkan and
Goate, 2005).
Notably, APLP2 has been identified as an immune response modulator. Studies
have identified the major histocompatibility complex (MHC) class I molecule, also known
as the human leukocyte antigen (HLA) class I molecule, as an interaction partner of APLP2
(Tuli A et al., 2008a; Tuli A et al., 2008b; Tuli A et al., 2009a; Tuli A et al., 2009b). The
MHC class I molecule facilitates presentation of antigen peptides for T lymphocyte
recognition and subsequent killing. This molecule is trafficked between the endoplasmic
reticulum and plasma membrane, as it is internalized from the cell surface and recycled
(Reid PA et al., 1990; Caplan S et al., 2002). Our lab has shown extensive co-localization
of APLP2 and MHC class I molecules from the cell surface and throughout the
internalization process with trafficking occurring via cytoplasmic vesicles, particularly in
early endosomes (identified by EEA1 and Rab5 staining) and some recycling endosomes
(identified by Rab11 staining), as well as in the Golgi apparatus (Figure 1.2) (Tuli A et al.,
2009a; Tuli A et al., 2008a; Tuli A et al., 2008b). Elevated levels of APLP2 result in
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decreased surface expression of MHC class I molecules via increased endocytosis, which
leads to immune editing in a variety of cancer cells including Ewing’s sarcoma and
pancreatic cancer (Tuli A et al., 2009a; Tuli A et al., 2008a; Tuli A et al., 2008b, Peters H
et al., 2013a; Peters H et al., 2013b).

APLP2 involvement with trafficking vesicles,

identified via colocalization of APLP2 with markers distinguishing early endosomes and
microvesicles, was also observed in neuroendocrine tumors within the gastrointestinal
tract (Arvidsson Y et al., 2008).

The regulation of APLP2 expression, subcellular

localization, and processing leads to an array of functions with vast complexity and tissue
specificity.

1.2 Role of APLP2 in Cancer
Several cancers have been found to aberrantly express APLP2, which has led to
a rapid expansion in studies centering on elucidating the function of APLP2 in various
malignancies, as atypical expression and processing of APLP2 corresponds to cancer
progression and metastasis with alterations in cellular migration, invasion, proliferation,
and survival (Figure 1.3). Decreased expression of APLP2 was observed in benign
thyroid follicular lesions in comparison to those classified as malignant (Arvidsson Y et al.,
2008). In a recent study, nuclear expression of APLP2 was elevated in benign lesions
(but not in malignant lesions) and demonstrated potential for development as a novel
marker, in combination with protein regulator of cytokinesis I and ribonucleotide reductase
M2 polypeptide proteins, for use in distinguishing between benign and malignant thyroid
follicular lesions (Castelblanco et al., 2016). APLP2 expression was decreased at both
the protein and mRNA level in clear cell renal cell carcinoma
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Figure 1.2. APLP2 mediates MHC class I internalization.
Cytotoxic T lymphocytes are presented tumor cell antigens by the MHC class I molecules
present at the cell surface. Upon recognition of the antigen peptide, the cytotoxic T
lymphocytes induce cancer cell lysis. APLP2 associates with the MHC class I molecule
in the plasma membrane and induces internalized of itself and MHC class I molecule via
cytosolic vesicles (such as early endosomes and recycling endosomes). Additionally,
APLP2 diverts MHC class I molecule recycling by funneling the internalized molecules to
lysosomes for degradation.

Figure from:
Peters HL, Tuli A, Sharma M, Naslavsky N, Caplan S, MacDonald RG, Solheim JC.
Regulation of major histocompatibility complex class I molecule expression on cancer cells
by amyloid precursor-like protein 2. Immunol Res. 2011; 51: 39-44. Figure used with
permission.
Modified from Tuli A. Regulation of the major histocompatibility complex class I antigen
presentation pathway by amyloid precursor-like protein 2. Doctoral dissertation, University
of Nebraska Medical Center. ProQuest Dissertations Publishing. 2009.
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Figure 1.3. Aberrant expression and processing of APLP2 and APP results in cancer
progression and metastases.
An illustration of APP and APLP2, as type I transmembrane proteins, with demarcation of
cleavage sites targeted by α-, β-, and γ-secretases as well as sites of glycosylation and
phosphorylation. Proteolytic processing of APP and APLP2 generates various fragments
with differing subcellular localization, expression, and function.
Post-translation
modification via glycosylation and/or phosphorylation influences the interaction of APP or
APLP2 with various other proteins (transcriptional regulators, signaling receptors, adaptor
proteins, etc.) to mediate downstream effects such as cell migration, survival, proliferation,
invasion, and metastases.

Figure from:
Pandey P, Sliker B, Peters HL, Tuli A, Herskovitz J, Smits K, Purohit A, Singh RK, Dong
J, Batra SK, Coulter DW, Solheim JC. Amyloid precursor protein and amyloid precursorlike protein 2 in cancer. Oncotarget. 2016; 7(15): 19430-19444. Figure used with
permission.
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(CCRCC); decreased APLP2 correlated to poor patient survival outcomes (Gao L et al.,
2019). This study suggests that APLP2 plays a tumor suppressive role in CCRCC.
In contrast, Ewing’s sarcoma, glioblastoma, and pancreas, testicular germ cell,
and gastrointestinal neuroendocrine cell cancers have all demonstrated overexpression
of APLP2 (Peters H et al., 2013a; Peters H et al., 2013b; Chen Y et al., 2018; Peters H
2012; Pandey P et al., 2015; Venkataramani V et al., 2012, Moass AC et al., 2007).
Previous studies by our laboratory have shown that Ewing’s sarcoma-derived cell lines
overexpress APLP2 and that this increased expression subsequently interfered with
radiation-induced apoptosis of Ewing’s sarcoma cells and was indicative of a subset of
cells resistant to lymphokine-activated killer cell-mediated lysis (Peters H et al., 2013a).
Overexpression of APP and APLP2 induced colon cancer growth and proliferation as
silencing of either APP family member lead to a reduction in these processes (Moss AC
et al., 2007). Human leukocyte antigen-B associated transcript (Bat3) expression was
found to positively correlate with the expression of APLP2 in colon cancer; the association
of Bat3 and APLP2 resulted in the inhibition of APLP2 ubiquitination and subsequent
proteasomal degradation, therefore preserving the stability of APLP2 and maintaining the
growth-stimulating effect APLP2 has on colon cancer cells (Wu W et al., 2012). Initial
studies in glioblastoma observed a correlation between patients with high expression of
APLP2 and shorter overall survival (Chen Y et al., 2018). While further investigation is
necessary, APLP2 is a potential prognostic factor for glioblastoma patients, as it may
correlate with tumor development.
Our research group has shown increased expression of full length and cleaved
APLP2 in both pancreatic cancer cell lines and in human pancreatic tumor samples
(Peters H et al., 2012; Pandey P et al., 2015). In brief, the CT fragment of APLP2 was
highly expressed in pancreatic cancer cells and demonstrated increasing expression
levels throughout the oncogenic transformation process; use of a β-secretase inhibitor
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reduced levels of the APLP2 CTF and caused a decrease in cell viability (Peters H et al.,
2012). During examination of human pancreatic cancer patient samples from primary
tumors and metastatic lesions in the liver, small intestine, and diaphragm, we observed
increased expression of APLP2 throughout disease progression (Pandey et al., 201).
Immunohistochemistry and tumor microarray analysis demonstrated enhanced staining of
APLP2 in primary tumor as well as maintenance or elevated levels in metastases,
particularly in the small bowel and diaphragm, when compared to normal pancreas
(Figure 1.4). In this study, we also reported on the role of APLP2 as a regulator of
pancreatic cancer cell growth and metastases, as loss of APLP2 resulted in alterations of
the actin cytoskeleton, decreased tumor weight, and a reduction in metastases in an
orthotopic pancreatic tumor model (Figure 1.5).

1.3 Dissertation Hypothesis: Part I

Elucidating the functions of APLP2 in cancer is a relatively new field of study and
novel discoveries have been made identifying APLP2 as a modulator of cellular processes
such as signaling, metabolism, adhesion, survival, and immune recognition. However, the
role of APLP2 in cancer development remains unclear. Primary pancreatic tumors and
metastases have demonstrated maintained or even elevated levels of APLP2 throughout
disease development. Additionally, patients with pancreatic cancer, particularly those with
advanced disease, face dismally poor survival prognoses. For those reasons, I chose to
utilize models of pancreatic cancer for my dissertation work. The overall aim of this portion
of my dissertation was to investigate how APLP2 affects malignant development and
progression in a spontaneous, murine model of pancreatic cancer.
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Figure 1.4. Human pancreatic primary tumors and metastases demonstrate elevated
levels of APLP2 expression in comparison to normal pancreas.
Immunohistochemistry analysis of formalin-fixed and paraffin-embedded tissue sections
stained with anti-APLP2 antibody and derived from (A) normal pancreas, (B) primary
pancreatic adenocarcinoma, and (C) pancreatic adenocarcinoma metastases to the small
bowel (400x magnification). Representative immunostaining images are shown. APLP2
staining is indicated in brown and the cell nuclei are blue due to the use of Mayer’s
hematoxylin counterstain.

Figure from:

Pandey P, Rachagani S, Das S, Seshacharyulu P, Sheinin Y, Naslavsky N, Pan Z, Smith
BL, Peters HL, Radhakrishnan P, McKenna NR, Giridharan SS, Haridas D, Kaur S,
Hollingsworth MA, MacDonald RG, Meza JL, Caplan S, Batra SK, Solheim JC. Amyloid
precursor-like protein 2 (APLP2) affects the actin cytoskeleton and increases pancreatic
cancer growth and metastasis. Oncotarget. 2014; 6: 2064-2075. Figure used with
permission.
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Figure 1.5. Loss of APLP2 resulted in decreased tumor growth, smaller primary tumor
weights, and less incidence of metastases, particularly in the diaphragm and small bowel.
A human pancreatic cancer cell line, S2-013, was transfected with a Dox-inducible APLP2shRNA-luciferase construct and transplanted into the pancreas of nude mice. Starting at
day 7 post-implantation, the APLP2 shRNA expression was induced. (A) Tumor
bioluminescence was monitored on Days 14 and 21 post-tumor cell injection. The
percentage of mice in the Dox group versus No Dox group was significantly different at
Day 14 (p = 0.01 by Fisher’s Exact Test). At day 21, luminescence was detectible in a
majority of mice in the No Dox group; there failed to be a statistically significant difference
between the Dox and No Dox groups in the percentage of mice exhibiting easily detectable
luminescence at Day 21. (B) Representative images of tumor bioluminescence at Days
14 and 21 are shown. (C,D) Animals were euthanized at 30 days post-tumor cell
implantation (9 mice in the control APLP2-shRNA-“off” No Dox group and 11 mice in the
APLP2-shRNA-“on” Dox group) and primary tumors are resected. (C) Representative
images of primary tumors are resected at 30 days post-tumor cell implantation are shown.
(D) The weights of all primary tumors resected at 30 days post-tumor cell implantation
were measured and are graphically displayed in the box-and whisker plot showing the
distribution of primary tumor weights for each group around the medians. Statistical
significance was assessed by the Mann-Whitney test; P=0.011. (E) The percentages of
tumor-bearing mice in the No Dox group or the Dox group that had metastases to various
anatomic sites were recorded. The incidences of pancreatic tumor metastases were
calculated as % incidence = number of mice with metastases in a particular site divided
by total number of mice. Statistical significance was assessed by Fisher’s Exact Test (Dox
versus No Dox P-value for spleen 0.642, mesenteric lymph nodes 0.670, diaphragm
0.005, peritoneum 0.074, liver 0.189, kidney 0.008, intestine 0.017, and ovary 0.189).

Figure from:
Pandey P, Rachagani S, Das S, Seshacharyulu P, Sheinin Y, Naslavsky N, Pan Z, Smith
BL, Peters HL, Radhakrishnan P, McKenna NR, Giridharan SS, Haridas D, Kaur S,
Hollingsworth MA, MacDonald RG, Meza JL, Caplan S, Batra SK, Solheim JC. (2015).
Amyloid precursor-like protein 2 (APLP2) affects the actin cytoskeleton and increases
pancreatic cancer growth and metastasis. Oncotarget. 2014; 6: 2064-2075. Figure used
with permission.
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As elevated expression of APLP2 has been found in human pancreatic cancer
primary tumors and metastatic samples via immunohistochemistry analysis, we
collaborated with the Olive laboratory to determine the expression of APLP2 in human
epithelial and stromal pancreatic adenocarcinoma samples via RNA-seq. Validation of
elevated APLP2 expression in human pancreatic cancer, at both the protein and mRNA
levels, led us to hypothesize that APLP2 expression would be elevated in cell lines derived
from murine pancreatic tumor specimens. To address this hypothesis, protein expression
was determined in three different pancreatic cancer cell lines as well as via
immunohistochemistry analysis of murine tumor samples. The tumor specimens and
tumor-derived cell lines were acquired from the conditional LSL-KrasG12D/+; LSLTrp53R172H/+; Pdx-1-Cre (KPC) mouse model.
Validation of APLP2 expression in murine pancreatic cancer-derived cell lines led
to the second aim, the generation of a quadrageneic conditional knockout to study how
loss of APLP2, in a pancreas-specific manner, alters cancer development and
progression.

Based on previous findings from our laboratory in which APLP2 loss

decreased tumor weight and metastatic progression in an orthotopic model of pancreatic
cancer, we hypothesized that loss of APLP2 within the pancreas of KPC mice would delay
cancer development and inhibit metastatic spread in those mice, compared to mice with
functional APLP2. We sought to generate this novel strain (KPCA) by utilizing the well
documented KPC mouse line combined with the Aplp2 strain (with conditional potential),
which we acquired from the Mutant Mouse Resources and Research Center (MMRRC)
(University of California, Davis, CA). Findings generated from this spontaneous model of
murine pancreatic cancer will provide details pertaining to the role of APLP2 in cancer
development and progression as well as provide new avenues of investigation.
Characterization of the KPC APLP2 mouse strain will provide information on
alterations in disease onset, invasiveness, metastatic spread, and overall impact on health
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(motility, aging, breeding, etc). Tumors, both primary and metastatic, as well as ascites,
will be collected and processed for continued study. Cell lines will be derived from both
tumor and ascites specimens from KPCA wildtype, homozygous APLP2 knockout, and
heterozygous APLP2 knockout, to allow for in vitro analysis of cellular proliferation,
migration, and invasion capacities. Immunohistochemistry analysis will also be performed
on paraffin-embedded tumor specimens from mice with wild type, homozygous, or
heterozygous knockout of APLP2. Cell lines and tumor specimens from the KPCA mouse
strain will allow us to further elucidate the role APLP2 plays in pancreatic cancer
development and progression as well as allow for identification of novel interaction
partners or mechanisms of action. These findings could potentiate the use of APLP2 as
a preventative or therapeutic target for pancreatic cancer.
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Chapter 2: Materials and Methods
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2.1 RNA-Seq
Frozen human tissue samples were chosen for analysis by a pathologist
specializing in gastrointestinal cancers based on the diagnosis of pancreatic
adenocarcinoma and the presence of intact RNA. The tissues were then microdissected
and several cell-type specific markers were used to confirm the complete separation of
epithelial (229 samples: 203 from primary tumors and 26 from low-grade PanINs) and
stromal (125 samples with matched epithelium: 102 from primary tumors and 23 from lowgrade PanINs) samples. From each patient, paired samples of isolated cells (>1000
cells/sample) were generated. The NuGEN Ovation RNA-Seq System V2 kit (Tecan
Genomics, Inc. Redwood City, CA, U.S.A.) was used to produce sequencing libraries.
The Illumina HiSeq (Illumina, Inc. San Diego, CA, U.S.A.) was used to generate 3500 to
30 million 100 base-pair, single-end reads of the sequenced cDNAs. To determine the
log2 Transcripts per Million (TPM), the APLP2 read counts were divided by the genetic
sequence length (kb) of APLP2 followed by a division of total reads per kb of all data set
genes / 1,000,000 and is shown on the y axis. Comparisons between samples of mapping
regions of a specific genes can be achieved using the TPM calculation. APLP2 was
detected with ³1 TPM in all samples. Differential APLP2 gene expression analysis
statistics (logFC, t-statistic, and False Discovery Rate): PanIN Epith:PanIN Stroma 0.719, -5.37, 8.87e-06; PDAC Epith:PDAC Stroma

-1.560, -18.80,4.71e-52; PanIN

Epith:PDAC Epith. 0.637, 3.84,1.58e-03; PanIN Stroma:PDAC Stroma -0.211, -1.78,
2.46e-01; All Epith:All Stroma -1.460, -19.40, 6.54e-57.

2.2 Bioinformatic Analysis
Construction of a regulatory network was done using the ARACNE algorithm.
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2.3 Immunohistochemistry
Tissue specimens were collected from 20-week-old KPC mice (n = 13 total
specimens, n = 6 normal pancreas specimens and n = 7 pancreatic tumors) and fixed in
10% neutral buffered formalin for 72 hours at room temperature prior to embedding in
paraffin (Fisher Scientific, Hampton, NH, U.S.A.). The immunohistochemical staining and
analysis was performed as per a published protocol (Pandey et al., 2013). In brief, the
slides were deparaffinized using xylene followed by rehydration in a series of 10-minute
incubations in alcohol solutions ranging from 100% to 20%. The tissues were immersed
in 3% H202 in methanol to block endogenous peroxidase activity prior to antigen retrieval
which involved incubation with 0.01 M citrate buffer (pH 6.8). The ImmPRESS Polymer
Detection kit (Vector Laboratories, Burlingame, CA, U.S.A.) was used as a blocking agent
for 2 hours at room temperature before the sections were incubated with primary antibody
in 1% BSA, 0.5% Tween in Tris-buffered saline (pH 7.3) at 4°C for 24 hours in a humidity
chamber. The tissues were washed then incubated with peroxidase-labeled secondary
antibody (universal anti-mouse/rabbit IgG antibody) for 30 minutes at room temperature.
The immunostaining was completed by using a peroxidase substrate detection kit (Vector
Laboratories, Inc.). The stained slides were scored by Dr. Yuri Sheinin (pathologist) and
representative pictures were taken and analyzed. Staining intensity was evaluated as
follows: negative staining = 0, weak staining = 1, moderate staining = 2, and strong or
intense staining = 3.

2.4 Mouse Strains and Genetic Mutations
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2.4.1 Mouse Strains
All mice were maintained and bred at the University of Nebraska Medical Center
following the Institutional Animal Care and Use Committee (IACUC) guidelines under an
approved protocol. Mouse strains for breeding the conditional KPC mouse model were
obtained from Dr. Surinder Batra, who received them as a kind gift from Dr. David Tuveson
who originally generated the KPC strain, and back crossed them to C57BL/6 mice. The
C57BL/6N-Atm1BRD APLP2tm2a(EUCOMM)Hmgu/BayMmucd mouse strain with conditional
potential was acquired from the Mutant Mouse Resources and Research Center
(MMRRC) (University of California, Davis, CA).

This strain was generated using a

knockout-first allele with promoter-driven cassette (KOMP) strategy which is part of the
European Conditional Mouse Mutagenesis Program (EUCOMM) (Skarnes et al., 2011 and
Coleman et al., 2015). The EUCOMM vector design is shown for a prototypical gene with
three exons, including the targeting and recombination processing (Figure 2.1).
In brief, the promoter-driven cassette, as well as the FRT and loxP (excision) sites,
were inserted into the APLP2 gene between exons 3 and 5. The breeding strategy is
shown in Figure 2.2. Initial crosses were set up between the APLP2 mouse strain
(APLP2tm2a/tm2a) and the B6.Cg-Tb(Pgk1-flpo)10Sykr/J strain, also known as the FLPo-10
mouse (Jackson Laboratory, Bar Harbor, ME, U.S.A.).

This cross resulted in the

generation of a pseudo-wild type mouse as the FRT-flanked region containing the
promoter-driven cassette was excised and recombined by the FLP recombinase. The
APLP2tm2a/tm2a x FLPo-10 progeny are denoted as APLP2tm1c/+ or floxed mice.

The

APLP2tm1c/+ mice were back crossed to produce the homozygous APLP2tm1c/tm1c or
floxed/floxed mice.

The floxed mice could then be used as a founder line for the

generation of a knockout line or as the control line for experimental use. For
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Figure 2.1. Schematic of the targeting vector.
The targeting vector is represented in the top line. This vector has been inserted between
exons 1 and 2 (grey numbered boxes). This construct is identified as tm1a; it has FRT
sites (green) flanking the lacZ/neo promoter cassette, as well as three loxP (red) sites
located between exons 1 and 3. If the tm1a mouse is bred with a Cre recombinasebearing mouse (right hand side, second row), the tm1b construct will be generated via
excising the second exon while maintaining the lacZ promoter cassette. However, if the
tm1a mouse is crossed with a Flp recombinase mouse (left hand side, second row), the
tm1c construct will be produced, which removes the lacZ/neo promoter cassette as it is
flanked by FRT sites. The tm1c construct has a loxP flanked second exon. Subsequent
breeding with a Cre recombinanse-bearing mouse will yield the tm1d construct, removing
the second exon.

Figure acquired from:
Skarnes WC, Rosen B, West AP, Koutsourakis M, Bushell W, Iyer V, Mujica AO, Thomas
M, Harrow J, Cox T, Jackson D, Severin J, Biggs P, Fu J, Vefedov, de Jong PJ, Stewart
AF, Bradley A. A conditional knockout resource for the genome-wide study of mouse gene
function. Nature. 2011; 474(7531): 337-342. Figure used with permission.
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Figure 2.1
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Figure 2.2. APLP2 vector targeting and recombination processes as well as the KPCA
breeding scheme.
(A) A representation of the APLP2 EUCOMM targeting vector. This vector has been
inserted between exons 3 and 5 (grey numbered boxes). This construct is identified as
tm1a; it has FRT sites (blue triangles) flanking the lacZ/neo promoter cassette, as well as
three loxP (purple triangles) sites. When the tm1a mouse is bred with a Flp recombinase
mouse (second row), the tm1c construct will be produced, which removes the lacZ/neo
promoter cassette as it is flanked by FRT sites. The tm1c construct has a loxP flanked
fourth exon. Subsequent breeding with a Cre recombinanse-bearing mouse (third row)
will yield the tm1d construct, removing the fourth exon. (B) Breeding strategy for
generating the KPCA mouse strain. (i) Crossing the APLP2tm1a/tm1a mice with the FLPo-10
mouse yields pseudo-wild type mice; the FLP recombinase excises the promoter cassette
and after recombination, the loxP sites flank the fourth APLP2 exon. The progeny of this
crossing is denoted as LSL-APLP2tm2c/+. These mice are interbred to generate LSLAPLP2tm2c/tm2c. (ii) The LSL-APLP2tm2c/tm2c mice are bred with the LSL-KrasG12D/+; LSLTrp53R172H/+ mice to yield LSL-KrasG12D/+; LSL-Trp53R172H/+; LSL-APLP2tm2c/+ or LSLKrasG12D/+; LSL-Trp53R172H/+; LSL-APLP2tm2c/tm2c. (iii) The final cross of LSL-KrasG12D/+;
LSL-Trp53R172H/+; LSL-APLP2tm2c/tm2c with the Pdx-1-Cre mouse will generate the LSLKrasG12D/+; LSL-Trp53R172H/+; LSL-APLP2tm2c/tm2c; Pdx-1-C mouse (KPCA) with
homozygous or heterozygous loss of APLP2 within the pancreas. KPC mice with wild
type APLP2 will be bred for use as experimental controls.
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Figure 2.2
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continuation in nomenclature, the APLP2tm1c/tm1c or floxed/floxed mice will be identified in
the same manner as the KPC mouse strains; LSL-APLP2tm1c/tm1c or LSL-APLP2tm1c/+.
The LSL-APLP2tm1c/tm1c or LSL-APLP2tm1c/+ mice now have conditional potential
and were interbred with the conditional LSL-KrasG12D/+; LSL-Trp53R172H/+mice. Finally, the
LSL-KrasG12D/+; LSL-Trp53R172H/+; LSL-APLP2tm1c/+mice or the LSL-KrasG12D/+; LSLTrp53R172H/+; LSL-APLP2tm1c/tm1c mice were crossed with the Pdx-1-Cre strain; yielding the
novel quadrageneic mutant with either homozygous or heterozygous loss of APLP2. The
progeny of such crosses are identified as LSL-KrasG12D/+; LSL-Trp53R172H/+; LSLAPLP2tm1d/+;

Pdx-1-Cre

(KPCA-/-)

or

as

LSL-KrasG12D/+;

LSL-Trp53R172H/+;

LSL-

APLP2tm1d/tm1d; Pdx-1-Cre (KPCA-/+) animals on a C57BL/6J background.
2.4.2 DNA Acquisition via Tail Digestion
Proteinase K in a lysis buffer consisting of 100 mM Tris (pH 8.8), 5 mM EDTA,
0.2% SDS, and 200 mM NaCl ( (Fisher Scientific) in H2O was used to extract DNA from a
small portion (< 5 mm) of each tail that was collected from pups 14-21 days of age.

2.4.3 Polymerase Chain Reaction of Genes of Interest
Polymerase chain reaction (PCR) amplification was performed using GoTaq
Master Mix (Promega, Madison, WI, U.S.A.) with a set of primers for each genes of interest
(Kras, p53, Pdx-1-Cre, and APLP2). The primer sequences were acquired form Eurofins
Scientific (Luxembourg) and consisted of the following sequences:
Kras-seq: 5’ GTCGACAAGCTCATGCGGGTG -3’,
Kras-seq: 5’-CCTTTACAAGCGCACGCAGACTGTAGA-3’,
Kras-seq: 5’-AGCTAGCCACCATGGCTTGAGTAAGTCTGCA-3’,
p53-seq: 5’-CTTGGAGACATAGCCACACTG-3’,
p53-seq: 5’-AGCTAGCCACCATGGCTTGAGTAAGTCTGCA-3’,
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p53s-seq: 5’-TTACACATCCAGCCTCTGTGG-3’,
Pdx-1-Cre-seq: 5’-CTGGACTACAATCTTGAGTTGC-3’,
Pdx-1-Cre-seq: 5’-GGTGTACGGTCAGTAAATTTG-3’,
APLP2-seq: 5’-ACATTTCCTGGCTACAATCCTGTGC-3’,
APLP2-seq: 5’-ATTATTAGACTTGGCAGGCATGCTG-3’.

2.4.4 DNA Agarose Gel Electrophoresis
The samples were run on 2% agarose (VWR, Radnor, PA, U.S.A.) gel with
GreenView Plus Gel Stain (GeneCopoeia, Rockville, MD, U.S.A.) in 1x TAE buffer. The
TAE buffer is composed of 40 mM Tris, 20 mM acetic acid, and 1 mM EDTA. The gels
were imaged using the Bio-Rad GelDoc per the manufacturer’s protocol.

2.5 Cell Lines, Culture Conditions, and Deriving Novel Lines
2.5.1 Cell Lines and Culture Conditions
The Panc02-H7 cell line was contributed by Dr. Keping Xie (MD Anderson Cancer
Center), and the KPC-0960, and KPC-0961 cell lines were kindly donated by Dr. Surinder
K. Batra (UNMC). All cells were cultured in complete medium consisting of Dulbecco’s
Modified Eagle Medium (DMEM) supplemented with the following additives: 1 mM sodium
pyruvate, 100 units/mL penicillin and 100 μg/mL streptomycin, 2 mM L-glutamine, 100X
MEM Non-Essential Amino Acids, along with 10% v/v heat inactivated fetal bovine serum
purchased from Atlanta Biologicals (Flowery Branch, GA). All media reagents, except for
the fetal bovine serum, were obtained from Life Technologies (Carlsbad, CA).
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2.5.2 Establishment of Tumor-Derived Cell Lines
Tumor-derived cell lines were generated from KPC mice and KPC APLP2 mice
bearing pancreatic tumors, following a previously published protocol (Torres 2013). In
brief, tumors were excised and rinsed 3x with sterile PBS before being transferred to a
petri dish containing complete medium. The tumors were minced into small pieces using
two sterile, single-edged razor blades and transferred to a sterile conical tube containing
10 mg/mL Collagenase P (Roche, Indianapolis, IN, U.S.A.) in complete medium. The
tumor collagenase mixture was then incubated for approximately 30 minutes at 37°C in a
shaking incubator. The digestion reaction was terminated upon addition of 45 mL DMEM,
after which the tumor solution was centrifuged for 5 minutes at 150 g. The pellets were
washed 3x prior to resuspension in complete medium, plated in a 10 mm dish, and
incubated overnight in a 37°C CO2 incubator. Following incubation, the culture medium
was replaced with fresh complete medium. Fibroblast growth was prevented by using
differential trypsinization, which consisted of incubating cells with trypsin for 10 seconds
followed by washing with PBS before replacing the medium with fresh complete medium.
Cell lines were maintained at 37°C and 5% CO2 in a humidified incubator.
Two cell lines were derived successfully and have been used alongside the
previously reported KPC-960 and KPC-961 cell lines (Torres 2013). The first cell line
(KPCA-1311) was derived from a tumor-bearing KPC mouse with pancreas-specific,
heterozygous loss of APLP2; the second line (KPC-1798) was generated from a tumorbearing KPC mouse with pancreas-specific, homozygous loss of APLP2. The cell lines
were passaged a minimum of 35 times prior to characterization in vitro.

2.6 Tissue Collection, Protein Lysis, and Protein Quantification
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Mouse pancreatic tissue was collected, washed once with cold, sterile PBS and
flash frozen in liquid nitrogen. Cell lysis buffer was added to the tissue before processing
with a mortar and pestle. The cell lysis buffer is composed of the following reagents from
Sigma (St. Louis, MO, U.S.A.) 1 mM EGTA, 1 mM EDTA, 50 mM Tris-HCl pH 7.5, 1%
Triton X-100, 2 mM DTT, and 0.1 mM PMSF in addition to 1 mM Na3VO4 and 1 μg/ml Halt
Cocktail from Thermo Fisher Scientific (Waltham, MA, U.S.A.) Following harvest, the
lysates were stored at -80°C overnight, then thawed on ice, and centrifuged at 13,000 rpm
for 30 min at 4°C. The supernatants were transferred to new tubes and stored at -80° C
until use. All samples underwent protein quantification using the Pierce BCA Protein
Assay Kit per the manufacturer’s protocol (Thermo Fisher Scientific).

2.7 Protein Electrophoresis and Western Blotting
Aliquots of the lysate supernatants were mixed with 5Í sodium dodecyl sulfate
loading dye (250 mM Tris-HCl pH 6.8, 10% w/v sodium dodecyl sulfate [Tokyo Chemical
Industry Company, Portland, OR, U.S.A.], 30% v/v glycerol [Sigma], 5% v/v βmercaptoethanol [Sigma], 0.02% w/v bromophenol blue [Sigma]) and heated for 5 minutes
at 95° C prior to loading. The samples were loaded on 4-20% or 10-20% Invitrogen Novex
Tris-glycine polyacrylamide pre-cast gels (Thermo Fisher Scientific). Electrophoresis was
performed at 90 V at room temperature followed by protein transfer at 50 V for 2.5 hours
at room temperature to polyvinylidene difluoride Immobilon-P Millipore membranes. The
membranes were blocked for 1 hour in a 5% w/v solution of nonfat dry milk prior to
incubation overnight at 4°C with primary antibodies. Next, the membranes were washed
3 times with 1% Tween-20 (Thermo Fisher Scientific) in PBS for 5 minutes.

The

membranes were incubated with secondary antibodies for 1 hour at room temperature
before being washed 3 times for 5 minutes with 1% Tween-20 in PBS. The proteins were
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then visualized, which involved incubating the membranes in Pierce ECL Western Blotting
Substrate (Thermo Fisher Scientific) and imaged using the ChemiDoc MP (Bio-Rad,
Hercules, CA)

2.8 Antibodies
The anti-APLP2 antibody used in IHC analysis was acquired from Abcam
(Cambridge, MA, U.S.A.). Detection of APLP2 and GAG-APLP2 by western blot analysis
was achieved using a polyclonal goat antiserum from R&D Systems (Minneapolis, MN,
U.S.A., AF3685). Cytokeratin 19, a recombinant rabbit monoclonal antibody was acquired
from Life Tech (MA531977).

Hsc70 was detected using a monoclonal rat antibody

purchased from Enzo Life Sciences (ADI-SPA-815B-F).

2.9 RNA Isolation, cDNA Synthesis, and qRT-PCR Analysis
RNA was isolated and purified from KPC-0960, KPC-0961, KPCA1311, and
KPCA1798 cell lines as well as from the pancreas of KPC mice with wild type APLP2,
heterozygous loss, or homozygous loss of APLP2 using the RNeasy Plus Mini Kit (Qiagen,
Germantown, MD, U.S.A.). Synthesis of complementary DNA (cDNA) from total RNA was
achieved by using the High Fidelity 1st Strand cDNA synthesis kit (Agilent Technologies,
La Jolla, CA, U.S.A.) per the manufacturer’s instruction. In brief, the synthesis reaction
consisted of a 1 hr incubation at 42°C followed by a 15 min. incubation at 70°C, which
terminated the reaction. The primers used to measure the relative messenger RNA
(mRNA) levels, as analyzed by quantitative real-time polymerase chain reaction (qRTPCR), are provided in Table 1. qRT-PCR analysis was performed using RT2 SYBR Green
qPCR mastermix (Qiagen) and the Bio Rad CFX96 Real time PCR detection system
(Hercules, CA, U.S.A). The transcripts for each gene were measured in triplicate.
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Table 1.1. Murine Aplp2 mRNA primer sequences used for qRT-PCR analysis.
Sequence
ID
APLP2-201
APLP2-202

Primer
Direction
Forward
Reverse
Forward
Reverse

Sequence (5’ – 3’)

Amino Acid Length

GTGATGCCTCGTTGGTACTTCG
TGCCATTCCAGAGCCTTCATT
ACGATGTTAAAGTTCCCCCGA
CAACTCCGGCTGAGTGTCTT

22
21
21
20
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All gene expression was normalized to an internal loading control, GAPDH. To determine
the relative expression of each transcript, the average change in cycle threshold (∆CT)
was calculated and used in the 2∆∆CT formula. Statistical analysis was performed using
the Student’s t-test and p values £ 0.05 were considered to be significant.

2.10 Statistical Analysis
2.10.1 Kaplan-Meier Survival Distributions
Survival distributions were assessed via Kaplan-Meier plots and log-rank test.
Reaching a tumor volume of 1000 mm3 or a time period of 54 days post-treatment initiation
was each designated as an experimental endpoint. Mice alive at the completion of the
study were treated as censored. The log-rank test allowed for the comparison of survival
distributions between groups.

2.10.2 Two-Way ANOVA and Fisher’s Exact Test
Two-way ANOVA and Tukey’s multiple comparisons analysis were performed in
GraphPad Prism Version 8 (San Diego, CA) and were used to compare the overall
metastatic spread between groups. Fisher’s Exact Test with Bonferroni adjustment was
used to compare individual metastatic sites between groups.

2.10.3 Statistical Significance
All p values of £ 0.05 were considered to indicate statistical significance. Asterisks
were used to denote levels of significance and are as follows: p ≤ 0.05 (*), p ≤ 0.01 (**),
p ≤ 0.001 (***), p ≤ 0.0001 (****).
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Chapter 3: Role of APLP2 in Pancreatic Cancer Development
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3.1 Introduction to Pancreatic Cancer and Associated Mouse Models
Pancreatic cancer is the fourth leading cause of cancer-related deaths in the
United States and patients face a dismal 5-year survival rate of approximately 9% (Siegel
2019). Late-stage diagnoses and limited treatment approaches for unresectable disease
hinder patient survival. More in-depth understanding of pancreatic cancer development
and the production of efficacious, targeted strategies are desperately needed. Pancreatic
ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer and
develops from aberrant growth of ductal cells within the pancreas. Analyses of patient
tumor samples has revealed the complexity of the genomic landscape of pancreatic
cancer. This landscape contains frequent alterations in a select cohort of genes (KRAS,
TP53, and SMAD4), high chromosomal instability, and relatively few somatic coding
mutations (Waddell N et al., 2015).

Previous studies from our laboratory have

demonstrated elevated levels of APLP2 in several human pancreatic cancer cell lines
(including S2-013, SUIT2, and HS766T) as well as in human tumor samples (Figure 1.4)
(Tuli A et al., 2009a; Pandey P et al., 2015). In addition, APLP2 has been shown to
modulate cell proliferation, migration, invasion, and MHC class I expression in pancreatic
cancer (Pandey P et al., 2015; Tuli A et al., 2008a; Tuli A et al., 2008b; Tuli A et al., 2009a;
Tuli A et al., 2009b). The availability of preclinical, genetically engineered mouse models
of pancreatic cancer that recapitulate human cancer biology provides opportunities to
study disease processes ranging from development and metastasis to identifying novel
therapeutic targets or treatment strategies.
To gain a more in-depth understanding of APLP2’s role in pancreatic cancer
development, we turned to the well studied KPC mouse model. The KPC mouse model
incorporates two of the most commonly mutated genes: KRAS, a proto-oncogene, and
TP53, a tumor suppressor (Biankin AV et al., 2012; Waddell N et al., 2015; Jones S et al.,
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2008; Hruban RH et al., 2001). Studies have found that 80-90% of all human pancreatic
ductal adenocarcinomas contain mutations in KRAS and 50-75% contain mutations in
TP53. Key benefits of the KPC model are its similarity (high degree of inflammation,
absence of effector T cells) to the tumor microenvironment of human PDAC,
immunocompetency, its mimicry of therapeutic clinical observations to therapies including
anti-PDL1 antibodies and CD40 agonists, and its spontaneously forming nature (Beatty
GL et al., 2015; Beatty GL et al., 2011; Feig C et al., 2013, Keenan BP et al., 2014,
Stromnes IM et al., 2015; Bayne LJ et al., 2012, Hingorani SR et al., 2003; Hingorani SR
et al., 2005; Hruban RH et al., 2001). This model also generates prominent clinical
features (ascites, cachexia, and obstruction of the bowel and biliary systems) and
histopathological characteristics (cellular morphology, metastatic spread, and fibrosis) that
have been observed in human patients (Hingorani SR et al., 2005; Beatty GL et al., 2011;
Feig C et al., 2013; Jacobetz MA et al., 2013; Provenzano PP et al., 2012; Olive KP et al.,
2009).
The KPC mouse model utilizes Cre-Lox technology, allowing for alterations in
endogenous KrasG12D (activation of G12D point mutation) and Trp53 (dominant negative
mutation in R172H), which are maintained specifically in the pancreas via conditional
activation. Mutations in KrasG12D and Trp53R172H within the mouse pancreas lead to the
formation of ductal lesions, subsequent formation of pancreatic intraepithelial neoplasias
(PanINs), and finally invasive carcinomas (Figure 3.1) (Guerra and Barbacid, 2013;
Hingorani SR et al., 2005). The Cre-Lox technology works via a Cre recombinase, which
is expressed by Pdx-1, a pancreas-specific promoter. The Cre recombinase acts as a
scissor to excise the loxP-flanked stop codon (LSL). This only occurs in Cre-expressing
cells, thus resulting in the conditional expression of the target genes (Kras, Trp53). The
typical breeding scheme for the KPC mouse model described below. In brief, LSLKrasG12D/+ mice are crossed with LSL-Trp53R172H/+ to produce LSL-KrasG12D/+; LSL-
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Trp53R172H/+ mice. Next, the LSL-KrasG12D/+; LSL-Trp53R172H/+ mice are crossed with LSLTrp53R172H/+ mice to generate mice with heterozygous mutant KrasG12D/+ and homozygous
mutant Trp52R172H/R172H mice. Finally, the LSL-KrasG12D/+; LSL-Trp53$172H/R172H mice are
crossed with Pdx-1-Cre mice to generate LSL-KrasG12D/+; LSL-Trp53$172H/R172H; Pdx-1-Cre
(KPC) mice. As the initial strains are on a mixed genetic background of C57BL/6 and
129Sv, the mice should be backcrossed to the C57BL/6 strain at least 10 generations to
yield a pure genetic background.
The KPC mouse model produces animals that demonstrate disease progression
in a manner that closely mimics that found in humans with the formation of PanIN lesions,
the development of invasive PDAC, and metastatic spread in various organs (Hingorani
SR et al., 2005). In this model, a newborn KPC pup displays a normal pancreas without
any neoplastic cells. At 8 to 10 weeks of age, precursor lesions or PanINs can be found
within the pancreas, and at 16 weeks of age or greater, the full onset of invasive PDAC
as well as metastatic spread is evident. A strong inflammatory response (indicated by
increased infiltration of F4/80+ macrophages) accompanies early disease stages and
typically persists from disease emergence through progression and invasion, and
throughout metastasis (Lee JW et al., 2017). It is important to note that, at early disease
stages, single cells within the pancreas can undergo epithelial-to-mesenchymal transition
which results in the loss of E-cadherin (an epithelial marker) as well as increases in Zeb1
and Fsp1 (mesenchymal markers). These cells are then able to undergo dissemination
to the liver through undefined mechanisms (Rhim AD et al., 2012; Rhim AD et al., 2014).
Changes in morphology are also observed as cells take on a more spindle or fibroblastlike morphology.

In later cancer stages, tumor formation occurs alongside dense

desmoplastic reactions and is often accompanied by biliary obstruction. Mice are prone
to weight loss, ascites
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Figure 3.1. An overview of the KPC mouse model for spontaneous pancreatic ductal
adenocarcinoma (PDAC).
(A) The development of preneoplastic lesions and subsequent progression into PDAC is
shown schematically. (B) Respresentative images of PanIN lesions and invasive PDAC.

Figure acquired from:

Guerra C, Barbacid M. Genetically engineered mouse models of pancreatic
adenocarcinoma. Mol. Oncol. 2013; 7(2): 232-247. Figure used with permission.
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A.

B.
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accumulation due to metastatic spread, and cachexia. In the KPC model, metastases can
occur in the liver, peritoneal cavity, diaphragm, lung, adrenal glands, and lymph nodes
(Hingorani SR et al., 2005). Evidence of early dissemination, as well as vast metastatic
spread, further drives the need to gain a clearer understanding of how pancreatic cancer
develops and to identify ways to decrease its invasive and metastatic nature. Generating
this murine PDAC model will allow for us to investigate the role of APLP2 in pancreatic
cancer development, to gauge how APLP2 loss modulates PDAC invasive and metastatic
potentials, and to identify novel interaction partners or functions. Importantly, this model
will potentiate the use of APLP2 as a preventative or therapeutic target for PDAC.

3.2 Human Primary Tumors and Metastases Express Higher Levels of APLP2 than
PanIN Epithelial and Stromal Cells
We investigated the expression of APLP2 in human patient samples of pancreatic
adenocarcinoma using RNA-Seq technology via collaboration with Dr. Kenneth Olive
(Columbia University Medical Center). Frozen tissue samples were selected based on
the diagnosis of pancreatic adenocarcinoma as well as the presence of intact RNA. All
samples were validated by a pathologist specializing in gastrointestinal cancer prior to
being processed and verified by microdissection. We analyzed several cell type-specific
markers to confirm the complete separation of stromal and epithelial samples. As shown
in Figure 3.2, human primary tumor epithelial cells have increased expression of APLP2
compared to human PanIN epithelial cells. We also observed higher expression of APLP2
in epithelial cell samples compared to stromal cell samples.
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Figure 3.2. Human primary tumor epithelial cells more highly express APLP2 than human
PanIN epithelial and stromal cells.
Patient samples of pancreatic adenocarcinoma primary tumors and PanIN lesions, as
confirmed by a pathologist, underwent microdissection and were separated into epithelial
(229 samples: 203 from primary tumors, 36 from low-grade PanIn) and stromal (125
samples, with matched epithelium, 102 from primary tumors, 23 from low-grade PanINs)
samples. Cell isolation was then performed to generate paired samples for each patient
(>1000 cells/sample). Libraries were generated using the NuGEN Ovation RNA-Seq
System V2 Kit and the cDNAs were sequenced with an Illumina HiSeq (3500 to 30 million
100 base-pair single-end reads). The y axis shows log2 Transcripts Per Million (TPM),
calculated by dividing the read counts for APLP2 by the length of the APLP2 genetic
sequence in kb, and then dividing by a scaling factor (total reads per kb for all genes in
the dataset/1,000,000). The TPM unit allows comparison of the proportion of reads
mapping to a particular gene between samples. APLP2 was detected with ³1 TPM in all
samples. Differential APLP2 gene expression analysis statistics (logFC, t-statistic, and
False Discovery Rate): PanIN Epith:PanIN Stroma -0.719, -5.37, 8.87e-06; PDAC
Epith:PDAC Stroma
-1.560, -18.80,4.71e-52; PanIN Epith:PDAC Epith. 0.637,
3.84,1.58e-03; PanIN Stroma:PDAC Stroma -0.211, -1.78, 2.46e-01; All Epith:All Stroma
-1.460, -19.40, 6.54e-57.
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Bioinformatic analysis using the ARACNE algorithm, which has been validated in many
different cancers (Basso K et al., 2005; Margolin AA et al., 2006; Basso K et al., 2010;
Della Gatta G et al., 2012; Carro MS et al., 2010; Lim WK et al., 2009; and Aytes A et al.,
2014) to infer target relationships and network analysis using MARINa (Compagno M et
al., 2009) characterized APLP2 as a master regulator of pancreatic cancer. As such,
APLP2 has differential activity and expression throughout the development of pancreatic
adenocarcinoma, from initial lesion formation to adenocarcinoma development to
metastases.

3.3 APLP2 Expression is Increased in Murine Pancreatic Tumor-Derived Cell Lines,
Primary Tumor Tissues, and Metastases
To determine the function(s) of APLP2 in murine pancreatic cancer development,
we first determined the expression of APLP2 in three different cell lines, Panc02-H7, KPC0960, and KPC-0961. Panc02-H7 is a subline with increased metastatic capacity that was
generated from the Panc02 cell line (Wang B et al., 2003), which was derived from PDAC
tumors that were generated by implanting 2-methyl cholanthrene (3-MCA)-saturated
threads of cotton into the pancreas of C57BL/6 mice (Corbett TH et al., 1984). Although
widely used, the Panc02 cell line provides limited clinical significance due to the lack of
sufficient mutational burdem in comparison to the spectrum of mutations observed in
patients.

The other two cell lines (KPC-0960 and KPC-0961) were derived from

spontaneously forming PDAC tumors in KPC mice, at 17 weeks of age (Torres MP et al.,
2013). As shown in Figure 3.3, APLP2 is highly expressed in all three murine PDAC cell
lines.
We then determined the expression of murine APLP2 in normal and PDAC tissue
samples acquired from KPC mice (Figure 3.4). Minimal to no expression of APLP2 was
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Figure 3.3. APLP2 is highly expressed in three murine PDAC-derived cell lines.
Western blot to detect HSC70 (as a control), as well as APLP2, was performed on cell
lysates from three murine PDAC-derived cell lines (Panc02-H7, KPC-0960, KPC-0961).
The results shown are representative of experiments performed on 3 separate lysates of
each cell type.

Western blotting was performed by Poomy Pandey, UNMC.
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Figure 3.4. APLP2 is expressed in a mouse model of pancreatic adenocarcinoma.
Immunohistochemistry was used to analyze the expression of APLP2 in tissue samples
from 20-week old KPC mice. APLP2 staining was absent in normal pancreas tissues.
PanIN1, 2, and 3 displayed weak to moderate staining of APLP2 in the cytoplasm.
However, pancreatic cancer samples, both low- and high-grade, with intensely positive
cytoplasmic APLP2 staining >80% are shown. The expression of murine APLP2 in normal
and pancreatic tissue is graphically represented in a box plot, which shows the
immunohistochemistry data based on H-scores. These scores indicate a statistically
significant (p < 0.05) increase in APLP2 expression in murine PanIN1 and PanIN2
compared to normal murine pancreas. The staining was scored according to intensity on
a 0 – 3 scale (0 = negative, 1 = weak, 2 = moderate, 3 = strong). The percentage of cells
stained for murine APLP2 was evaluated based on absolute stain (i.e., 10-100 % is scored
as 0.1 to 1). The Histo-score (H-score) was calculated by multiplying the staining intensity
by the percentage of cells positive for APLP2 expression. Statistical analysis was
performed using the Student’s t-test.

Immunohistochemistry was performed by Poomy Pandey and Dr. Parthasarathy
Seshacharyulu, UNMC, and pathology evaluation was done by Dr. Yuri Sheinin (UNMC).
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observed in normal pancreas tissue (n = 6). However, we saw significant increases in
APLP2 staining throughout disease development (n = 7) relative to normal pancreas.
Further classification of the tissues into developmental stages of the disease (PanIN 1,
PanIN2, PanIN3, low grade, and high-grade carcinoma) revealed weak to moderate
staining in PanIN1 lesions with 60-70% of the cells displaying immunoreactivity. PanIN2
lesions exhibited moderate staining for APLP2 while PanIN3 samples showed strong
staining of APLP2 with approximately 90-100% of cells positively stained, particularly in
ductal epithelial cells. Specimens determined to be low-grade pancreatic cancer had
weak to moderate expression of APLP2 in varied locations with 60-70% of cells staining
positive.

In comparison, high-grade invasive pancreatic cancer tissues had robust

expression of APLP2 with 90-100% of cells exhibiting positive staining. Overall, we have
found that APLP2 expression, as determined by immunohistochemistry analysis,
increases as the disease develops from normal to PanIN1 to low- and high-grade
pancreatic cancer in KPC mice.

3.4 Generating a Conditional APLP2 Knockout Mouse within the KPC Model of
PDAC

Determining the function(s) of APLP2 in PDAC development was investigated by
employing the KPC mouse model with an added pancreas-specific, conditional mutation
of Aplp2 (Figure 2.2). We were successfully able to generate a conditional APLP2 mouse
strain (LSL-APLP2tm1c) that was viable and fertile. No deficits or abnormalities (compared
to wild type C57BL/6 mice) were observed as the conditional APLP2 mice demonstarted
similar weight, organ size and appearance, behavior, and breeding tendencies. The
conditional APLP2 mouse strain underwent cryopreservation for later use in generating
new models centering around APLP2. Following breeding with animals from the KPC
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colony, we were able to acquire KPC mice with pancreas-specific APLP2 homozygous
(KPC APLP2-/-) and heterozygous (KPC APLP2-/+) mutations.

The conditional KPC

APLP2mice (containing pancreas-specific homozygous and heterozygous loss of APLP2)
were viable, fertile, and showed no obvious signs of neurological deficits, loss of
locomotion, organ appearance, or weight loss. Mice were monitored for overall health and
behavior along with tumor development and survival. Genotyping was confirmed by PCR
analysis of DNA acquired from tail biopsies.
Pancreatic tissue specimens were collected from mice bearing wild type,
floxed/floxed, heterozygous loss, and homozygous loss of APLP2.

Following lysis,

western blot analysis was performed to determine APLP2 expression with HSC70 used
as the control (Figure 3.5). The highest APLP2 expression level was observed in the
APLP2 wild type (+/+) sample followed by the floxed (fl/fl) lysate. Removal of the FRT
sites excised the promoter cassette but should not disrupt APLP2 expression or function.
The heterozygous deletion (-/+) of APLP2 (via Cre recombinase) greatly reduced the
protein level while homozygous deletion (-/-) of APLP2 resulted in undetectable protein
levels. The results shown are representative of experiments performed on 3 separate
lysates of each APLP2 genotype.

3.5 APLP2 Loss in Tumor Development and Tumor-Derived Cell Lines
Conditional KPC mice with pancreas-specific, homozygous loss (-/-) of APLP2
demonstrated a delayed onset of palpable tumors in comparison to mice with pancreasspecific, heterozygous loss (-/+) of APLP2 or wild type (+/+) APLP2. The survival of each
genotype is discussed in the subsequent section. Pancreas, liver, kidney, and lung
specimens were collected from mice (wild type, homozygous, and heterozygous loss of
APLP2) aged 0-30 weeks of age, fixed in formalin, and embedded in paraffin to
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Figure 3.5. Expression of APLP2 in pancreatic tissue samples.
Simple western blot to detect HSC70 (as a control), as well as APLP2, was performed on
tissue lysates acquired from mice with wild type (+/+), floxed (fl/fl), heterozygous deletion
(-/+), or homozygous deletion (-/-) of APLP2. The results shown are representative of
experiments performed on 3 separate lysates of each tissue type.
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investigate disease development (appearance and progression of PanIN lesions to
invasive carcinoma) and metastases. Additional samples are needed prior to analysis by
immunohistochemistry.
We successfully derived cell lines from pancreatic tumors resected from
conditional KPC mice with pancreas-specific APLP2 mutation. One cell line (KPCA-1311)
was derived from a pancreatic tumor with heterozygous loss (-/+) of APLP2. The other
cell line, KPCA-1798, was derived from a pancreatic tumor with homozygous deletion (-/) of APLP2. Initial western blot analysis determined the levels of APLP2 in these tumorderived cell lines. The KPC-0960 and KPC-0961 cell lines, which have wild type APLP2,
were included as positive controls. Robust protein expression of APLP2 was seen in the
APLP2 wild type tumor-derived cell lines. Heterozygous loss (-/+) of APLP2 within the
pancreas, resulted in a moderate decrease in expression intensity. Pancreas-specific
homozygous loss (-/-) of APLP2 resulted in minimal expression of APLP2 in the pancreas
of conditional KPC mice. Loss of APLP2 within the pancreas was also confirmed via qRTPCR. These experiments need to be replicated to confirm APLP2 expression levels in the
KPC tumor-derived cell lines.

3.6 Pancreas-Specific Loss of APLP2 Prolongs the Survival of KPC Mice

The survival distributions of mice with or without APLP2 expression in the pancreas
were assessed via Kaplan-Meier Survival Distributions (Figure 3.6). We observed a
significant (p = 0.012 and p = 0.009, respectively) prolongment in the survival (mean
survival time ± standard error of the mean) of KPC APLP2-/- mice (n = 19, 30.2 weeks ±
2.1) and KPC APLP2-/+ mice (n = 15, 31.3 weeks ± 2.2) compared to KPC APLP2+/+ mice
(n = 8, 21.0 weeks ± 1.4). Although delayed, we still observed development of the primary
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Figure 3.6. Pancreas-specific loss of APLP2 delays pancreatic cancer development and
prolongs the survival of KPC mice.
The KPC APLP2+/+ mice (n = 12) had an average survival time of 20.8 weeks ± 1.2, in
comparison the KPC APLP2-/+ mice (n = 19) survived 30.7 weeks ± 2.9 and the KPC
APLP2-/- mice (n = 25) lived an average of 31.0 weeks ± 2.8. The graphs display
cumulative survival time in weeks, where week 0 indicates birth. Mean survival time ±
standard error of the mean was determined for each group. Mice were monitored at least
3 times weekly and euthanized per IACUC guidelines.
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tumor, along with small bowel and biliary blockages, in KPC mice with either homozygous
or heterozygous pancreas-specific loss of APLP2.

3.7 Loss of APLP2 Resulted in Decreased Metastases to the Various Sites within
the Peritoneal Cavity

Conditional KPC mice with pancreas-specific APLP2 loss were necropsied to
assess metastatic spread and disease progression to sites of the liver, lung, diaphragm,
and peritoneum (Figure 3.7). KPC mice with wild type APLP2 (KPC APLP2+/+) expressed
in the pancreas demonstrated extensive metastases to the liver, diaphragm, and
peritoneum. Lung metastases were observed at a decreased frequency compared to
other sites studied. In comparison, KPC mice with homozygous loss of APLP2 (KPC
APLP2-/-) in the pancreas showed significantly (p = 0.0004) fewer metastases in total than
mice with pancreas-specific wild type expression of APLP2. Heterozygous, pancreasspecific loss of APLP2 (KPC APLP2-/+) also resulted in significantly (p = 0.0018) fewer
overall metastases, relative to KPC mice with expression of APLP2 in the pancreas. When
comparing homozygous and heterozygous loss of APLP2 within the pancreas, there was
no significant difference between all metastatic sites. Two-way ANOVA and Tukey’s
multiple comparisons test, including all metastatic sites assessed, determined the above
statistical comparisons.
Fisher’s Exact Test with pairwise comparisons (between groups) and adjusted with
the Bonferroni Method was used to compare specific metastatic sites between groups.
Mice with homozygous, pancreas-specific loss of APLP2 had significantly fewer
metastases to the lung (p = 0.029), diaphragm (p = 0.015), and peritoneum (p = 0.045)
compared to KPC mice with APLP2 expressed in the pancreas. A trend in decreased
metastatic spread to the liver was also observed as mice with homozygous, pancreas-
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specific loss of APLP2 had fewer (p = 0.092) liver metastases compared to KPC mice with
pancreas-specific expression of APLP2. In contrast, heterozygous loss of APLP2 in the
pancreas was only able to significantly decrease metastases to the diaphragm (p = 0.045).
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Figure 3.7. Metastatic spread of PDAC was decreased upon homozygous, and
heterozygous to a lesser extent, loss of APLP2.
Metastatic spread was determined visually upon necropsy. Sites of the liver, lung,
diaphragm, and peritoneum were assessed. Homozygous loss of APLP2 resulted in
significantly fewer metastases to the lung (p = 0.029), diaphragm (p = 0.015), and
peritoneum (p = 0.045) than in wild type mice. Heterozygous loss of APLP2 resulted in
significantly (p = 0.045) fewer metastases to the diaphragm than in mice with wild type
APLP2. Two-way ANOVA and Tukey’s multiple comparisons test were used to compare
overall metastatic spread between groups. Fisher’s Exact Test with Bonferroni Method
Adjustment was used to compare specific metastatic sites between groups.
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Chapter 4: Discussion, Summary, and Future Directions
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4.1 Discussion and Summary of Research

Our work throughout this study has confirmed APLP2 as a highly expressed
master regulator of pancreatic cancer. Past studies from our laboratory have identified
varied functions of APLP2 in pancreatic cancer and Ewing’s sarcoma (Pandey P et al.,
2015; Tuli A et al., 2008a; Tuli A et al., 2008b; Tuli A et al., 2009a; Tuli A et al., 2009b;
Peters H et al., 2013a; Peters H et al., 2013b; Peters H 2012;). For pancreatic cancer,
overexpression of APLP2 was reported throughout disease progression, including
metastatic spread to the liver, small intestine, and diaphragm in patient samples, as well
as in human PDAC cell lines (Figure 1.4; Peters H et al., 2012; Pandey P et al., 2015).
Initial studies determined APLP2 expression via immunohistochemistry and western
analysis. To obtain a more in-depth perspective, we collaborated with the Olive laboratory
to perform RNA-seq on epithelial and stromal samples from human PDAC patients. In
this study, we found elevated expression of APLP2 in human primary tumor epithelium
when compared to either PanIN stroma or epithelial cells (Figure 3.2). The results from
our RNA-seq analysis further confirmed increased APLP2 expression throughout disease
progression in human PDAC.
In an effort to further understand how APLP2 regulates PDAC development, we
utilized various mouse models of PDAC. Strong expression of APLP2 was observed in
three different murine cell lines (Panc02-H7, KPC-0960, and KPC0961), two of which were
derived from spontaneously forming PDAC tumors in the KPC mouse model (Figure 3.3).
We also performed immunohistochemistry analysis on murine pancreas tissue samples
and PDAC specimens, from early PanIN lesions to advanced, invasive carcinoma (Figure
3.4). In Figure 1.5, we show that inducible knockdown of APLP2 (via shRNA) was able
to delay tumor development, reduce tumor burden, and decrease metastases to the
diaphragm, kidney, and intestine in an orthotopic implantation model of PDAC (Pandey et
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al., 2015). Our findings strongly implicate APLP2 as a pro-tumor regulator of PDAC.
Therefore, we employed the conditional KPC mouse model with an additional mutation
(conditional, pancreas-specific knockdown of APLP2) to elucidate the function(s) of
APLP2 in PDAC development (Figure 2.2).
Previous mouse models centered around APLP2 have shown its necessity in
neurological development and processes, as mice lacking APLP2, in combination with
either APP or APLP1, were peri- and postnatally lethal. We acquired a mouse strain with
conditional potential for APLP2 knockdown from the MMRCC at UC Davis. Breeding of
this strain with a FLP recombinase produced a pseudo-wild type mouse by removing the
lacZ/neomycin promoter cassette. The progeny are considered “floxed” as they have a
loxP flanked fourth exon. Subsequent breeding of the floxed mice with a Cre recombinase
led to the excision of exon 4 and loss of APLP2. Confirmation of APLP2 loss was
determined via western analysis of pancreas tissue lysates (Figure 3.5). The expression
of APLP2, from highest to lowest, was the wild type (+/+) mouse, the floxed mouse (fl/fl),
the heterozygous knockout (-/+), and the homozygous knockout (-/-). Although the floxed
mouse demonstrates a less robust expression of APLP2, the insertion of the loxP sites
should not alter APLP2 protein expression or function. The decrease in APLP2 expression
was augmented by loss of the second allele as observed when comparing the
heterozygous and homozygous knockouts. Loss of APLP2 did not hinder viability, fertility,
development, or behavior.
Assessing the role(s) of APLP2 in PDAC development was achieved by
incorporating the conditional APLP2 knockout into the KPC mouse model. We selected
the conditional KPC model as it has been well studied, allows for the spontaneous
formation and progression of tumors, and mimics human disease relatively well. Upon
generating the conditional KPC mice with pancreas-specific APLP2 loss (either
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homozygous or heterozygous loss of APLP2), we were able to assess tumor development,
progression, and survival in comparison to the KPC mice with functional APLP2.
We observed a delay in primary tumor development, a decline in metastatic
spread, and a significant improvement in survival of the KPC mice with pancreas-specific
homozygous loss of APLP2 compared to KPC mice with wild type APLP2. The delay in
tumor development observed in KPC mice with pancreas-specific homozygous loss of
APLP2 did not prevent tumor growth as primary tumors were found upon necropsy. We
observed bowel and/or biliary blockages in KPC mice with all three APLP2 genotypes,
which is common within the KPC model. We were able to derive cell lines from the primary
tumor of a KPC mouse with pancreas-specific heterozygous loss of APLP2 (KPCA1311)
as well as from a KPC mouse with pancreas-specific homozygous loss of APLP2
(KPCA1798). We compared the pancreatic expression of APLP2 in these two cell lines
(KPCA1311 and KPCA1798) to two previously established KPC-derived cell lines (KPC0960 and KPC-0961) by western blot and qRT-PCR analysis. In the initial analysis, the
protein expression of APLP2 was strong in both wild type (KPC-0960 and KPC-0961) cell
lines and in KPCA1311, which has heterozygous loss of APLP2. Minimal expression of
APLP2 was found in KPCA1798 lysates, the tumor-derived cell line with homozygous
knockout of APLP2. We also assessed the tumor-derived cell lines at the mRNA level
and found variation in APLP2 between KPC-0961 and KPC-0960, the two cell lines with
wild type APLP2. Interestingly, KPCA1311 had nearly as high levels of APLP2 mRNA as
KPC-0961. Minimal APLP2 mRNA was detected within the KPCA1798 (homozygous
APLP2 knockout) cell line. Additional experimental replicates are needed to confirm
modulations in APLP2 expression in these tumor-derived cell lines.
Kaplan-Meier survival distributions revealed a significant improvement in the
survival of KPC mice with either pancreas-specific heterozygous or homozygous APLP2
knockout compared to the KPC mice with wild type APLP2 (Figure 3.6). An increased
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survival duration was observed in the population of KPC mice with pancreas-specific
heterozygous loss of APLP2 (31.3 weeks) and in the population of KPC mice with
pancreas-specific homozygous loss of APLP2 (30.2 weeks). The increased survival time
of KPC mice with pancreas-specific loss of APLP2 was determined via comparisons to the
approximate 21-week survival time of KPC mice with wild type APLP2. A significant
decrease in metastases to the lung, diaphragm, and peritoneum was observed when
comparing pancreas-specific homozygous loss of APLP2 in KPC mice to KPC mice with
wild type APLP2 (Figure 3.7). Pancreas-specific APLP2 loss in KPC mice also resulted
in the inhibition of metastatic spread to the liver compared to KPC mice with wild type
APLP2. The pancreas-specific heterozygous APLP2 mutant mice demonstrated varying
degrees of primary tumor development and metastatic spread. Some mice appeared to
mimic their KPC counterparts while others more closely resembled the pancreas-specific
homozygous APLP2 mutant KPC mice. This is also supported by the variation in APLP2
expression observed in pancreas tissue samples and tumor-derived cell lines.
Our initial findings from this novel KPC APLP2 mouse model show a significant
improvement in the survival of KPC mice with pancreas-specific, hetero- or homozygous
knockout of APLP2. Additional samples are required prior to assessment of disease
development and progression by immunohistochemistry.

Overall, our findings

demonstrate the significance of APLP2 as a regulator of pancreatic cancer development
and support future studies to evaluate APLP2 as a preventative or therapeutic target.

4.2 Future Directions
The aim of this section is to propose experiments for further investigation into the
functional roles of APLP2 in pancreatic cancer development and progression. Initial
studies have been performed to confirm knockdown of APLP2 within the KPC mouse
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model, but additional samples are needed to assess cancer development over time (from
birth to approximately 35 weeks of age). Generating more tumor-derived cell lines will
strengthen any findings generated from the functional assays proposed below.

4.2.1 Further Characterization of Tumor Development and Progression in the KPCA
Mouse Model
To further investigate how APLP2 loss influences PDAC development and
progression, immunohistochemistry analysis will be performed on formalin-fixed, paraffinembedded pancreas tissue and tumor tissue specimens. Ideally, 5 male mice and 5
female mice of wildtype APLP2, heterozygous APLP2 knockdown, and homozygous
APLP2 knockdown will be collected for each time point; time points will range from birth
to approximately 35 weeks in age and be collected every 5 weeks.

Analysis by a

pathologist will help with the identification and classification of PanIN lesions, carcinoma
stage, invasion, and metastases. These samples will be compared to the well published
disease model and time frame exhibited by KPC mice (Figure 3.1; Lee JW et al., 2017).
The utilization of ultrasound imaging will allow for tumor development and progression to
be monitored and measured for animals in real time without requiring euthanization of the
animals at predetermined timepoints. This would reduce the number of mice needed to
achieve a high enough power for significance to be observed. Samples would be collected
upon necropsy, fixed in formalin, and paraffin embedded prior to analysis by
immunohistochemistry.

Additionally, tissue lysates will be collected for downstream

analyses including western blot and qRT-PCR.

The collection of primary tumors,

metastases, and tissues of interest (such as the lung or liver) will allow for investigation
into the expression of immune cells, proliferative markers, and known or potential
interaction partners of APLP2. Loss of APLP2 has been reported to alter the actin
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cytoskeleton, thus intravital imaging of KPC mice with pancreas-specific APLP2 mutation
could provide greater detail into these modulations (Pandey P et al., 2015).

4.2.2 Determination of Proliferation, Migration, and Invasion Properties of Tumor-Dervied
Cell Lines from KPC mice with Pancreas-Specific APLP2 Mutations.
We have confirmed loss or modulation of APLP2 in the murine PDAC tumorderived cell lines generated from KPC mice with wild type and pancreas-specific loss of
APLP2. To further understand how APLP2 regulates these various cellular processes,
additional experiments are needed. Changes in proliferation could be measured via MTT
or trypan blue exclusion assay. Proliferation could also be monitored by cell proliferation
dyes, such as those offered by BD Horizon. The dye molecules are non-fluorescent and
diffuse passively into cells. Once inside a cell, the dye undergoes hydrolysis by nonspecific esterases, which results in the formation of fluorescent products. Once the
hydrolysis event occurs, the dye becomes trapped inside the cell. Each time a cell
proliferates, the new population of cells will have approximately half of the fluorescent
intensity as the previous division. These dyes can be combined with other markers (either
intracellular or cell surface) to determine changes over time and how that differs with or
without APLP2.
Assessment in cell migration could be studied through the use of transwell and
scratch assays.

We observed decreased metastatic progression in KPC mice with

pancreas-specific APLP2 loss as well as in an orthotopic implantation model that utilized
an inducible knockdown of APLP2 (Pandey et al., 2015). In vitro confirmation of the
changes in migratory capabilities, as a result of APLP2 loss, will substantiate our in vivo
findings. Changes in invasive properties of the KPC tumor-derived cell lines (with wild
type, hetero-, or homozygous loss of APLP2) will further clarify how APLP2 alters PDAC
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progression.

The various splice variants of APLP2 may also facilitate invasion and

migration properties and should be investigated.

4.2.3 Assessing APLP2 Immune Modulation
Past studies have demonstrated the role of APLP2 in downregulating MHC class I
surface expression by internalization (Tuli et al., 2008 a, Tuli et al., 2008b, Tuli et al.,
2009a). In pancreatic cancer and Ewing’s sarcoma, elevated levels of APLP2 induced
immune editing via loss of MHC class I at the cell surface (Tuli A et al., 2009a; Tuli A et
al., 2008a; Tuli A et al., 2008b, Peters H et al., 2013a; Peters H et al., 2013b). Therefore,
the MHC class I cell surface expression levels should be determined for the KPC tumorderived cell lines with mutated APLP2. The results may validate the role of APLP2 in
modulation of MHC class I molecules and of the immune editing processes in the KPC
APLP2 mouse model. Loss of MHC class I molecule expression at the cell surface
decreases immune recognition of tumor antigens. It is currently unknown as to whether
the loss of APLP2 in the KPC model results in a rescue or increase in MHC class I cell
surface expression.

These findings are important for future development of

immunotherapies and targeting of APLP2 in human pancreatic cancer.
4.2.4 Combining APLP2 Loss and Therapy
In pancreatic cancer models, APLP2 has been shown to modulate survival,
immune responses, tumor development, and metastases.

Loss of APLP2 leads to

delayed tumor development and decreased metastases in the KPC APLP2 mouse model.
The survival of tumor-bearing KPC mice with homozygous or heterozygous loss of APLP2
could potentially be enhanced if resection of the primary tumors could be performed
efficiently, as their metastases are minimal; however, surgical resection of mouse primary
pancreatic tumors is typically not technically feasible. The KPC APLP2 mouse model
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provides for numerous treatment agents to be tested in combination with APLP2 loss.
These combination studies could utilize immunotherapies, chemotherapy, and novel
agents to further potentiate the development of APLP2 as a preventative or therapeutic
target.

92
Chapter 5: Introduction to C-C Motif Chemokine Ligand 21 (CCL21)
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5.1 CCL21: A Chemotactic Cytokine
C-C motif chemokine ligand 21 (CCL21) is a chemokine with a broad array of
functions. Chemokines are small, secreted, signaling proteins with chemotactic abilities
that facilitate the cellular positioning necessary for various processes including
development and homeostasis of immune cells, initiation of immune responses (both
adaptive and innate), and pathophysiological recruitment of immune cells. There are
approximately 40-50 endogenous chemokines in both humans and mice; they can be
constitutively expressed at specific locations (homeostatic chemokines) or expressed
upon stimulation (inflammatory chemokines) (Zlotnik and Yoshie, 2012; Love M et al.,
2012). Classification as a chemokine is dependent upon the presence of four conserved
cysteine residues, which are required for the formation of a 3-dimensional structure
(Baggiolini M et al., 1997, Luster AD, 1998). Chemokines are typically 8-10 kDa in mass
and can be grouped into two major subfamilies based on the arrangement of two cysteine
residues located within the N-terminal. The cysteines are located adjacent to one another
(known as CC chemokines) or separated by a non-conserved amino acid (known as CXC
chemokines).
Based on the aforementioned characteristics, CCL21 is classified as a
homeostatic, C-C motif chemokine. CCL21 is unique in that it contains two additional
cysteine residues within an extended C-terminus and is located on chromosome 9p13
(Hedrick and Zlotnik, 1997; Nagira M et al., 1997; Hromas R et al., 1997). The cDNA
sequence encodes a basic polypeptide of 134 amino acids, 23 of which form an assumed
signaling peptide; the mature form is 111 residues in length (Nagira M et al., 1997). CCL21
is secreted by stromal cells and high endothelial venules (HEVs) in secondary lymphoid
organs such as the lymph node, appendix, and spleen (Luther SA et al., 2000; Willimann
K et al., 1998; Hedrick and Zlotnik, 1997; Nagira M et al., 1997; Nagira M et al., 1998).
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Expression of CCL21 can also be found in endothelial cells of the lymphatics within
nonlymphoid tissues (Gunn MD et al., 1999).

Notably, murine CCL21 is broadly

expressed with the spleen and lungs demonstrating the highest levels (Hendrick and
Zlotnik, 1997). CCL21, like other chemokines, functions through binding to its respective
receptors, present on the surface of target cells.
C-C motif chemokine receptors (CCRs) are G-protein coupled receptors with 7
transmembrane domains (Griffith J et al., 2014). Binding of the chemokine ligand to its
receptor induces a conformational change, causing intracellular signaling pathways to
take on an asymmetric organizational structure with a polarized distribution of signaling
molecules, leading to random or directional cell migration (Schumann K et al., 2010;
Hauser and Legler, 2016).

CCRs can bind multiple chemokines and interact with

numerous signaling proteins; as such, different signaling cascades can be stimulated
depending on the ligand bound.

One such receptor, CCR7, binds two known C-C

chemokine ligands, CCL21 and CCL19, with similar affinities (Figure 5.1). Despite their
similarities in binding affinities and ability to induce chemotaxis, the two ligands are
divergent in structure, expression, and function. CCL19 is expressed by stromal cells,
dendritic cells (DCs), and macrophages (mΦ) in secondary lymphoid organs (Luther SA
et al., 2000; Ngo VN et al., 1998). Unlike CCL21, CCL19 lacks the extended C-terminal
tail and leads to the phosphorylation, internalization, and desensitization of CCR7 (Kohout
TA et al., 2004; Bardi G et al., 2001; Byers MA et al., 2008). Disparities in signaling may
indicate differences in signaling duration induced upon CCL21 or CCL19 binding to CCR7.
The CCR7/CCL19/CCL21 chemokine axis has numerous functions within the immune
system that are detailed below.
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Figure 5.1. Schematic representation of chemokines CCL21, CCL19, and their receptor,
CCR7.
CCL21 and CCL19 have similar binding affinities to CCR7, a 7-transmembrane G-protein
coupled receptor. CCL21 and CCL19 stimulate chemotaxis, actin polymerization, and
intracellular calcium trafficking via CCR7. However, only CCL19 is able to induce
ERK/arrestin activation as well as the phosphorylation, desensitization, and internalization
of CCR7.

Figure from:
Comerford I, Harata-Lee Y, Bunting MD, Gregor C, Kara EE, McColl SR. A myriad of
functions and complex regulation of the CCR7/CCL19/CCL21 chemokine axis in the
adaptive immune system. Cytokine Growth Factor Rev. 2013; 24: 269-283. Figure used
with permission.
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5.2 CCL21 as a Component of the Immune System

CCR7 and its ligands (CCL19 and CCL21) are essential components of
lymphocyte homing and the regulation of adaptive immunity.

A key function of the

CCR7/CCL19/CCL21 chemokine axis is to facilitate interactions between antigenpresenting cells (APCs) and antigen-specific lymphocytes (Comerford I et al., 2013;
Forster R et al., 2008).

Additionally, this chemokine axis participates in thymocyte

development, regulatory and memory T cell function, secondary lymphoid organogenesis,
and high affinity antibody responses (Comerford I et al., 2013; Forster R et al., 2008, Ohl
L et al., 2004). The expression of CCR7, CCL21, and CCL19 by various cells within the
immune system further demonstrates their functional importance. As shown in Figure
5.2, CCL21 is expressed by medullary thymic epithelial cells (mTECs) and in secondary
lymphoid organs, specifically in HEVs, lymphatic endothelial cells (LECs), and fibroblastic
reticular cells (FRC). In contrast, CCL19 is expressed by FRCs, mature dendritic cells
(DCs) and mTECs. Studies have shown CCR7 expression on DCs, T cell subsets (naïve,
central memory, and regulatory T cells), B cells, natural killer cells (NK), macrophages
(MΦ), and various thymocyte subsets (Comerford I et al., 2013; Sallusto F et al., 1999ac; Muller and Lipp, 2003; Campbell DJ et al., 2003; Forster R et al., 2008, Willimann W et
al., 1998, Misslitz A et al., 2004, Sallusto F et al., 1998a,b; Campbell JJ et al., 2001, Feif
K et al., 2002; Dieu MC et al., 1998; Ato M et al., 2004; Beauvillain C et al., 2011).
Following secretion, chemokines diffuse away as soluble proteins.

However,

chemokines may become tethered to the extracellular matrix or cell surface via
interactions with glycosaminoglycans (GAGs). It is unclear as to whether chemokines are
able to signal through their respective receptors when in a tethered state or if they must
first dissociate from their GAG-associated moorings. The accessibility of GAG-
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Figure 5.2. Expression of CCR7, CCL21, and CCL19 in the immune system.
CCR7 is expression has been reported on a variety of immune cells pertaining to the
adaptive immune system. Subsets of T cells, thymocytes, B cells, macrophages, and DCs
express CCR7. CCL21 is expressed by high endothelial venules (HEVs), lymphatic
endothelial cells (LECs), and fibroblastic reticular cells (FRC). CCL19 is expressed by
FRCs, mature dendritic cells (DCs) and mTECs.

Figure from:
Comerford I, Harata-Lee Y, Bunting MD, Gregor C, Kara EE, McColl SR. A myriad of
functions and complex regulation of the CCR7/CCL19/CCL21 chemokine axis in the
adaptive immune system. Cytokine Growth Factor Rev. 2013; 24: 269-283. Figure used
with permission.
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associated chemokines to leukocytes is also poorly understood. However, chemokineGAG interactions are required for leukocyte adhesion to the luminal surface of endothelial
cells that occurs during leukocyte homing to various tissues and during inflammatory
responses (Rot A 1992; Tanaka Y et al., 1993). Studies have shown that CCL21 and
CCL19 are expressed as soluble molecules; however, only CCL21 is immobilized to
surfaces via its unique C-terminus. The signaling pathways or cellular processes induced
by CCR7 activation are dependent upon the soluble or immobilized form of either CCL19
or CCL21.

5.2.1 Immune Cell Homing is Mediated by the CCR7/CCL19/CCL21 Chemokine Axis.
Immune cells require migration to, from, and within various lymphoid organs for
processes including development, proliferation, and differentiation, as well as to carry out
their respective functions.

CCR7, and other chemokines, organize the trafficking of

immune cells through migration (both through random or directed means) or by stimulating
integrins and subsequently cell adhesion (Schumann K et al., 2010). CCR7 mediated cell
migration, through random adhesion (mediated by immobilized CCL21) or directional
movements via chemokine gradients (orchestrated by soluble CCL21 and CCL19)
generates dynamic and spatially restricted lymphocyte trafficking.

Verification of

CCR7/CCL19/CCL21-mediated homing of DCs and lymphocytes was achieved by studies
utilizing the CCR7-/- and plt (paucity of lymph node T cells) mouse models. The plt mouse
model is deficient in both CCL21 and CCL19. Loss of CCR7 or its ligands resulted in
decreased quantities and distribution irregularities of B and T cells within the spleen,
Peyer’s patches, and lymph nodes (Forster R et al., 1999; Gunn MD et al., 1999; Nakano
H et al., 1998). The generation of an effective immune response requires the sequential
interaction of DCs, T cells, and B cells within secondary lymphoid organs, thus highlighting
the importance of CCR7/CCL19/CCL21-mediated chemotaxis (Cyster JG et al., 1999).
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The CCR7/CCL19/CCL21 chemokine axis facilitates the trafficking of DCs from
peripheral tissues to the lymph node, entrance into the blood, antigen sampling, and cellto-cell interactions (Forster R et al., 2008; Randolph GJ et al., 2005; Alvarez D et al., 2008;
Colonna M et al., 2004). Immature DCs, located in peripheral tissues, encounter and
phagocytose proteins for the production of immunogenic peptides, which are presented
as immunogenic peptides via MHC molecules on the cell surface. Antigen uptake and
cytokine-mediated stimulation induce DC maturation and activation, yielding antigen
presenting cells (APCs) with altered expression of CCR7 (Sallusto F et al., 1998b; Sozzani
S et al., 1998). The upregulation of CCR7 allows for DC entrance into the afferent
lymphatic vessels of the lymphatic system via CCL21 gradients, which are produced by
lymphatic endothelial cells in the peripheral tissue (Figure 5.3) (Dieu M et al., 1998;
Sallusto F et al., 1998b). Once inside the draining lymph nodes, the mature DCs localize
to the subcapsular sinus before moving along FRC networks until reaching T-cell zones
(paracortex) where they interact with naïve lymphocytes (Comerford I et al., 2013).
Studies have identified MAPK family members (ERK1/2, p38, and JNK) and the
Rho/Pyk2/cofilin signaling cascade as downstream targets of CCR7 signaling that mediate
DC trafficking (Figure 5.4) (Riol-Blanco L et al., 2005, Thelen M, 2001; Wong and Fish,
2003). The MAPK family members were found to regulate CCR7-induced chemotaxis,
while Rho/Pyk2/cofilin directed the migratory speed of DCs. CCR7-mediated activation of
the PI3K/AKT signaling cascade prolongs the survival of mature DCs by inhibiting
apoptosis (Sanchez-Sanchez et al., 2004; Sotsios and Ward, 2000; Curnock AP et al.,
2002). CCL21 production by FRCs, which is stimulated by migrating DCs, forms a binding
site on the cell surface and promotes T cell retention in the lymphoid tissues (Wendland
M et al., 2011).
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Figure 5.3. The CCR7/CCL19/CCL21 chemokine axis facilitates the recruitment and
migration of cells to and within the lymph node.
Schematic representation of the structure and cellular composition of the lymph node
along with CCR7-dependent processes. (Top left segment) CCL21 is expressed on
lymphatic endothelial cells (LECs) and acts as an entry signal for DCs to enter the lymph
node via lymphatic vessels in the peripheral tissues. CCR7-mediated trafficking directs
the DCs into the paracortex. (Top right segment) Naïve lymphocytes enter the lymph node
and undergo CCR7-mediated arrest in the HEVs of the paracortex. (Bottom left segment)
Activated B cells in the cortex stimulate CCR7 expression, which allows for B cell migration
towards the T cell-rich paracortex.

Figure from:

Comerford I, Harata-Lee Y, Bunting MD, Gregor C, Kara EE, McColl SR. A myriad of
functions and complex regulation of the CCR7/CCL19/CCL21 chemokine axis in the
adaptive immune system. Cytokine Growth Factor Rev. 2013; 24: 269-283. Figure used
with permission.
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Figure 5.4. Chemotaxis and migratory speed in DCs is mediated by CCR7.
CCR7 signaling induces Gi-mediated activation of ERK1/2 and p38, followed by JNK
activation. This signaling cascade regulates CCR7-dependent chemotaxis. CCR7
signaling mediates Rho and Pyk2 activation and cofilin inactivation. This signaling
cascade was found to mediate the migratory speed of DCs, with speed amplification
occurring upon CCR7 activation. CCR7 also regulates DC survival through activation of
PI3K/AKT signaling.
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CCR7/CCL19/CCL21 expression also mediates the migration and development of
T cells. Naïve lymphocytes differentiate from their lymphoid progenitors within primary
lymphoid organs. Following differentiation, the naïve lymphocytes constantly
recirculate through secondary lymphoid organs searching for their cognate antigen. As
lymphocytes pass through the HEVs, they roll along the vessel walls, interacting with
chemokines on the luminal surface of the endothelium (Stein JV et al., 2000). CCL21 and
other chemokines induce the firm adhesion of lymphocytes to endothelial cells by altering
the affinity and avidity of integrins and intercellular adhesion molecules (Gunn MD; 1998).
In this environment, CCL21 stimulates CCR7+ T cells to arrest in the HEVs of secondary
lymphoid organs (Stein JV et al., 2000; Warnock RA et al., 2000).

The secondary

lymphoid organ provides sites of T cell and DC interactions. If the T cell recognizes its
cognate antigen on passing APCs and receives the appropriate co-stimulatory signal, the
T cell begins to proliferate and differentiate into effector or memory T cells. Studies have
shown a transient upregulation of CCR7 upon activation of the T cell receptor (TCR) and
that the TCR signal threshold decreases upon CCR7 activation by CCL21 (Gollmer K et
al., 2009). These findings suggest that CCR7 may cause transient retention of recently
stimulated naïve or memory T cells in certain areas of the secondary lymphoid organs as
well as act as a co-stimulatory molecule for these T cell subsets (Lipp M et al., 2000;
Sallusto F et al., 1999b; Gollmer K et al., 2009).
B cells undergo CCR7/CCL19/CCL21-mediated homing to lymphoid organs.
Unlike DCs and T cells, B cells can be stimulated to adhere to endothelial cells by other
CCRs in addition to CCR7 (Okada T et al., 2002). B cells upregulate the cell surface
expression of CCR7 once they become antigen primed. This allows for B cells to localize
to the edges of lymph node follicles, thus potentiating the interaction of primed B and T
cells. The precise localization of B cells to the follicle and T cells to the paracortex is
dependent upon a regulated balance of chemokines. The CCR7/CCL19/CCL21 signaling
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axis regulates a broad range of signaling modules and cell types to facilitate the migration
of lymphocytes and DCs.

5.2.2 The CCR7/CCL19/CCL21 Signaling Axis Mediates Thymus Structure and Function.
An adaptive immune response requires self-MHC restricted, non-self reactive T
cells that develop within the thymus. Chemokines stimulate thymocytes to migrate within
the various compartmental niches of the thymus, allowing for lineage differentiation and
clonal selection dependent upon antigen receptor specificity (Figure 5.5) (Bunting MD et
al., 2011). In the thymus, bone marrow-derived precursors develop into T cells by traveling
through the medulla, cortex, and subcapsular zones. During these migratory stages, the
TCR gene loci undergo recombination, CD4 or CD8 lineage is determined, and the
thymocytes undergo positive and negative selection prior to their release as functional,
naïve T cells. Thymocytes of all stages are exposed to CCL19 and CCL21 to facilitate
their trafficking between niches. Studies have found that loss of CCR7 impairs TCR
signaling (Haessler U et al., 2011). The CCR7/CCL19/CCL21 chemokine axis mediates
many stages of T cell development in the thymus and functions in generating a non-selfreactive T cell population.

5.2.3 Lymphoid Organogenesis is Mediated by CCR7/CCL19/CCL21.
Secondary lymphoid organs facilitate antigen accumulation and the priming of
lymphocytes; as such, they are essential for inducing adaptive immune responses.
Studies using the CCR7-/- mouse strain have determined that loss of CCR7 does not
prevent secondary lymphoid organs from developing but it does result in architectural
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Figure 5.5. The role of the CCR7/CCL19/CCL21chemokine axis in the thymus.
CCR7 and its ligands are involved throughout T cell development in the thymus, as shown
in the schematic. (1) Thymocyte precursors express CCR7, allowing them to cross the
cortico-medullary junction and enter the thymus. (2) Double negative (DN) 1 and DN2
cells utilize CCR7 as a method of egress out of the subcapsular zone. The thymic medulla
predominantly expresses CCL21 and CCL19. CCR7 expression is dynamic throughout
the development process as it is lost on thymocytes during the DN3 and DN4 stages (3)
but is re-expressed during positive selection and used to migrate to the medulla. (4) If a
thymocyte passes negative selection, CCR7 expression is maintained and utilized by
mature thymocytes for egress from the thymus.

Figure from:

Comerford I, Harata-Lee Y, Bunting MD, Gregor C, Kara EE, McColl SR. A myriad of
functions and complex regulation of the CCR7/CCL19/CCL21 chemokine axis in the
adaptive immune system. Cytokine Growth Factor Rev. 2013; 24: 269-283. Figure used
with permission.
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defects, particularly in lymphocyte compartmentalization. The development of secondary
lymphoid structures is facilitated, in part by the recruitment of various cells and molecules
by the CCR7/CCL19/CCL21 chemokine axis (Luther SA et al., 2003; Mebius RE, 2003).
Notably, CCL21 has also been found to facilitate the formation of tertiary lymphoid tissues
which resemble secondary lymphoid organs with compartments, HEVs, local activation of
resident stromal cells, and recruitment of DCs and lymphocytes (Figure 5.6) (Ashour AE
et al., 2007; Mueller CG et al., 2018). Ectopic expression of CCL21 can trigger lymphoid
neogenesis, from simple accumulation of B and T cells to highly developed lymphoid
structures complete with cellular niches (Luther SA et al., 2000; Fan L et al., 2000). The
level of immune cell infiltration dictates the organizational extent of the tertiary lymphoid
structures and can occur during chronic infections, atherosclerosis, cancer, and
autoimmune conditions (Aloisi and Pujol-Borrell, 2006). The broad array of functions
exhibited by the CCR7/CCL19/CCL21 signaling axis is critical for proper development and
functioning of the immune system. A simple schematic shown in Figure 5.7 depicts some
of these roles.

5.2.4 CCR7 and CCL21 Modulates Immunity.
CCL21 and CCR7 play essential roles in the induction of an adaptive immune
response. Studies have shown that loss of CCR7 or its ligands results in decreased or
delayed immune responses, especially during periods of limited antigen. The interactions
between DCs and T cells, which occur in the lymph node, were decreased upon loss of
CCR7 (Forster R et al., 1999; Mori S et al., 2001). CCL21, which is bound to lymphatic
vessels, amplifies the trafficking of antigen-laden DCs from the stroma to the lymphatic
system during periods of inflammation (107, 108, 109). As mentioned previously, CCL21
is also required for DC migration through various lymph node compartments, results in the
upregulation of integrins and the adhesion of DCs to the
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Figure 5.6. Schematic of an immune response and formation of tertiary lymphoid
structures.
In tumors with successful induction of an immune response, transcription factors (such as
NF-kB and STAT) regulate chemokines and cytokines needed for tertiary lymphoid
structure formation. Tumors secrete CCL21 and CCL19, which results in the recruitment
of CCR7+ DCs and T cells. CCL21 and CCL19 can also stimulate the T cell secretion of
lymphotoxins that when bound to their respective receptors (LTαβR), stimulate lymph
node formation and augment inflammatory cytokine release from tumors cells. Tumor
cells also secrete CXCL13, which recruits CD4+ CXCR5+ T follicular helper (Tfh) cells and
B cells. B cell differentiation and activation is stimulated by Tfh cells and IL-21, resulting
in anti-tumor memory B cell and plasma cell development and subsequent antibody
production. Tertiary lymphoid structures provide a location for antigen presentation,
activation and differentiation of various immune cell populations, and the induction of antitumor immune responses. Lack of tertiary lymphoid structures and related chemokines
potentiates immune evasion techniques employed by the tumor cells.
Figure from:

Pimenta EM, Barnes BJ. Role of tertiary lymphoid structures (TLS) in anti-tumor immunity:
potential tumor-induced cytokines/chemokines that regulate TLS formation in epithelialderived cancers. Cancers. 2014; 6: 969-997. Figure used with permission.
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Figure 5.7. Schematic of the CCL21/CCR7-mediated functions in the immune system.
Expression of CCR7 on immature DCs, naïve T cells, NK cells, and B cells stimulates
various processes including cellular homing (i.e. to secondary lymphoid organs or the
thymus), maturation, differentiation, and proliferation. This chemokine axis has also been
found to induce organogenesis, resulting in the formation of tertiary lymphoid structures.
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extracellular matrix, stimulates rapid antigen endocytosis by DCs, and promotes DC
survival (Schumann K et al., 2010; Mueller and Ahmed, 2008; Sanchez-Sanchez et al.,
2004; Escribano C et al., 2009). Additionally, CCL21 and CCR7 can act as costimulatory
factors for T cell priming, lower the threshold for T cell activation, and direct T cell
differentiation to a T helper 1 profile with augmented proliferation (Gollmer K et al., 2009;
Flanagan K et al., 2004). Humoral, or antibody-mediated, immune responses require
interactions between B cells and antigen-specific T cells, which occur in the germinal
center or follicular area of secondary lymphoid organs (124). Mouse models have shown
that loss of CCR7 or its ligands results in deficient T cell-dependent antibody responses
(Forster R et al., 1999; Aritomi K et al., 2010). The CCR7/CCL21 signaling axis is also
essential for B cell maturation, proliferation, and differentiation (Reif K et al., 2002; Luther
SA et al., 2000). In addition, the CCR7/CCL19/CCL21 signaling axis can contribute to
tolerance and immune suppression. T regulatory (Treg) cells express CCR7 and utilize
CCL19/CCL21 chemotactic gradients for migration to and from lymphoid organs and
peripheral tissues to induce a localized suppressive environment (Schneider et al., 2007;
Menning A et al., 2007; Ueha S et al., 2007).

Overall, the CCR7/CCL19/CCL21

chemokine axis mediates a broad array of cellular processes needed for proper
development and induction of immune responses.

5.3 CCL21 in Cancer

Chemokines exhibit essential functions for the benefit or detriment of cancer
development and can modulate tumor initiation, angiogenesis, invasion, and metastases.
Tumor-associated immune responses are dependent upon the quantity and type of
chemokines expressed by tumor and stromal cells as well as the subsequent infiltration of
immune cells. As shown in Figure 5.8, tumor-secreted cytokines
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Figure 5.8. Chemokine networks and cellular associations in cancer.
Tumors directly secrete chemokines that act upon innate and adaptive immune cells,
subsequently stimulating tumor progression (indicated in red, right-side panel) or inhibiting
tumor development (indicated in green, left-side panel). (Bottom right) Tumor-associated
macrophages, monocytes, and granulocytes that promote metastatic spread are shown in
red while granulocytes that inhibit metastases are shown in green. In tertiary lymphoid
structures immunostimulating (bottom left) are shown in green while tolerogenic
interactions (bottom middle) are shown in red. Abbreviations: MDSCs, myeloid-derived
suppressor cells; TAMs, tumor-associated macrophages; TILs, tumor-infiltrating
lymphocytes; ActT, activated T lymphocytes; DC, dendritic cells; Treg, regulatory T
lymphocytes.

Figure from:

Viola A, Sarukhan A, Bronte V, Molon B. The pros and cons of chemokines in tumor
immunology. Cell. 2012; 33(10): 496-504. Figure used with permission.
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demonstrate an intricate network of signaling cascades and interactions. The spatial and
temporal arrangement of chemokines in the local microenvironment can enhance
angiogenesis, tumor growth, and recruitment of immunosuppressive immune cells into the
tumor (Galvez BG et al., 2005; Singh S et al., 2011). Chemokines secreted by tumor cells,
cancer-associated fibroblasts, and infiltrating leukocytes can stimulate growth and
proliferation through induction of PI3K/AKT/NK-kB or MAPK/ERK signaling cascades or
by inhibiting pro-apoptotic molecules such as caspases 3 and 9 (Teicher and Fricker,
2010; Balkwill F, 2004; Lian K et al., 2018). Tumor cells can appropriate chemokine
receptors and utilize chemokine ligands for trafficking, adhesion, and survival for
metastatic progression (Zlotnik A et al., 2011). Expression of inflammatory cytokines
(such as CCL2, CCL3, CXCL2, CXCL5, etc.) can induce the recruitment of monocytes
and neutrophils to the tumor microenvironment and stimulate their differentiation into
tumor-associated macrophages or tumor-associated neutrophils (Balkwill FR, 2012;
Caronni N et al., 2016; Massara M et al., 2017).
CXCL9 and CXCL10 are chemokines that have been associated with a Th1
immune response and when expressed in the tumor microenvironment, stimulate antitumor immune responses by recruiting NK cells, CD4+ Th1 cells, and CD8+ cytotoxic
lymphocytes (Wendel M et al., 2008; Hensbergen PJ et al., 2005). Studies have shown
that type I and II interferons are able to inhibit angiogenesis, proliferation and migration
while recruiting innate and adaptive immune cells such as NK cells and CXCR3expressing tumor-infiltrating lymphocytes (Romagnani P et al., 2001; Andreu P et al.,
2010; Ohtani H et al., 2009). A positive feedback loop within the tumor microenvironment
has also been reported and consists of infiltrating Th1 CD4+ T cells, CD8+ T cells, and NK
cells that induce interferon gamma (IFN-γ) secretion, augmenting tumor cell production of
CXC chemokines and subsequently limiting neoangiogenesis (Strieter et al., 2006).
Additionally, chemokine-induced formation of tertiary lymphoid structures can improve
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patient survival and facilitate the activation of tumor-specific T cells (Dieu-Nosiean M-C et
al., 2008; Coronella J et al., 2002; Deola S et al., 2008). Chemokines are multifaceted in
nature and CCL21 has demonstrated cancer-specific pro- and anti-tumor functions.
The CCR7/CCL19/CCL21 chemokine axis has demonstrated aberrant regulation
and functionality in various cancer types. Overexpression of CCR7 can lead to increased
lymphogenesis, migration and invasion. CCR7 signaling has been shown to promote
epithelial-to-mesenchymal transition in gastric cancer and oral squamous cell carcinoma
(Ma H et al., 2015; Ryu H et al., 2018; Chen Y et al., 2020). A correlation between poor
prognosis and increased expression of CCR7, in addition to increased metastasis, has
been reported in lymphomas and oral squamous cell carcinoma as well as in urinary
bladder, cervical, colorectal, esophageal, and prostate cancers

(Xiong Y et al., 2017a;

Xiong Y et al., 2017b; Mo M et al., 2015; Kodama J et al., 2007; Pitkin L et al., 2007; Li J
et al., 2011; Sun RH et al., 2009; Schimanski CC et al., 2005; Yang Y et al., 2011; Fleige
H et al., 2018; Cai Q-Y et al., 2017; Goto and Liu, 2019; Shi M et al,. 2015; Makino T et
al., 2019; Maolake A et al., 2019; Chen Y et al., 2020). Overexpression of CCR7 in various
cancers has led to targeting CCR7 as a cancer therapy. Studies have found that inhibition
of CCR7 can reduce metastatic spread in colon carcinoma and breast cancer, inhibit
prostate cancer growth, and decrease brain metastases in T cell acute lymphoblastic
leukemia (Yu S et al., 2008; Chi B-J et al., 2015; Cunningham H et al., 2014; Kim S-J et
al., 2012). Preclinical models are currently evaluating the use of CCR7 inhibition via
siRNA for efficacy in metastatic colorectal carcinoma and prostate cancer (Yu S et al.,
2008; Chi B-J et al., 2015).
In other cancer types, such as Ewing’s sarcoma, renal cell carcinoma, and lung
cancer, CCL21/CCR7 signaling has demonstrated anti-tumor properties (Xiong y et al.,
2017b; Sand LGL et al., 2016; Sharma S et al., 2001; Yousefieh N et al., 2009; Kar UK et
al., 2011).

An inverse correlation between CCL21 expression and metastases was
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observed in Ewing’s sarcoma (Sand LGL et al., 2016).

Additionally, high CCL21

expression was associated with enhanced responses to chemotherapy, decreased
metastases and improved survival. In renal cell carcinoma, low expression of CCL21 was
associated with shorter overall and progression free survival (Xiong y et al., 2017b). In a
clinical study, colon cancer patients had a better prognostic value if their tumors
demonstrated a high level of infiltrating CD8+ CCR7+ cytotoxic T cells compared to patients
with low infiltration of CCR7+ and regulatory lymphocyte cells (Correale P et al., 2012).
Similar findings were reported in patients with renal cell carcinoma as tumor expression
of CCL21 resulted in increased accumulation of mature DCs and proliferating T-cells
(Middel P et al., 2010). Notably, in patients with non-small cell lung cancer, the presence
of tertiary lymphoid structures correlated with improved patient survival (Dieu-Nosjean MC
et al., 2008). In a hepatocellular carcinoma model, tumor secretion of CCL21 resulted in
delayed tumor progression and increased accumulation and activation of DCs and CD4+
and CD8+ T cells (Liang CM et al., 2007). Overall, the role of CCL21 in tumor development
and progression is multifaceted and complex. Induction of an effective immune response
is very intricate, requiring numerous components and interactions (Figure 5.9).

The

promotive or inhibitory actions of CCL21 are likely dependent on the tumor itself and on
microenvironmental cues as well as the timing and quantity of CCL21 expressed. Many
studies have promoted the development of CCL21 as an anti-tumor therapy.

5.4 CCL21 as an Immunotherapy in Cancer
CCL21 has been included in the National Cancer Institute’s list (13 out of 20) of
ranked biological agents with potential for use as a cancer therapy. The CCL21/CCR7
chemokine axis has been studied for its role(s) in cancer immunology due to its ability to
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Figure 5.9. Schematic representation of an anti-tumor immune response and the
chemokine network involved.
Dendritic cells (DCs) and macrophages (MΦ) recognize pathogen-associated molecular
patterns (PAMP) and release various chemokines as a result of this stimulus. The
secreted chemokines then recruit and activate MΦ, natural killer (NK), and natural killer T
cells (NKT), which are able to carry out tumor cell lysis. DCs are able to phagocytose
apoptotic tumor cells and peptides before trafficking to the lymph node via
CCR7/CCL19/CCL21 chemokine axis for antigen presentation. The mature DCs now
function as antigen presenting cells (APCs) and present tumor antigens (ag) to T cells.
Upon activation and stimulation, cytotoxic T lymphocytes (CTLs) are able to infiltrate and
eradicate tumors. Chemokines can also recruit immunosuppressive immune cells such
as Tregs and myeloid derived suppressor cells (MDSCs) into the tumor microenvironment.

Figure from:

Franciszkiewicz K, Boissonnas A, Boutet M, Combadiere C, Mami-Chouaib F. Role of
chemokines and chemokine receptors in shaping the effector phase of the antitumor
immune response. Cancer Res. 2012; 72: 6325-6332. Figure used with permission.
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attract DCs, T cells, and NK cells.

As many cancers exhibit poor immunogenicity,

therapies capable of augmenting the host’s immune response and overcoming immune
suppressive and evasive maneuvers are needed. The Dubinett and Sharma group has
contributed a large body of work dedicated to investigating CCL21, in various modalities,
as an immunotherapy for lung cancer. The administration of recombinant CCL21 induced
a T cell-dependent anti-tumor response in a syngeneic mouse model of lung cancer that
consisted of DC, CD4+ and CD8+ T cell infiltration into the tumor and draining lymph nodes
(Sharma S et al., 2000). The anti-tumor immune response generated by CCL21 therapy
required both CD4+ and CD8+ T cell subsets and corresponded to an increase in IFN-γ,
CXCL9, CXCL10, IL-12, and GM-CSF with a concomitant decrease in PGE-2 and TGF-β
(Sharma S et al., 2013; Sharma S et al., 2003; Yang SC et al., 2004). Augmented cytolysis
abilities were exhibited by lymphocytes from CCL21-treated mice (Sharma S et al., 2000).
In recent years, the use of a vault nanocapsule containing CCL21 was found to increase
DC and T cell infiltration while decreasing myeloid derived suppressor cells (MDSC) and
Tregs (Kar UK et al., 2011). A phase I clinical trial utilized intratumoral CCL21 genemodified autologous DC therapy in lung cancer and found the agent to be well tolerated
with an enhanced immune response and tumor growth inhibition (Sharma S et al., 2020).
Increased CD8+ T cell infiltration into the tumor was observed along with increased IFN-γ
production (Lee JM et al., 2017). The use of a polymer-based delivery system for CCL21
or chemotherapy drugs for the treatment of head and neck squamous cell carcinoma in
order to inhibit tumor recurrence was also investigated (Hu D et al., 2012; Pellionisz PA et
al., 2018; Lin Y et al., 2014). With the Lewis lung cancer model, CCL21 vault nanoparticles
were utilized to induce antitumor immune responses and to inhibit tumor growth (Kar UK
et al., 2011).
Studies from our lab have demonstrated the efficacy of intratumoral CCL21
therapy in murine models of pancreatic and mammary cancers with increased infiltration
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of DCs, T cells, NK cells, and natural killer T cells (NKT) into tumor tissues and
concomitant decreases in tumor growth and metastastic spread (Turnquist HR et al., 2007;
Ashour AE et al., 2007a,b). We have also reported on the use of CCL21 as an effective
surgical neoadjuvant in a mouse model of mammary cancer (Ashour AE et al., 2007b).
Other groups have shown successful induction of anti-tumor immune responses following
treatment with CCL21 in ovarian tumors and fibrosarcoma models (Nomura T et al., 2001).
CCL21 has strong potential as a cancer immunotherapy agent due to its ability to recruit
anti-tumor immune cell populations (DCs, NKT, T cells) and to stimulate tertiary lymphoid
organogenesis, resulting in decreased or abrogated tumor growth.

5.5 Dissertation Hypothesis: Part II
Investigating CCL21 as a novel immunotherapy has been an evolving field for the
past two decades.

The development of novel immunotherapies is fascinating and

necessary for the improvement of therapeutic efficacy, especially for the treatment of solid
tumors. Neuroblastoma is a cancer of the sympathetic nervous system that occurs
predominantly in early childhood and represents 6% of all pediatric cancer cases (Siegel
RL et al., 2020). In children, neuroblastoma is the most common extracranial solid tumor
diagnosed, and it results in 12-15% of all pediatric cancer-related deaths (Brodeur GM,
2003; Maris JM, 2010; Johnsen JI et al., 2018; Park JR et al., 2009). Neuroblastoma
staging takes into account DNA ploidy, histological features, genetic alterations, and
clinical data (as specified by the International Neuroblastoma Risk group) to define classes
of risk as being low, intermediate, or high (Monclair T et al., 2009; Cohn SL et al., 2009).
Patients with high-risk disease have a low 5-year survival rate of <50% (Monclair
T et al., 2009; Cohn SL et al., 2009; Davidoff AM, 2012). Aggressive treatment strategies
utilizing radiation, chemotherapy, surgery, and hematopoietic stem cell transplantation are

125
severely limited in their abilities to prolong the lives of children diagnosed with advanced
stage neuroblastoma or relapse/recurrent disease, and for patients who have relapsed the
5-year survival is only 20% (Lau L et al., 2004; Li R et al., 2017; Matthay KK et al., 1999;
Matthay KK et al., 2009; London WB et al., 2011; Zage PE, 2018).

Survivors of

neuroblastoma have been shown to experience long-term toxicities (secondary
malignancies, failure to grow, hearing loss, hypothyroidism, renal toxicities, and ovarian
failure) and even increased mortality as a result of their treatments (Oeffinger KC et al.,
2006; Applebaum MA et al., 2017; Mertens AC et al. 2001; Laverdiere C et al., 2005;
Perwein T et al., 2011).
Innovative

treatment

strategies

for

neuroblastoma

are

needed,

and

immunotherapies tend to have milder side effects than chemotherapies or radiation
therapies, which makes them attractive for use in pediatric patients. Several studies have
shown neuroblastoma cells to be susceptible to killing by immune cells, such as natural
killer cells and T cells (Bausero MA et al., 1996; Rousseau FG et al., 2003; Singh N et al.,
2015, Navid F et al., 2009; Zenarruzabeitia O et al., 2017; Spel L et al., 2015; Semeraro
M et al., 2015; Wang W et al., 2015; Rujkijyanont P et al., 2013). Efficacious anti-tumor
immune responses are dependent upon APCs, lymphocytes, and other effector cell types.
For those reasons, I chose to utilize CCL21 and a syngeneic mouse model of
neuroblastoma for my dissertation work. The overall aim was to determine how prolonged
intratumoral delivery of CCL21 modulates tumor growth and immune responses. CCL21
was selected due to its multifaceted nature and ability to recruit and colocalize immune
effector cells into the tumor microenvironment.
Initial studies in our laboratory determined the kinetics and responding immune cell
types to subcutaneous injection of CCL21. Populations of DCs and effector T cells within
local lymph nodes were increased by day 4 post injection (Ashour AE et al., 2007b).
Importantly, we observed the formation of small structures (tertiary lymphoid organs) in
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the injection areas at day 4 post injections (Ashour AE et al., 2007b). Intratumoral
administration of CCL21 resulted in significantly higher immune cell infiltrates and
decreased tumor growth in a murine pancreatic tumor model utilizing subcutaneous (SC)
Panc02 tumors (Turnquist H et al., 2007). Flow cytometry and confocal analysis revealed
that CCL21 treatment induced infiltration of tumors by DCs, T cells, NK cells, and NKT
cells. The antitumor effect induced by CCL21 intratumoral therapy was immunologically
mediated, transferrable to naïve mice via splenocytes, and able to inhibit primary tumor
growth as well as metastatic spread (Turnquist H et al., 2007). In an orthotopic mammary
tumor model, we found that CCL21 intratumoral administration decreased tumor growth,
increased DC, NK, and T cell infiltration into the tumor, and prolonged the survival of tumor
bearing mice (Ashour AE et al., 2007a).
Based on our previous findings, we collaborated with the Bronich laboratory to
generate a slow release nanoparticle capable of delivering CCL21 or therapeutic agent
directly into the tumor. We hypothesized that prolonged release of CCL21 would facilitate
a sustained influx of APCs and immune effector cells into the tumor, thus inhibiting tumor
growth while stimulating a robust antitumor immune response in a manner that was
superior to CCL21 alone.

Studies were carried out to optimize the nanoparticle

components, release rates, and batch reproducibility.

Fluorescent dyes and in vivo

imaging were employed to assess the localization and persistence of CCL21 and
nanoparticles following intratumoral administration. Use of a syngeneic mouse model with
subcutaneous injection of Neuro2a cells allowed for alterations in tumor growth and
immune cell infiltrates to be determined. The varied capabilities of CCL21 (chemotaxis of
immune effector cells, subsequent evocation of immune responses, augmentation of
chemotherapy effectiveness, and improved functionality of DCs and cytotoxic T cells)
strongly support CCL21’s development and use as a therapeutic agent.
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Chapter 6: Materials and Methods

Data in this chapter have been published in the following manuscript:
Poelaert BJ, Romanova S, Knoche SM, Olson MT, Sliker BH, Smits K, Dickey BL, MoffittHolida AEJ, Goet BT, Khan N, Smith L, Band H, Mohs AM, Coulter DW, Bronich TK,
Solheim JC. Nanoformulation of CCL21 greatly increases its effectiveness as an
Immunotherapy for Neuroblastoma. Journal of Controlled Release. 2020; In press.
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6.1 CCL21

Lyophilized recombinant murine CCL21 (stored at -20° C) from Peprotech (Rocky
Hill, NJ) was reconstituted in either sterile buffer control (phosphate-buffered saline [PBS],
from

GE

Healthcare

Life

Sciences,

Marlborough,

MA)

or

purified

water

(Barnstead/Thermolyne Nanopure Water System, Dubuque, TX). Reconstituted CCL21
was stored at 4°C until use.

6.2 Nanoparticle Formulation and Characterization
6.2.1 Standard Gelation Processes
The alginate nanoparticles were made by Dr. Svetlana Romanova in the Bronich
laboratory at UNMC via standard ionotropic gelation processes (Figure 6.1) using a
diluted stock solution of alginic acid sodium salt (pH 8.0, medium viscosity, obtained from
Sigma-Aldrich, St. Louis, MO), which adopted a pre-gel formation upon addition of calcium
counter ions (calcium chloride, Thermo Fisher Scientific, Hampton, NH). A polyelectrolyte
complex was then formed with the incorporation of protamine sulfate (MP Biomedicals,
Santa Ana, CA).
In brief, an alginate aqueous solution (1.0 mL of a 1.5 mg/mL solution) was gently
mixed at 4°C with 250 µg (for a 6:1 alginate : protein ratio) or 25 µg (for a 60:1 alginate :
protein ratio) of cytochrome c or CCL21. For formulations that included Pluronic F127,
100 µl of a 10% w/w solution of Pluronic F127 (Thermo Fisher Scientific) was added to
the alginate mixture and stirred for an additional 10 minutes following an initial period (5
minutes) of mild agitation at 4°C 300 rpm. The stirring speed was
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Figure 6.1. Schematic representation of the formulation process of protein (cytochrome
C or CCL21) – loaded alginate nanoparticles via ionotropic gelation.
An aqueous solution of alginate, protein, and Pluronic F127 were combined prior to the
addion of CaCl2, which induces the formation of cross-linked matrices in a pre-gelation
state. Addition of Pluronic F127 strengthened the matrices of the alginate nanoparticles
and prolonged the release of the protein payload. Incorporation of protamine sulfate
allowed for the formation of a polyelectrolyte complex, stabilizing the alginate pre-gel
nucleus into individual particles.

Schematic diagram by Dr. Tatiana Bronich, UNMC.
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Figure 6.1
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adjusted to 800 rpm before 125 µl of a 2 mg/mL solution of CaCl2 was added drop by drop
to induce gelation of the alginate mixture. After 30 min of the gelation process,
protamine sulfate (75 µl of a 2 mg/mL solution) was incorporated and the resultant, slightly
opalescent dispersions were stirred for an additional 1 h (800 rpm, 4ºC) to complete
formation of the nanoparticles. Simultaneously, with each batch of protein-containing
nanoparticles, empty nanoparticles (at the same concentrations of alginate, CaCl2,
protamine sulfate, and Pluronic F127) were prepared as a control. All nanoparticles, with
or without protein cargo, were stored at 4°C until use.

6.2.2 Diameter, Polydispersity, and Distribution
Protein-loaded and empty alginate nanoparticles were characterized by dynamic
light scattering (DLS) for intensity-weighted z-averaged hydrodynamic diameter (Deff, nm)
and polydispersity index (PDI), and by Nanoparticle Tracking Analysis for numberweighted diameter and particle concentration. DLS measurements were performed in
PBS at 25°C and at a fixed 173° scattering angle using a Nano ZS Zetasizer (Malvern
Instruments, Worcestershire, UK). Software provided by the manufacturer (Zetasizer
software Version 7.11, Malvern Panalytical) was used to calculate the Deff and PDI. In
addition, the hydrodynamic diameter of the particles was measured using the field flow
fractionation technique (FFF) coupled to an online DLS detector (Eclipse DualTech
Asymmetric FFF System, Wyatt Technology, Santa Barbara, CA). Particle dispersion in
PBS (1.35 mg/mL) was injected through a 50 µL loop into AS4 channel (350 µm spacer
W type, 10 kDa regenerated cellulose membrane) and PBS was used as a mobile phase.
After a focus step at 1 mL/minute, a gradient elution exerting a cross-flow decreasing
exponentially between 3 mL/minute and 0 mL/minute was applied for 9 minutes (detector
flow: 0.8 mL/minute). The hydrodynamic diameter of the particles was determined in the

132
elution window between 5 and 7 minutes using the Astra 7.1.3 software provided by the
manufacturer. For Nanoparticle Tracking Analysis, samples were diluted 10X with PBS
and measurements were done with a NanoSight NS300TM (Malvern Instruments) at 25°C.
Five individual videos (60 sec duration each) for every sample were recorded and
analyzed using the Nanoparticle Tracking Analysis Software Version 3.2.

6.2.3 Transmission Electron Microscopy and Atomic Force Microscopy
The morphology of the alginate nanoparticles was studied using transmission
electron microscopy (TEM). Samples for TEM imaging were spotted onto formvar/silicon
monoxide-coated 200 mesh copper grids. Grids were glow discharged for 60 seconds at
20 μA with a GloQube glow discharge unit prior to use. Samples were negatively stained
with NanoVan and examined on a Tecnai G2 Spirit TWIN (FEI, Hillsboro, OR) operating
at an accelerating voltage of 80 kV. Images were acquired digitally with an AMT (Woburn,
MA) digital imaging system.

Cryo-transmission electron microscopy (cryo-TEM)

measurements were performed on alginate NPs prepared at a concentration of 2 mg/ml
in distilled water. Sample preparation for cryo-TEM was done in a temperature and
humidity-controlled chamber using a fully automated vitrification robot (Vitrobot, FEI Co.,
Hillsboro, OR). A thin aqueous film of nanoparticle solution was formed on a carbon grid
at 22°C and at 100% relative humidity. The thin film was rapidly vitrified by shooting the
grid into liquid ethane. The grids with the vitrified thin films were transferred into the
microscope chamber. Micrographs were taken using a FEI Tecnai F30 microscope
operating at 300 kV, equipped with Gatan 626 cryo-holder with α +/- 70° tilt range and
ability to keep samples at -170°C during imaging.
The morphology of the alginate nanoparticles was also analyzed by atomic force
microscopy (AFM). Samples for AFM imaging were prepared by depositing 5 µL of an
aqueous dispersion of nanoparticles (concentration 2.5 x 10-3 mg/mL) onto positively
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charged 1-(3-aminopropyl) silatrane mica (APS-mica) surfaces for 2 min, followed by
surface drying under argon atmosphere. AFM imaging was performed in air with a
Multimode NanoScope IV system (Veeco, Santa Barbara, CA) operating in a typing mode
and silicon probes (spring constant of 42 N/m).

Femtoscan software (Advanced

Technologies Center, Moscow, Russia) was used to characterize nanoparticle
dimensions.

6.2.4 Encapsulation and Loading Efficiency
To measure the encapsulation efficiency and loading capacity for cytochrome c,
1.0 mL of each formulation was centrifuged at 10,000 rpm (30,000 x g) for 30 min at 4ºC
in a Beckman Coulter Optima L-90K ultracentrifuge, the supernatant was carefully
collected without disturbing the pellet, and absorbance values were measured with the
NanoDrop spectrophotometer to determine the amount of free cytochrome c in the
supernatant. The concentration of cytochrome c in the supernatant was determined by
UV/Vis (absorbance max at Soret band, 409 nm) and calculated using a standard curve.
For calculation of encapsulation efficiency, the following formula was used: encapsulation
efficiency (EE%) = [mass of protein in alginate nanoparticles/mass of initial protein added]
X 100%. To calculate the loading capacity, this formula was used: loading capacity (LC%)
= [mass of protein in alginate nanoparticles/mass of the alginate nanoparticles] X 100%.
An enzyme-linked immunosorbent assay (ELISA) was used to determine the efficiency of
CCL21 loading into the nanoparticles. Fresh samples of alginate nanoparticles with
CCL21 cargo were centrifuged at 35,000 rpm (122,000 x g) in a Beckman Coulter Optima
L-90K ultracentrifuge for 40 min at 4ºC. After centrifugation, the supernatant samples
were tested by ELISA per the manufacturer’s protocol, using a Molecular Devices
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SpectraMax microplate reader with comparison to known levels of CCL21 in a standard
curve (established with recombinant murine CCL21).

6.2.5 Loading and Release via Dialysis Assay and Enzyme-Linked Immunosorbent Assay
(ELISA)
A membrane dialysis method was used in vitro to simulate cytochrome c or CCL21
release in vivo. The nanoparticle formulation (1 mL of each formulation) was placed into
a 50 kDa Float-A-Lyzer dialysis tube, submerged in a 50 mL conical vial containing 45 mL
of PBS (pH 7.4), and incubated at 37°C with constant shaking at 100 rpm. At specified
time points, an aliquot of PBS was removed from the outer volume of the dialysis
apparatus and replaced with an equivalent amount of fresh PBS to maintain a constant
volume in the tube. The dialysate samples were concentrated by 60 min centrifugation at
4°C, 1,200 rpm (314 x g) in a Sorvall Legend X1R centrifuge (Thermo Scientific) to
approximately 500 μL using an Amicon 3000 Da protein concentrator before analysis. The
amount of cytochrome c released at each time point was determined by measuring
absorbance at 450 nm with a NanoDrop spectrophotometer (Thermo Fisher Scientific).
ELISA was used to quantify the amount of CCL21 released over time from the
nanoparticles during dialysis. For either cytochrome c or CCL21, the amount of protein
released from the alginate nanoparticles was expressed as a percentage of the total
loaded protein and plotted as a function of time.

6.3 Cell line, Culture Conditions, and a Mouse Model
6.3.1 Mouse Neuroblastoma Cell Line: Neuro2a
Neuro2a cells (clonal derivative of a spontaneous tumor, C1300) were thawed from
a bank of low passage, parental stock vials and subcultured no more than 5 times before
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use in vivo with a syngeneic mouse (A/J) strain [63-64]. The Neuro2a cells were cultured
in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with the following additives:
1 mM sodium pyruvate, 100 units/mL penicillin and 100 μg/mL streptomycin, 2 mM Lglutamine, 100X MEM Non-Essential Amino Acids, along with 10% v/v heat- inactivated
fetal bovine serum.
6.3.2 Mouse Strain: A/J
Female A/J mice, 4 weeks of age, were purchased from Jackson Laboratories (Bar
Harbor, ME) and acclimated to their new, pathogen-free environment for 2 weeks before
study initiation. All experiments were performed according to the Institutional Animal Care
and Use (IACUC) protocol.

6.4 Tumor Cell Injections, Administration of Treatments, and Monitoring

6.4.1 Injection of Tumor Cells
Neuro2a cells, passaged no more than 5 times, were trypsinized and resuspended
in sterile PBS. Cell viability of at least 95% was determined via trypan blue staining. The
prepared cell suspensions were stored on ice until use, with gentle agitation/inversion
used to ensure uniform suspension and no aggregation immediately prior to injection.
The A/J mice were subcutaneously injected with 1 X 106 Neuro2a cells/100 µL PBS in the
lower right flank using a tuberculin syringe with 25G needle. Mice subjected to rechallenge
by tumor cells, or mice used as naïve age-matched controls, received an injection of 1 X
106 Neuro2a cells/100 µL PBS in the lower left flank using the same preparations
described above.
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6.4.2 Intratumoral Treatment
Upon detection of palpable tumors (volume ³ 50 mm3), which occurred
approximately 9-12 days post-implantation, the mice were divided into blinded treatment
or control groups (n ³ 6 mice/group per experimental replicate), with the groups having
matched average tumor volumes. The nanoformulated CCL21 treatment or controls were
administered intratumorally twice daily (in the morning and evening for 2 consecutive days
(days 0 and 1), providing 6 µg of CCL21/25 µL, or 6 µg of CCL21 in nanoformulation/25
µL per dose, or an equal amount of empty nanoparticles/25 µL, or an equal volume (25
µL) of buffer.

6.4.3 Assessing Tumor Growth and the Survival of Tumor-Bearing Mice
Visual quartering of the tumor allowed for equal distribution of injection sites and
treatment delivery. Figure 6.2 depicts the strategy used throughout the in vivo studies
performed.

The mice were monitored for 54 days, at least 3 times weekly, with

documentation of tumor growth and overall health (weight, food/water consumption, and
any indications of reduced mobility or responsiveness). Survival time indicates the number
of days until tumors reach a volume of 1000 mm3 (per IACUC requirements) and the mice
were euthanized. Tumor volume (in mm3) was determined using caliper measurements
(in 2 perpendicular directions) and the following formula: (tumor width2) X (tumor length/2).
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Figure 6.2. Strategy for evaluating the therapeutic efficacy of nanoformulated CCL21 in
a murine neuroblastoma model.
Neuro2a cells (1 X 106 cells/100 μL) were subcutaneously injected into the lower right
flank of female A/J mice and, after palpable tumor formation, the mice were randomly
sorted into blinded treatment groups with groups having matched average tumor volumes
(n ≥ 6 mice per group). The mice received intratumoral injections of the respective
therapeutic agent twice daily for two consecutive days, delivering 6 μg CCL21/25 μL, or 6
μg of CCL21 in nanoformulation/25 μL per dose, or an equivalent amount of empty
nanoparticles/25 uL, or the equivalent volume of buffer. To facilitate equal distribution of
the injection sites, as well as equal disbursement of the treatments, tumors were visually
quartered, and injections were placed as indicated. This strategy was employed for three
replicate studies.
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Figure 6.2
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6.5 Fluorescent Dye Tagging
CCL21 amino groups were labeled with IR800 dye. In brief, 500 µg (1.05 µmole
of amino groups) were labeled with NHS-active form of IR800 dye (6.13 µg, 0.5% mol. in
2 mL water).

The reaction was stirred overnight at room temperature before the

unconjugated dye was removed by dialyses against water. Protein recovery was achieved
through lyophilization and stored at -20°C prior to use. The labeled CCL21 was then used
in the nanoformulation process as described above.
6.6 Fluorescent Imaging
A/J mice received intratumoral injections of the nanoparticles, free CCL21, or
buffer control (as detailed above). Images in vivo were collected on the Pearl® Trilogy
Small Animal Imaging System over a 120-hour time course (pre-injection and at 24, 48,
72, 96, and 120 hours following treatment initiation). Upon conclusion of the study, tumors,
various organs (kidney, spleen, and liver) and draining lymph nodes were collected from
the euthanized mice for imaging. The images were analyzed using Image Studio software
version 5.0 (LI-COR Biosciences; Lincoln, NE). Briefly, a region of interest was manually
drawn around the tumor or necropsied organ or lymph node to obtain the mean fluorescent
signal. Differences between treatment groups were calculated with GraphPad Prism
software version 7.03.

6.7 Fluorescent Microscopy
Necropsied tissues were embedded in Optimal Cutting Temperature Compound
(OCT) and stored at -20°C until processing for histology. Tissues were cut into 10 µm
sections using a cryostat (Leica, Buffalo Grove, IL), and mounted on charged microscope
slides. The slides were imaged with an Olympus DP80 Digital Camera and CellSense
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Dimension Software in the 800 nm channel to detect the presence of the nanoparticle and
CCL21 (respectively).

6.8 Analysis of Cell Viability

Cell viability was assessed via trypan blue staining.

In brief, the cells were

collected, resuspended with trypan blue stain, and counted using a hemocytometer. The
cells, both live and dead, were counted and analyzed to determine the percentage of live
cells using the following formula: total number of live cells / the total number of cells.

6.9 Flow Cytometry Analysis

Direct immunofluorescent staining was used to analyze immune cell populations
in tumor samples. Neuro2a tumor-bearing female mice (n >5 mice per group) were treated
intratumorally with CCL21 only, nanoformulated CCL21, or buffer control. Following
excision, each tumor was gently rinsed 2-3 times with sterile PBS. On the last rinse, most
of the PBS was removed, such that less than 1 mL of PBS remained. The tumor was
minced into small pieces using two sterile razor blades, transferred to a 15 mL conical with
digestion media (DMEM + 10% FBS, 2 mg/mL Collagenase A, and 0.25 units/mL DNase
I), and incubated for 45 minutes at 37ºC with constant shaking. The tumor mixture was
then transferred to a pre-moistened sterile 40 µm cell strainer attached to a 50 mL sterile
conical tube and macerated through the strainer using the back of a syringe plunger. The
cell strainer was then washed 3 times with ~5 mL of sterile PBS per wash before
centrifugation of the tube at 1,500 rpm (453 x g), 4ºC, for 5 min in an Eppendorf 5810R
centrifuge. The supernatant was decanted, and the pellet was resuspended in 2 mL of
ammonium-chloride-potassium (ACK) buffer to lyse erythrocytes. After incubation of the
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suspension in the ACK buffer at room temperature for 5 min, 30 mL of PBS was added
and the suspension was centrifuged at 1,500 rpm (453 x g), 4ºC, for 5 min. The cells were
resuspended in PBS, and cell number and viability were determined by mixing a small
aliquot of the cell suspension with 0.4% trypan blue and counting the cells in the mixture
on a hemocytometer. Viability of the cells was determined to be at least 95% prior to flow
cytometry.
Throughout the staining process, the cells and reagents were kept on ice and
protected from light. The cells were stained with antibodies against surface markers of
macrophages, DCs, NK cells, NKT cells, T cells, and B cells (see Fig. 6.3 and Table 6.1
for antibody lists, dilutions, and clone information).

Cells were also stained with

LIVE/DEAD Fixable Blue Dead Cell Stain following the manufacturer’s protocol to assess
cell viability. In brief, the digested tumor samples were resuspended in 500 µL of PBS
before being dispersed equally (100 µL of tumor cell suspension per panel) into the 4
immunoprofiling panels with the additional 100 µL being incorporated into a pooled sample
for use in control wells (i.e. unstained cells, fluorescents minus one, etc.). The cells were
washed 3x with 100 µL PBS and centrifuged at 1,500 rpm (453 x g), 4ºC, for 5 min. The
cells were then resuspended in 100 µL of the antibody cocktail and incubated for 30
minutes at 4ºC, protected from light. After incubation, the cells were washed 3x with 100
µL PBS and centrifuged at 1,500 rpm (453 x g), 4ºC, for 5 min prior to fixation in 1%
paraformaldehyde in PBS. The stained cells were processed using the BD LSRII flow
cytometer (Franklin Lakes, NJ) and analyzed by FlowJo software (Ashland, OR). The
percentage of each lymphocyte population within a tumor was calculated as % CD45+ =
(number of cells positive for a specific marker)/(total number of cells) X 100.

The

percentages of T cells, DCs, NK cells, and macrophages were calculated as % marker =
(number of cells marker positive)/(number of live cells) X 100.
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Figure 6.3. Schematic of the immunophenotyping strategy that was used to characterize
the frequencies of immune cells within treated neuroblastoma tumors.
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Figure 6.3
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Table 6.1 Markers used for immunophenotyping.
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6.10 Multiplex Proteome Array
To investigate differences in cytokine profiles, a 2 mm x 2 mm tumor biopsy was
acquired from each mouse (that had been treated with nano-CCL21, free CCL21, or buffer
only) at the time of necropsy. Each biopsied tumor was plated in 1 well of a 12-well plate
in 2 mL of base medium (DMEM) and incubated at 37ºC for 72 hours to allow for cytokine
secretion. After incubation, the samples were centrifuged at 1,500 rpm (453 x g) for 5
minutes at 4ºC followed by collection of the culture supernatant. The culture supernatant
samples were then stored at -20ºC. Prior to analysis, the culture supernatant samples
were thawed and approximately 300 µL of culture supernatant from each mouse was
pooled into a total volume of 2 mL per time point per treatment group. Each pooled culture
supernatant sample was then concentrated using the Amicon Ultra-2 Ultracel-3 (Sigma)
centrifugal filter unit per the manufacturer’s protocol by loading it into the Ultra-2 device
and centrifuging for 40 minutes at 4,454 rpm (4,000 x g). The concentrated culture
supernatant sample was recovered with an additional centrifugation at 2,227 rpm (1,000
x g) for 2 minutes. The concentrated samples were then used to determine cytokine
profiles for each treatment group.
The concentrated, pooled tumor culture supernatant from each treatment group
(buffer control, nanoformulated CCL21, and CCL21 alone) at day 2 and day 7 post
treatment were analyzed via the Proteome Profiler Mouse Cytokine Array Kit, Panel A
(R&D Systems) as directed by the manufacturer. Briefly, a mixture of concentrated culture
supernatant and antibody cocktail solution was prepared and incubated for 1 hour at room
temperature followed by incubation with a membrane overnight at 4ºC on a shaking
platform. The membranes were washed 3x for 10 minutes each before incubation in a
Streptavidin-HRP solution for 30 minutes at room temperature on a rocking platform.
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Another series of washes was performed before visualization using the provided Chemi
Reagent solution and Bio-rad Gel Doc Documentation system.

6.11 Statistical Analysis
6.11.1 Linear Mixed Model Analysis
Linear Mixed Models analysis, IBM SPSS Statistics version 25 (Armonk, NY), was
used to compare tumor growth rates between treatment groups over time. A first-order
autoregressive covariance structure was used to model the covariance structure between
mice. The model included fixed effects for treatment group, day, and the group x day
interaction where day is modeled as a continuous variable.

6.11.2 Kaplan-Meier Survival Distributions
Survival distributions were assessed via Kaplan-Meier plots and log-rank test.
Reaching a tumor volume of 1000 mm3 or a time period of 54 days post-treatment initiation
was each designated as an experimental endpoint. Mice alive at the completion of the
study are treated as censored. The log-rank test allowed for the comparison of survival
distributions between groups.

6.11.3 Two-Way ANOVA
Two-way ANOVA analysis in GraphPad Prism Version 8 (San Diego, CA) was
used to compare the mean fluorescent intensity levels in imaging experiments, the
presence of immune cell populations with the tumors, and mean pixel densities of
Proteome Profiler array results for cytokine assessments. Multiple comparisons across
treatment groups, as well as across separate time points for the same treatment group,
were also determined via two-way ANOVA.
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6.11.4 Statistical Significance
All p values of £ 0.05 were considered to indicate statistical significance. Asterisks
were used to denote levels of significance and are as follows: p ≤ 0.05 (*), p ≤ 0.01 (**),
p ≤ 0.001 (***), p ≤ 0.0001 (****).
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Chapter 7: Nanoformulation of CCL21 and Its Efficacy as an Intratumoral
Immunotherapy

Data in this chapter have been published in the following manuscript:
Poelaert BJ, Romanova S, Knoche SM, Olson MT, Sliker BH, Smits K, Dickey BL, MoffittHolida AEJ, Goet BT, Khan N, Smith L, Band H, Mohs AM, Coulter DW, Bronich TK,
Solheim JC. Nanoformulation of CCL21 greatly increases its effectiveness as an
Immunotherapy for Neuroblastoma. Journal of Controlled Release. 2020; In press.
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7.1 Introduction to Alginate and the Nanoformulation Process
Sustained drug release can contribute to the rate and extent of availability of
therapeutic agents, which are crucial factors for treatment efficacy. The aim of any drug
delivery system is to provide a therapeutic amount of the drug to specific sites within the
body in order to maintain the desired drug concentration over a period of time, thus leading
to a more pronounced effect. Drug delivery systems that allow sustained release provide
promising approaches for better control over the concentration of therapeutic agents. Such
tactics not only allow for preserving the therapeutic efficacy of the treatment agent(s) but
can also potentially reduce the frequency of drug administration or the fluctuation of drug
levels, thereby resulting in a shorter treatment period. Drug delivery systems are rapidly
evolving to provide novel treatment strategies with reduced dosage and administration
frequency, improved control over treatment release, and enhanced therapeutic efficacy.
In this context, encapsulation of CCL21 into implantable devices or particulate
systems as chemokine depots may provide better control over the duration of its
chemotactic gradient. Liposomes and poly(lactide-co-glycolide) (PLGA) microspheres or
nanoparticles are the most extensively explored as particulate platforms for local cytokine
delivery (Christian and Hunter, 2012). While a number of studies demonstrated the
promise of these strategies for anticancer immunotherapies, the challenge for these
formulations is related to relatively low protein loading. In this study, we have designed
novel alginate nanoparticles that combine a drug-encapsulating matrix with the beneficial
effects of a sustained release formulation. Alginate, a derivative of brown seaweed, is a
naturally occurring polysaccharide that contains 1-4’-linked b-D-mannuronic acid (M) and
a-L-guluronic acid (G) residues that form alternating homo-polymeric block regions.
Alginate has a negative charge at neutral pH, and in the presence of divalent cations such
as calcium ions (Ca2+) that bind specifically to blocks of G residues, it forms a cross-linked
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gel (Lee and Mooney, 2012). This polymer has been approved by the Food and Drug
Administration as a component in various products for use in the treatment of wounds,
tissue engineering, and drug delivery (Lee and Mooney, 2012; Kuo and Ma, 2001;
Tonnesen and Karlsen, 2002).

Properties such as biocompatibility, mild gelation

conditions, low cost, and minimal toxicity allow for its extensive medical usage (Gombotz
and Wee, 1998). Additionally, alginate-based microspheres have previously been tested
for encapsulation and in vitro release of chemokines, including CCL21 (Wang and Irvine,
2011). Therefore, providing sustained release of CCL21 in the neuroblastoma tumor
environment should allow for the continuance of an influx of immune cells over a prolonged
period of time, and thereby improve the immunological and therapeutic effects beyond
what might be attainable with CCL21 alone.

7.2 Optimization and Characterization of the Alginate Nanoparticles
Production, optimization and characterization of the alginate nanoparticles was
performed by Dr. Svetlana Romanova, Bronich Laboratory, UNMC. CCL21 release, as
determined by ELISA, was performed by Kaitlin Smits.

7.2.1 Component Ratio Optimization Allowed for the Generation of Uniform, Stable
Nanoparticles
Various nanoparticle formulations were generated and analyzed to define the
optimum ratios of alginate-to-CaCl2, alginate-to-protein, alginate-to-protamine sulfate, and
the optimal percentage of Pluronic F127. In early formulation studies, cytochrome c was
used due to its relatively low cost and to its almost identical molecular weight (CCL21 12.3
kD vs. cytochrome c 12.4 kD) and very similar isoelectric point (CCL21 10.13 versus
cytochrome c 10.10) in comparison to CCL21. Pluronic F127 was not incorporated in
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these early formulations. Since the ratio of sodium alginate to CaCl2 in a nanoformulation
could influence particle size and dispersity, nanoparticles with varied mass ratios of
alginate to CaCl2 [NaAlg : CaCl2] from 2 to 20) were assessed by DLS to determine the
impact of this parameter. At all given ratios, formation of nanoparticles was observed
(Figure 7.1A). However, particles with monomodal and relatively narrow particle size
distribution (PDI < 0.2) were formed in the range of ratios between 4 and 8. Above this
ratio, dual and poly-size distributions were detected on DLS, while below this ratio the
formation of aggregates was pronounced. Based on these data, we selected the [NaAlg
: CaCl2] = 6:1 (w/w) that corresponds to formation of stable nanoparticles with 180 nm
diameter and uniform particle size distribution.
Prior to establishing the final protamine sulfate concentration, alginate to protamine
sulfate ratios [NaAlg : PSU] over a range from 20:1 to 2:1 (w/w) were analyzed for use in
the nanoformulation.

Optimization of protamine sulfate was done at a constant

concentration of CaCl2, added for gelation. The size of the particles was practically
unchanged in the [NaAlg : PSU] range from 12.5 to 8. Using a higher concentration of
protamine sulfate in the reaction mixture led to particle aggregation, while at [NaAlg : PSU]
> 12.5 the amount of protamine sulfate was not sufficient to form stable nanoparticle
dispersions. Thus, the ratio [NaAlg : PSU] = 10 was set for the alginate nanoparticle
formulation.

This ratio appeared optimal for achieving unimodal distribution and

minimizing alginate nanoparticle size (Figure 7.1B). In preliminary experiments, Pluronic
F127 was tested over a range of 0.1% to 1.0% in the alginate nanoformulation process.
We determined that the concentration of 1% Pluronic F127 resulted in stable nanoparticles
with low PDI and small diameter (Figure 7.1C).
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7.2.2 Addition of Pluronic F127, as a Nanoparticle Component, Prolonged Protein Release
and Improved Encapsulation Efficiency and Loading Capacity
To investigate protein release rates from our alginate nanoparticles, we tested 4
formulations, which consisted of different alginate : cytochrome c ratios (60:1 w/w versus
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Figure 7.1. Optimization of nanoformulation component ratios.
(A) Optimization of the ratio of sodium alginate (NaAlg) to CaCl2. (B) Optimization of the
ratio of NaAlg to protamine sulfate (PSU). (C) Optimization of the percentage of F127
pluronic. (D) Stability of the alginate nanoformulation over a period of time (the
nanoformulation was stable for up to 2 months).

Figure generated by Dr. Svetlana Romanova, Bronich Laboratory, UNMC.
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6:1 w/w) with or without 1% w/w Pluronic F127, in a dialysis assay at 37°C, pH 7.4 for a
prolonged period of time (up to 15 days), which enabled us to simulate CCL21 secretion
in vitro (Figure 7.2A). The amount of cytochrome c released at each time point was then
determined by spectrophotometric analysis. Faster release of cytochrome c was exhibited
by formulations lacking Pluronic F127 when comparing the same protein : alginate ratios
(i.e. cyt. C. (60:1) vs cyt. C. (60:1) + F127, as indicated in Figure 7.2A). The (60:1)
alginate : cytochrome c formulation without Pluronic F127 had the fastest release rate,
followed by the (60:1) alginate : cytochrome c formulation with Pluronic F127. The addition
of Pluronic F127 prolonged the release of cytochrome c from the nanoparticles, as
indicated by the decreased amount of released cytochrome c across all time points tested
when comparing similar protein : alginate ratios. The (6:1) alginate : cytochrome c
formulation without Pluronic F127 released cytochrome c at an even more delayed rate,
while the (6:1) alginate : cytochrome c formulation with Pluronic F127 released
cytochrome c yet more slowly.

Overall, the alginate : cytochrome c (6:1) + F127

nanoformulation had the slowest rate of release across all 4 formulations tested. The
release results for the alginate : cytochrome c (6:1) + F127 nanoformulation obtained with
the dialysis assay were also confirmed by the incubation method (Figure 7.2B).
In addition to assessing the rate of release at the varied alginate : cytochrome c
ratios and in the presence versus absence of Pluronic F127, we also analyzed the
influence of these parameters on the encapsulation efficiency and loading capacity of the
nanoparticles. At a (60:1) alginate : cytochrome c ratio, in the presence versus absence
of Pluronic F127, the encapsulation efficiency and loading capacity were 56.0% and 1.5%
(respectively) versus 44.0% and 1.1%. At a (6:1) alginate : cytochrome c ratio, in the
presence versus absence of Pluronic F127, the encapsulation efficiency and loading
capacity were 99.2% and 17.7% (respectively) versus 87.2% and 18.0% (Table 7.1).
Thus, with the (6:1) alginate : cytochrome c ratio, in the presence versus absence
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Figure 7.2. Sustained release of protein cargo from the alginate nanoparticles was
demonstrated.
(A) Inclusion of Pluronic F127 and reduction of the alginate : protein ratio prolonged protein
cargo release from the nanoparticles. Cytochrome C release rates were determined in
vitro to define the optimum alginate : protein ratio and impact of Pluronic F127 (1% w/w)
inclusion in the nanoparticles. For these formulations, ratios of alginate : cytochrome c at
60:1 or 6:1 were compared, either with or without 1% Pluronic F127. All of the
nanoformulations also included CaCL2 and protamine sulfate. The nanoformulations,
along with free cytochrome c as a control, were subjected to dynamic dialysis at 37ºC, pH
7.4, and cytochrome c release was monitored by spectrophotometric analysis of aliquots
from the dialysate. Similar results were obtained in experiments and repeated 4 times for
the F127-containing formulation and 3 times for the formulations without F127, using
freshly prepared formulations each time and making independent release measurements
for each of the formulation batches. (B) Cytochrome c-loaded alginate nanoparticles
(formulation alginate : cytochrome c 6:1+F127) were prepared, using 50 μg of cytochrome
c for encapsulation. The nanoparticles were concentrated (5X) and resuspended in PBS
(pH 7.4). The solution was divided into several 1 mL aliquots and the initial cytochrome c
concentration was determined (~ 6 μg/mL). The remaining aliquots were incubated at
37ºC in a water bath. At predetermined time points, the suspension was centrifuged at
10,000 rpm (30,000 x g) for 30 minutes at 4ºC to separate the nanoparticle pellets and
supernatants, and the concentration of cytochrome c in each of the supernatants was
determined. All measurements were taken in triplicate.

Figure generated by Dr. Svetlana Romanova, Bronich Laboratory, UNMC.
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Table 7.1 Evaluation of encapsulation efficiency (EE) and loading capacity (LC) of alginate
nanoparticles.

Table generated by Dr. Svetlana Romanova, Bronich Laboratory, UNMC.

160
of Pluronic F127, the encapsulation efficiency was much improved. In the presence of
Pluronic F127, the encapsulation efficiency was particularly high (99.2%). For the
remainder of the experiments described in this report, all nanoformulations were prepared
with Pluronic F127 (at 1% w/w), alginate : CaCl2 at a ratio of 6:1, alginate: protamine
sulfate ratio of 10:1, and an alginate : protein ratio of 6:1, since this was the best overall
combination for prolonged release, excellent encapsulation efficiency, and optimal loading
capacity.

7.2.3 Nanoparticle Loading and CCL21 Release
ELISA was used to assess the efficiency of CCL21 loading. After encapsulation,
alginate nanoparticles bearing CCL21 were ultracentrifuged and the supernatant from the
centrifugation was collected and analyzed by ELISA (in comparison to a CCL21 standard
curve made with known concentrations). Only trace amounts of CCL21 (<1%) were
detected in the supernatant, indicating that the efficiency of loading was very high (~99%).
For CCL21-loaded alginate nanoparticles, we determined the release rate by
dialysis assay at physiological temperature (37°C) followed by ELISA. The percentage of
CCL21 released was calculated using the line of equations generated by the CCL21
standards. As expected, a similar cumulative, prolonged release of CCL21 was observed
upon 37°C incubation of the corresponding alginate : CCL21 nanoparticle formulation
(containing Pluronic F127) as seen in our previous findings using the (6:1) alginate :
cytochrome c nanoparticles that included Pluronic F127 (Figure 7.3).

161
Figure 7.3. Alginate nanoparticles release CCL21 over an extended period of time.
CCL21 release, from the alginate nanoparticle, was assayed by dialysis at 37°C, using
PBS, pH 7.4, followed by enzyme-linked immunosorbent assay (ELISA).
Figure generated by Kaitlin Smits, Solheim Laboratory, UNMC
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7.2.4 Alginate Nanoparticles Demonstrated Spherical Shape, Unimodal Size Distributions,
and Neutral Charge
Our analysis of optimized formulations by DLS revealed that the empty and
protein-loaded alginate nanoparticles were < 200 nm in size and had approximately
neutral zeta-potential (pH 7.4). Representative values for the sizes of the empty and
protein-loaded nanoparticles are shown in Table 7.2. The empty alginate nanoparticles
had a hydrodynamic diameter of 176 ± 5 nm with a PDI value of 0.18, which was the
largest of the formulations tested. The cytochrome c-loaded alginate nanoparticles had a
diameter of 164 ± 1 nm with a PDI value of 0.11, and the alginate nanoparticles loaded
with CCL21 measured 158 ± 3 nm in diameter and had a PDI value of 0.16. Uniform
distribution and similarities in size were confirmed by Nanoparticle Tracking Analysis
(Table 7.2).

Furthermore, the protein-loaded nanoparticles remained stable in

dispersions; no changes in size or PDI were detected for at least 2 months upon storage
at 4°C (Figure 7.1D).
Visualization of alginate nanoparticles, in both empty and loaded states, was
accomplished using AFM and TEM.

A representative AFM image of nanoparticles

containing CCL21 is shown in Figure 7.4A, and similar AFM results for nanoparticles
loaded with cytochrome c and for empty nanoparticles are in Figure 7.5. TEM images are
also displayed in Figure 7.4 and Figure 7.5, including both empty nanoparticles (Figure
7.4B) and nanoparticles bearing CCL21 (Figure 7.4C). The images demonstrate that
both the empty and CCL21-loaded nanoparticles were well dispersed and had relatively
uniform diameters of ~50 nm by TEM and 163 nm by cryo-TEM (Table 7.2). (It is important
to note that, in air, imaging typically results in decreased dimensions due to the drying
process.) Taken together, the image analysis demonstrated that the nanoparticles were
round in shape, had narrow size distributions, and formed little to no aggregates across
all 3 formulations.
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Table 7.2 Physicochemical characteristics of alginate nanoparticles.

Table generated by Dr. Svetlana Romanova, Bronich Laboratory, UNMC.
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Figure 7.4. AFM and TEM demonstrated uniform, spherical alginate nanoparticle
structures with minimal to no aggregation.
The picture shown in (A) is a representative tapping- mode AFM image of CCL21containing alginate nanoparticles deposited from aqueous solution onto APS-mica. The
panels shown in (B) and (C) display TEM-negative staining of the empty alginate
nanoparticles and CCL21-loaded nanoparticles, respectively.

Figure generated by Dr. Svetlana Romanova, Bronich Laboratory, UNMC.
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Figure 7.5. Additional AFM imaging.
Tapping mode AFM images in air of (A) empty alginate nanoparticles and (B) cytochrome
c-loaded alginate nanoparticles. Samples for the AFM imaging were deposited on APS
mica from aqueous solutions and dried without washing. In both (A) and (B), the scale bar
indicates 200 nm. (C) Cryo-TEM image of cytochrome c-loaded alginate nanoparticles are
displayed (scale bar in left panel = 200 nm). The right panel shows a magnified inset from
the left panel.

Figure generated by Dr. Svetlana Romanova, Bronich Laboratory, UNMC.
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7.3 In vivo Application of Nanoformulated CCL21 Inhibited Tumor Growth and
Increased Survival

7.3.1 Introduction to Neuroblastoma and the Study Model
We examined the therapeutic efficacy of intratumoral injection of the alginatenanoformulated CCL21 on neuroblastoma tumor growth in a mouse model in 3 separate
experiments, which each included 4 treatment groups: nanoformulated CCL21-treated
mice (n = 21), CCL21-treated mice (n = 20), empty nanoparticle-treated mice (n = 12), or
buffer control-treated mice (n = 12). In our studies, the survival endpoint was defined as
a tumor volume of 1000 mm3 or day 54 post-treatment initiation. As described in detail
below, the 3 replications yielded consistent results in agent tolerability, tumor growth rates,
and modulations in survival, thus validating our experimental strategy and the therapeutic
efficacy of the CCL21 nanoformulation.

7.3.2 Nanoformulated CCL21’s Effect on Neuroblastoma Tumor Growth and Survival
As shown in Figure 7.6A, nanoformulated CCL21-treated mice had a significantly
(p < 0.001) slower tumor growth rate (6.5 mm3 average increase/day) compared to mice
that received buffer control (72.0 mm3 average increase/day), empty nanoparticles (80.3
mm3 average increase/day), or CCL21 alone (73.8 mm3 average increase/day).
Importantly, in 33% of the nanoformulated CCL21-treated mice, the palpable tumors
completely regressed, in contrast to the mice treated with buffer, nanoparticles alone, or
CCL21 alone (Figure 7.6).

Treatment with nanoformulated CCL21 did not cause

significant changes in mouse weight over time (as shown in Figure 7.7A up to day 8 posttreatment initiation, which was the time that the first mouse reached the tumor volume
endpoint and was euthanized). The tumors were removed
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Figure 7.6. Intratumoral treatment with nanoformulated CCL21 caused complete
regression in 7 out of 21 Neuro2a tumor-bearing mice treated with nanoformulated CC21,
and the average tumor growth was slower for nanoformulated CCL21-treated mice
compared to controls.
Tumors were initiated by subcutaneous injection of 1 X 106 Neuro2a cells/100 µL PBS into
the lower right flank, allowed to grow until palpable, and then treated as described in
Section 2. Materials and methods. (A) Average tumor volumes over time are shown for
mice treated with buffer control, empty nanoparticles, nanoformulated CCL21, or CCL21.
The tumor growth rate was significantly slower for nanoformulated CCL21-treated mice (p
< 0.001) as compared to mice that were administered buffer control, empty nanoparticles,
or CCL21 alone. Tumors were measured in 2 perpendicular directions with a caliper at
least 3 times weekly. Tumor volumes were calculated as tumor width2 X tumor length/2,
and they were averaged across treatment groups and compared using Linear Mixed
Models analysis. The bars represent standard deviation. Mice were euthanized if the
tumor volume reached 1000 mm3. The data shown are a cumulative representation of 3
independent experiments. (B) Percent change in tumor volume from baseline was
calculated via the following formula (final tumor volume – initial tumor volume)/initial tumor
volume X 100, where the final tumor volume was 1000 mm3 or the tumor volume at 54
days post treatment initiation. If a tumor failed to be detected via palpation or necropsy at
day 54 post treatment initiation, a tumor volume of 0 mm3 was entered as the final volume.
The initial tumor volume (day 0) was set as the baseline and is indicated graphically as
0%. Tumors that had smaller initial volumes (~50 mm3) showed the greatest percent
change from baseline while tumors with slightly larger volumes demonstrated smaller
percent changes. All treatment groups exhibit positive changes in tumor growth from
baseline, which indicates increasing tumor volume over time following treatment initiation.
Most notably, only nanoformulated CCL21 therapy was able to induce complete tumor
regression in a subset of mice (n = 7). The regressed subset is graphically depicted as a
negative percent (-100%) due to the tumor shrinking past a palpable stage and failure to
be detected upon necropsy. Therefore, the change in tumor volume from baseline in mice
with regressed tumors was found to be -100 %. (C, D, E, F) The changes in tumor volumes
for each mouse treated with (C) nanoformulated CCL21, (D) buffer control, (E) empty
nanoparticles, or (F) CCL21 alone are shown. After treatment, the mice were monitored
and their tumors were measured at least 3 times weekly until their tumor burdens reached
1000 mm3, and the mice with regressed tumors were monitored until day 54.
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Figure 7.7. Average mouse weight was not significantly affected upon intratumoral
treatment with nanoformulated CCL21, but average tumor weight was significantly
reduced (due to tumor regression in some of the mice).
(A) Mouse weights were monitored for the duration of the experiment, and are depicted
here until day 8 post-treatment, which was the first day that a mouse reached an endpoint
criterion. (B) Primary tumors were resected and weighed at the time of euthanasia of each
mouse (once the tumor reached 1000 mm3), and the weights are shown here. The twotailed t-test was used for comparison of the tumor weights. Nanoformulated CCL21 versus
buffer control p = 0.019, versus empty nanoparticles p = 0.0049, and versus CCL21 p =
0.0052. Statistical significance was defined as p < 0.05* and p < 0.01**. For both (A) and
(B), the bars represent the mean and SD.
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from all the mice at the time of necropsy and weighed (with regressed tumors
counted as weighing 0 g) (Figure 7.7B).
Figure 7.8 depicts the survival distributions of all 4 treatment groups.
Nanoformulated CCL21 significantly prolonged survival in tumor-bearing mice, compared
to those treated with buffer control (p = 0.008), empty nanoparticles (p = 0.002), or CCL21
only (p = 0.003). Mice treated with nanoformulated CCL21 had a mean survival time (i.e.,
average duration of survival post-treatment initiation) of 26 ± 4.2 days, which was
significantly longer than the mean survival of mice that received buffer control (11 ± 0.8
days), empty nanoparticles (11 ± 1.2 days), or CCL21 alone (12 ± 1.3 days).

7.4 Nanoformulated CCL21 Induced a Systemic, Protective Response

To determine whether an immune response was induced in the mice that had
experienced complete tumor regression, we challenged all the nanoformulated CCL21treated mice that had undergone complete tumor regression by subcutaneous injection of
Neuro2a neuroblastoma cells into the lower left flank (opposite to the original injection site
of Neuro2a cells) on day 54 post-treatment. In parallel, treatment-naïve, age- and sexmatched (female) mice were subcutaneously injected with Neuro2a cells in the lower left
flank. The mice were then monitored daily for the emergence and growth of palpable
tumors (tumor volume ³50 mm3; Figure 7.9). All other treatment groups (buffer control,
empty nanoparticles, and free CCL21) failed to induce complete tumor clearance following
the initial treatment cycle, and therefore there were no mice from those other groups that
could be included in the rechallenge studies.
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Figure 7.8. Survival distributions of tumor-bearing mice were significantly prolonged by
nanoformulated CCL21 treatment.
A/J mice bearing subcutaneous Neuro2a neuroblastoma tumors received intratumoral
therapy with one of the following agents: nanoformulated CCL21 (n=21), CCL21 alone
(n=20), empty nanoparticles (n=12), or buffer control (n=12). After receiving the
treatments, the mice were monitored at least 3 times weekly until their tumor burdens
reached 1000 mm3 or 54 days had elapsed since treatment initiation (day 0).
Nanoformulated CCL21-treated mice survived significantly longer than mice treated with
buffer control (p = 0.008), empty nanoparticles (p = 0.002), or CCL21 alone (p = 0.003).
Kaplan-Meier and log-rank analyses were used to compare survival distributions of mice
between treatment groups. Survival distributions were generated using Kaplan-Meier
Survival Methods and portray cumulative survival in time (days), where day 0 indicates
treatment initiation, not the implantation of tumor cells. Mean survival time post-treatment
initiation ± standard deviation was determined for each treatment group. These data are
a cumulative representation of 3 independent experiments.
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Figure 7.9. Systemic, protective, antitumor responses were observed in a subset of
nanoformulated CCL21-treated mice, a phenomenon not seen with the other treatments
tested.
The subset of cured, nanoformulated CCL21-treated mice (tumor free at day 54, n = 7)
were rechallenged with subcutaneous injection of 1 X 106 Neuro2a cells/100 µL PBS into
the lower left flank (opposite to the initial site of Neuro2a cell injection and intratumoral
treatment). A group of treatment naïve, age- and sex-matched A/J mice were challenged
in parallel. The cured, nanoformulated CCL21-treated, rechallenged mice failed to
develop tumors by the experimental end point (day 70), unlike their age-matched,
treatment naïve counterparts, which developed palpable, steadily growing tumors. The
graph displays tumor growth over time, with the challenge (second challenge for cured
mice, initial challenge for treatment naïve, age-matched controls) date indicated as day 0.
The tumors were measured in 2 perpendicular directions using a caliper at least 3 times
weekly. Tumor volumes were calculated as tumor width2 X tumor length/2, averaged
across treatment groups, and compared using Linear Mixed Models analysis. The bars
represent the standard error of the mean. The data shown consist of a cumulative
representation of 3 independent experiments.
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The mice that were formerly nanoformulated CCL21-treated and that had showed
complete tumor regression remained tumor free upon rechallenge by subcutaneous tumor
cell injection of Neuro2A cells (Figure 7.9). In contrast, the tumor cell-injected, treatmentnaïve control group developed palpable, steadily growing tumors at approximately 8 days
post-injection with Neuro2a cells (p = 0.05; Figure 7.9). Furthermore, the mice in which
the tumors had completely regressed had no detectable metastatic disease following
rechallenge (as demonstrated by necropsy at day 70 post treatment). These results
suggest that nanoformulated CCL21, when administered as an intratumoral therapy, is
capable of inducing durable, systemic antitumor protection.

7.5 Intratumoral Retention and Clearance of Nanoformulated CCL21

To determine the level of CCL21 in the tumor following administration via the
nanoformulation, CCL21 was fluorescently labeled with IR800 for visualization in vivo in
the 800 nm channel with the Pearl® Trilogy Small Animal Imaging System. Three groups
(n = 5 mice/group) were analyzed in this study: buffer control, CCL21 labeled with IR800
(IR800-CCL21), and nanoformulated IR800-CCL21 (Nanoparticles + IR800-CCL21).
Prior to testing in the mice, Nanoparticles + IR800-CCL21 were characterized by DLS
analysis for determination of the diameter (average Deff = 169 nm) and PDI (average PDI
= 0.17), confirming unimodal distribution and similar diameter to nanoformulated
unlabeled CCL21.
We examined the intratumoral persistence of the injected Nanoparticles + IR800CCL21 and the IR800-CCL21 (as compared to buffer control), using the same Neuro2a
subcutaneous model of neuroblastoma as described above. In brief, the each group
received twice daily injections (one dose in the morning and one dose in the evening) for
two consecutive days, delivering 25 µL per dose of buffer control, IR800-CCL21, or
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Nanoparticles + IR800-CCL21, respectively. The treatment strategy employed is shown
in Figure 6.1. Imaging was performed immediately after each intratumoral injection
followed by imaging once daily for 5 consecutive days. The strongest fluorescent signal
was observed immediately following the treatments with labeled nanoformulated CCL21
(Figure 7.10A, Figure 7.10B). Since our treatment regimen consists of 4 treatments over
a 2-day period, the marginally (p = 0.0810) increased retention of Nanoparticles + IR800CCL21 relative to IR800-CCL21 at the time of initial imaging (day 0, at 4 hours following
the last injection) suggests a very early trend toward nanoformulation-induced potentiation
of CCL21 intratumoral accumulation. In comparison with mice treated either with IR800CCL21 or with buffer, the mice treated with the fluorescently labeled, nanoformulated
CCL21 (Nanoparticles + IR800-CCL21) exhibited significantly amplified CCL21 presence
in comparison to IR800-CCL21 at days 1 and 2 after the cessation of treatment (p = 0.0005
at day 1 and 0.0241 at day 2) (Figure 7.10B). Prolonged fluorescence, indicating CCL21
presence, was detectable by in vivo imaging for at least 120 hours for both the
Nanoparticles + IR800-CCL21-treated mice and the IR800-CCL21-treated mice.
After monitoring the fluorescence intensity over time for all of the mice, at 120
hours we performed necropsies to determine which organs were being utilized for
clearance of the nanoparticle components. As shown in Figure 7.10C and Figure 7.10D,
the kidneys exhibited more fluorescence than the liver, spleen, or draining lymph nodes,
and thus appear to be functioning as the main clearance organ for the labeled CCL21 (for
both the Nanoparticles + IR800-CCL21-treated mice and the IR800-CCL21-treated mice).
Notably, at 120 hours, the tumors of Nanoparticles + IR800-CCL21-treated mice had
significantly more fluorescence versus the kidneys (p = 0.0009 for kidney 1 and p = 0.0020
for kidney 2), indicating that a greater proportion of the CCL21 was still held in the tumor
rather than cleared. In contrast, the tumors of the IR800-
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Figure 7.10. Fluorescently labeled CCL21 delivered to neuroblastoma tumors in
nanoparticles was found to be present at a higher level at day 1 and day 2 following
treatment, as compared to fluorescently labeled CCL21 delivered alone.
The mean fluorescent signal of IR800 dye was visualized in the 800 nm channel by the
Pearl Trilogy Small Animal Imaging System for 5 days post-treatment initiation in mice
bearing subcutaneous neuroblastoma tumors that were treated with Nanoparticles +
IR800-CCL21 or with IR800- CCL21. In parallel, a group of mice injected with nonfluorescently labeled buffer control were imaged and used as a negative control. (A)
Representative images of treated mice are shown. (B) Mice receiving the Nanoparticles +
IR800-CCL21 (nanoformulated CCL21) demonstrated the highest mean intratumoral
fluorescent signal over time, with significantly higher fluorescent intensity at day 1 (p =
0.0005) and day 2 (p = 0.0241) when compared to the IR800-CCL21-treated mice. The
mean fluorescent signal was marginally (p = 0.0810) higher at day 0 in mice treated with
the Nanoparticles + IR800-CCL21. Two-way ANOVA analysis was used to assess
differences in the intratumoral mean fluorescent signal in vivo at 800 nm. (C) Imaging of
fluorescently labeled CCL21 delivered in nanoparticles (Nanoparticles + IR800-CCL21)
and fluorescently labeled CCL21 (IR800-CCL21) within neuroblastoma tumors, as well as
in various organs (spleen, kidney, liver, and lymph nodes), was performed at the time of
necropsy, 5 days post-treatment initiation, using the Pearl Trilogy Small Animal Imaging
System. (D) Nanoparticles + IR800-CCL21-treated mice exhibited a trend towards the
highest mean fluorescent signal in the 800 nm channel in the tumor, spleen, and kidney
specimens. Minimal signal in the liver, lymph nodes, and spleen indicate that the
fluorescently labeled CCL21 (either alone or in nanoformulation) is cleared through the
kidneys following intratumoral administration. Two-way ANOVA analysis was used to
assess differences in the mean fluorescent signal (800 nm) of organs from mice treated
with Nanoparticles + IR800-CCL21, IR800-CCL21, and buffer control. Statistical
significance is defined as p < 0.05*, p < 0.01**, p < 0.001***, and p < 0.0001****.
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CCL21-treated mice were not significantly more fluorescent than the kidneys (p = 0.5592
for kidney 1 and 0.5344 for kidney 2) at 120 hours.

7.6 Effects of Nanoformulated CCL21 on Infiltrating Intratumoral Immune Cells
To investigate the fluctuations of immune cell populations within treated
neuroblastoma tumors, as a step toward understanding why nanoformulated CCL21 had
better therapeutic efficacy than CCL21 alone, we again utilized the neuroblastoma mouse
model described above and compared nanoformulated CCL21, CCL21 alone, or buffer
control (n = 5-10 mice per group) at days 2, 3, and 7 post treatment initiation. Flow
cytometry analysis using antibody panels (Figure 6.1, Table 6.1) allowed for
immunophenotypic profiling based on surface marker expression on infiltrating immune
cells within the tumor.

7.6.1 Frequencies of Intratumoral Total Leukocytes, NK Cells, and NKT Cells were
Significantly Elevated in both the Nanoformulated CCL21 and CCL21 Treatment Groups
The frequency of leukocytes (identified by the CD45 marker) was significantly
higher (p < 0.0001) at day 2 post-treatment initiation in both the nanoformulated CCL21
and CCL21-alone treatment groups in comparison to tumors treated with buffer control
(Figure 7.11). Analysis of the CD45+ cell population frequencies at day 3 post-treatment
initiation also revealed significantly increased percentages of CD45+ cells in the
nanoformulated CCL21 treatment group (p = 0.019) and in the CCL21 treatment group (p
= 0.009) versus the control group. At day 7, similar percentages of CD45+ cell frequencies
were observed in all groups.
NK and NKT cell populations demonstrated increased frequencies in
nanoformulated CCL21 and CCL21-treated groups (compared to buffer control) over
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Figure 7.11. Elevated frequencies of CD45+ cells were observed in tumors treated with
either nanoformulated CCL21 or CCL21 in comparison to the control.
The frequency of CD45+ cells was significantly (p < 0.0001) higher in tumors treated with
either nanoformulated CCL21 or CCL21 compared to those treated with buffer control at
day 2 post treatment initiation. Significantly higher percentages of CD45+ cells were also
seen at day 3 post treatment in nanoformulated CCL21-treated tumors (p = 0.0190) or
CCL21-treated tumors (p = 0.0090) compared to the control. Gating strategy for CD45+
cells: single cells, live cells, CD45+. Frequency was calculated as % marker = (number of
cells that were marker positive) / (number of live cells) X 100. Graphical representation of
the data depicts the mean frequency overlaid with individual data points for each group.
Statistical comparisons were made via two-way ANOVA. The bars indicate standard
deviation. Statistical significance was defined as p < 0.05*, p < 0.01**, p < 0.001***, and
p < 0.0001****. Groups consisted of 5-10 mice per treatment group per time point.
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time (Figure 7.12). The nanoformulated CCL21 and CCL21 treatments resulted in a
significantly higher frequency of NK cells within the tumor at day 2 (p = 0.0168 and p =
0.0169, respectively). The nanoformulated CCL21-treated tumors, but not the CCL21
alone-treated tumors, also exhibited a significantly (p = 0.0138) higher percentage of NK
cells within the tumor at day 3 compared to those treated with buffer control, indicating a
difference in the effects of the 2 treatments at day 3. The percent of NKT cells at day 2
was significantly higher in both treatment groups (p = 0.0039 and p = 0.0029, respectively)
compared to the control.

Comparisons within treatment groups show significant

decreases in the percentages of NK and NKT cells within tumors treated with either
nanoformulated CCL21 or CCL21 alone over time, whereas buffer control-treated tumors
remained relatively low throughout the study (Figure 7.12).

7.6.2 Dendritic Cell and Macrophage Frequencies Were Increased Following Treatment
with Either CCL21 Modality
The percentage of DCs was significantly lower in the buffer control group on day
2 in comparison to the nanoformulated CCL21 group (p = 0.0081) and the CCL21 group
(p = 0.0259) (Figure 7.13). Thus, in the tumors of both nanoformulated CCL21-treated
and CCL21-treated mice, there was a significant increase in the frequency of DCs, as well
as in the DCs expressing higher levels of CD80 and CD86, indicating activation (Figure
7.13C). In our study, we found that macrophage frequencies within tumors were
significantly higher for nanoformulated CCL21 (p = 0.0007) and for CCL21-alone (p =
0.0038) treatment groups than for the buffer control group at day 2 post-treatment initiation
(Figure 7.14). Furthermore, comparing macrophage frequencies within each treatment
group over time shows nanoformulated CCL21 and CCL21-alone treatment resulted in
significant (p < 0.01) stepwise decreases over time (Figure 7.14A). Mer, as a marker of
increased macrophage phagocytic activity, was analyzed and the data for
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Figure 7.12. Intratumoral injection of nanoformulated CCL21 and CCL21 alone resulted
in increased frequencies of NK and NKT cells.
(A) NK cell frequency was significantly higher in tumors treated with nanoformulated
CCL21 (p = 0.0168) or CCL21 (p = 0.0169) in comparison to the control at day 2 post
treatment. Sustained augmentation of NKT cell frequencies within treated tumors was
observed in the nanoformulated CCL21 (p = 0.0039; day 2) and CCL21 (p = 0.0029; day
2) groups versus tumors treated with buffer control. (B) Intragroup comparisons, from day
2 to day 7, reveal a significant loss in the frequency of NK cells within the tumor in
nanoformulated CCL21-treated (p = 0.0384) and CCL21-treated (p = 0.0244) groups.
Tumors treated with buffer control remained relatively low throughout the duration of the
study. (C) The percentage of NKT cells per live cells was higher at day 2 post treatment
and demonstrated a decrease over time. There was a significant reduction in NKT
frequency from day 2 to day 7 in the nanoformulated CCL21-treated (p = 0.0270) and
CCL21-treated (p = 0. 0191) group. However, a majority of buffer control mice had a small
percentage of NKT cells within the tumor. NK and NKT cells were determined using the
following gating strategy: CD45+, CD3+/-, CD49b+, with NK cells being CD3- and NKT cells
being CD3+. Frequency was calculated as % marker = (number of cells that were marker
positive) / (number of live cells) X 100. Graphical representation of the data depicts the
mean frequency overlaid with individual data points for each group. Statistical
comparisons were made via two-way ANOVA. The bars indicate standard deviation.
Statistical significance was defined as p < 0.05* and p < 0.01**. Groups consisted of 510 mice per treatment group per time point.
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Figure 7.13. Recruitment of DCs into the tumor was increased in the nanoformulated
CCL21 and CCL21 treatment groups.
(A) Comparisons across treatment groups show a significant increase in the percentage
of DCs at day 2 post treatment in the nanoformulated CCL21-treated (p = 0.0081) and
CCL21-treated (p = 0.0259) tumors compared to the control. While not significant, this
increase was also observed at day 3 post treatment. (B) Observations within the treatment
groups (nanoformulated CCL21 or CCL21) demonstrate a slight decrease from day 2 to
day 3 and a larger decrease from day 2 or 3 to day 7. It is also of note that subgroups of
high versus low frequencies of DCs were seen in the nanoformulated CCL21 and CCL21
treated groups across time points. (C) Further analysis showed that activated DCs (CD80+
and CD86+) were increased in both treatment groups compared to the control. Gating
strategy for DCs: CD45+, CD3-, CD11c+, with an activation state identified as CD45+, CD3, CD11c+, CD80+, CD86+. Frequency was calculated as % marker = (number of cells that
were marker positive) / (number of live cells) x 100. Graphical representation of the data
depicts the mean frequency overlaid with individual data points for each group. The bars
indicate standard deviation. Groups consisted of 5-10 mice per treatment group per time
point. Statistical comparisons were made via two-way ANOVA, and p values of ≤ 0.05
were considered to indicate statistical significance.
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this marker are shown in Figure 7.14B and Figure 7.14C.

The frequency of Mer-

expressing macrophages was significantly elevated at day 2 post-treatment in the
nanoformulated CCL21-treated tumors (p = 0.0131) and in CCL21-treated tumors (p =
0.0047) versus the control group. Analysis of the median fluorescent intensity (MFI) of
Mer showed that a robust (p <0.03) increase in MFI occurred on day 3 post-treatment in
the groups treated with either CCL21 modality compared to the control. Differentiating the
F4/80+ macrophage population into either M1 (CD38+) or MDSC (Gr-1+) revealed that only
the nanoformulated CCL21 treatment, and not the free CCL21 treatment, was able to
induce a trend toward a rise in the frequency of M1 macrophages within the tumor at day
3 (Figure 7.14D).

MDSC-type macrophages trended higher at day 2 for both the

nanoformulated CCL21-treated tumors and CCL21-treated tumors, compared to buffer
control (Figure 7.14E).

7.6.3 The Frequency of CD4+ and CD8+ T Cells, but not Memory B Cells, Increased in
Both Nanoformulated CCL21-Treated and Free CCL21-Treated Tumors,
As shown in Figure 7.15A, at day 2 post-treatment initiation there was a
significantly higher percentage of CD4+ T cells in tumors treated with nanoformulated
CCL21 (p = 0.0105) or CCL21 alone (p = 0.0178) versus the buffer control.
Nanoformulated CCL21-treated tumors, but not free CCL21-treated tumors, at day 3 posttreatment initiation had marginally (p = 0.0608) more CD4+ T cells than the buffer control.
Additional analysis of CD4+ T cells subpopulations revealed no significant differences
among groups or among any group’s days post-treatment results for T regulatory cells
(Figure 7.15B), effector T cells (Figure 7.15C), effector memory T cells (Figure 7.15D),
central memory T cells (Figure 7.15E), or naïve T cell populations (Figure 7.15F).
Effector (Figure 7.15C) and effector memory (Figure 7.15D) CD4+ T cell populations were
either maintained or trended toward an increase over time for all groups.
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Figure 7.14. Nanoformulated CCL21 and CCL21 treatment groups induced changes in
the frequency, Mer surface expression levels, and subpopulations of macrophages over
time in a manner more varied than the buffer control group.
(A) F4/80+ macrophages were significantly higher (p = 0.0007, p = 0.0038) in
nanoformulated CCL21-treated and CCL21-treated tumors day 2 post treatment than the
tumors treated with buffer control. (B) Analysis of Mer surface expression revealed a peak
in the frequencies of Mer+ macrophages at day 2 post treatment in the nanoformulated
CCL21 and CCL21 treatment groups. These frequencies were significantly higher in the
nanoformulated CCL21-treated tumors (p = 0.0131) and CCL21-treated tumors (p =
0.0047). There was marginally (p = 0.0564) higher frequencies of Mer+ macrophages at
day 3 post treatment in the nanoformulated CCL21 group compared to the buffer control.
(C) Subsequently, a significant (nanoformulated CCL21 p = 0.0282, CCL21 p = 0.0240)
peak in the MFI of Mer was observed at day 3 post treatment in either CCL21 modality
versus the control. (D) Importantly, nanoformulated CCL21 treatment resulted in a rise in
the frequency of M1 macrophages at day 3 post treatment, which was not observed in
other groups. (E) Additionally, a stepwise decrease in the percentage of MDSCs appeared
to decrease over time in the nanoformulated CCL21-treatment group while the buffer
control treatment resulted in increasing percentages of MDSCs within the tumor. Gating
strategy for macrophages: CD45+, CD11c-, CD11b+, and F4/80+; Mer: CD45+, CD11c-,
CD11b+, F4/80+, Mer+; M1 macrophage: CD45+, CD11c-, CD11b+, F4/80+, CD38+, GR-1-;
MDSC macrophage: CD45+, CD11c-, CD11b+, F4/80+, CD38-, GR-1+. Frequency was
calculated as % marker = (number of cells that were marker positive) / (number of live
cells) x 100. Graphical representation of the data depicts the mean frequency overlaid with
individual data points for each group. Statistical comparisons were made via two-way
ANOVA. The bars indicate standard deviation. Statistical significance was defined as p <
0.05*, p < 0.01**, and p < 0.001***. Groups consisted of 5-10 mice per treatment group
per time point.
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Figure 7.15. CD4+ T cell populations and subpopulations are differentially modulated
following treatment with either nanoformulated CCL21 or CCL21 alone.
(A) At day 2 post treatment initiation, CD4+ T cell population frequencies were significantly
increased in tumors treated with either nanoformulated CCL21 (p = 0.0105) or CCL21
alone (p = 0.0178) compared to the buffer control. Marginally elevated frequencies of the
CD4+ T cell population in the CCL21 modalities versus the control, were also observed at
day 3 post treatment initiation. (B) CD4+ T regulatory cell frequencies appear to decrease
from day 2 to day 7 in the nanoformulated CCL21 or CCL21 alone treatment groups.
However, the buffer control treatment group appears to have increased frequencies of
CD4+ T regulatory cells over time. (C) Effector CD4+ T cell population frequencies
remained constant or were slightly elevated over time across treatment groups. (D)
Marginal increases (p = 0.0665, p = 0.0659) in effector memory CD4+ T cell population
frequencies was seen in the nanoformulated CCL21-treated or CCL21-treated groups
compared to the control-treated group at day 2 post treatment initiation. (E) Central
memory CD4+ T cell population frequencies were maintained or increased in either CCL21
modality treatment group over time. (F) The frequency of CD4+ naïve T cells were
increased in the CCL21-treated and nanoformulated CCL21-treated groups compared to
the buffer control. Gating strategy for CD4+ T cells: CD45+, CD3+, CD4+; CD4+ T regulatory
cells: CD45+, CD3+, CD4+, CD25+, CD127dim; Effector CD4+ T Cells: CD45+, CD3+, CD4+,
CD25+, CD44+; Effector Memory CD4+ T Cells: CD45+, CD3+, CD4+, CD25+, CD44+,
CD62L-, CD127-/+; Central Memory CD4+ T Cells: CD45+, CD3+, CD4+, CD25+, CD44+,
CD62L+, CD127+; CD4+ Naïve T Cells: CD45+,CD3+, CD4+, CD25+, CD44-, CD62L-,
CD127+. Frequency was calculated as % marker = (number of cells that were marker
positive) / (number of live cells) x 100. Graphical representation of the data depicts the
mean frequency overlaid with individual data points for each group. Statistical
comparisons were made via two-way ANOVA. The bars indicate standard deviation.
Statistical significance was defined as p < 0.05*. Groups consisted of 5-10 mice per
treatment group per time point.
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Central memory CD4+ T cell population frequencies were marginally elevated at days 2
and 7 in the nanoformulated CCL21-treated and CCL21-treated groups (p = 0.0665 and p
= 0.0659, respectively) compared to tumors treated with the buffer control (Figure 7.15E).
CD8+ T cell populations were significantly increased in tumors treated with nanoformulated
CCL21 (p = 0.007) or CCL21 (p = 0.041) when compared to the control at day 2 posttreatment (Figure 7.16A). Marginal increases in the percentage of CD8+ T cell populations
at day 3 post treatment initiation were also seen in nanoformulated CCL21-treated and
CCL21 alone-treated tumors versus the control (p = 0.0837 and p = 0.0739, respectively).
Effector and effector memory CD8+ T cell population frequencies were found to trend
higher or be maintained over time in all of the treatment groups (Figure 7.16B and Figure
7.16C). Trends toward higher frequencies in CD8+ central memory and naïve T cell
populations were observed with the nanoformulated CCL21 and CCL21 treatment groups
compared to the control (Figure 7.16D).
In addition to the assessment of T cell infiltration, the frequency of memory B cells
within the tumors was also examined. Relative to the buffer control, memory B cell
frequency was not significantly elevated in tumors treated with either nanoformulated
CCL21 or CCL21 alone following treatment (Figure 7.17). A trend toward higher memory
B cell infiltration was observed at day 3 post-treatment in all treatment groups (Figure
7.17).
7.6.4 Mice with Regressing Tumors Exhibited Specific Characteristics of Immune Cell
Infiltrates
As was the case in the abovementioned experiment focused on monitoring tumor
volume and survival, in our experiment to analyze intratumoral immune infiltration there
were some mice treated with nanoformulated CCL21 (but not CCL21 alone or buffer)
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Figure 7.16. Treatment with nanoformulated CCL21 or CC21 alone alters CD8+ T cell
populations and subpopulations frequencies within tumors.
(A) At day 2 post treatment initiation, CD8+ T cell population frequencies were significantly
increased in tumors treated with either nanoformulated CCL21 (p = 0.007) or CCL21 alone
(p = 0.041) compared to the buffer control. Frequencies of the CD8+ T cell populations
were marginally elevated in the nanoformulated CCL21-treated (p = 0.084) or CCL21treated (p = 0.074) versus the control at day 3 post treatment initiation (B) Effector CD8+
T cell population frequencies increased over time (disregarding the outlier in the buffer
control-treated group day 7). (C) Effector memory CD8+ T cell population frequencies
demonstrated an increase over time following treatment. (D) Central memory CD8+ T cell
population frequencies were marginally increased in the nanoformulated CCL21-treated
group (p = 0.0825) or the CCL21-treated group (p = 0.0606) at day 2 post treatment. (E)
The frequency of naïve CD8+ T cell populations were increased in the CCL21-treated and
nanoformulated CCL21-treated groups compared to the buffer control over time. Gating
strategy for CD8+ T cells: CD45+, CD3+, CD8+; Effector CD8+ T Cells: CD45+, CD3+, CD8+,
CD25+, CD44+; Effector Memory CD8+ T Cells: CD45+, CD3+, CD8+, CD25+, CD44+,
CD62L-, CD127-/+; Central Memory CD8+ T Cells: CD45+, CD3+, CD8+, CD25+, CD44+,
CD62L+, CD127+; Naïve CD8+ T Cells: CD45+, CD3+, CD8+, CD25+, CD44-, CD62L-,
CD127+. Frequency was calculated as % marker = (number of cells that were marker
positive) / (number of live cells) x 100. Graphical representation of the data depicts the
mean frequency overlaid with individual data points for each group. Statistical
comparisons were made via two- way ANOVA. The bars indicate standard deviation.
Statistical significance was defined as p < 0.05*. Groups consisted of 5-10 mice per
treatment group per time point.
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Figure 7.17. Elevated levels of memory B cells were observed in neuroblastoma tumors
treated with either nanoformulated CCL21 or CCL21 in comparison to the control.
Gating strategy for memory B cells: B220+, CD19+, PD-L2+, CD73+, CD80+, and CD38+.
Frequency was calculated as % marker = (number of cells that were marker positive) /
(number of live cells) x 100. Graphical representation of the data depicts the mean
frequency overlaid with individual data points for each group. Statistical comparisons were
made via two-way ANOVA. The bars indicate standard deviation. Statistical significance
was defined as p < 0.05*. Groups consisted of 5-10 mice per treatment group per time
point.
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whose tumors underwent regression. The frequencies of various types of immune cells
in the tumors that regressed, and in the tumor of an additional mouse that began to slightly
regress but quickly regrew to its original size are highlighted in circles with separate colors
(Figure 7.18A). (In the graph shown in Figure 7.18, if a colored circle is hidden behind
another circle, an arrow of the same color is used to indicate the position of that circle.)
The immune cell types included in the graph are NK cells (Figure 7.18B), NKT cells
(Figure 7.18C), DCs (Figure 7.18D), CD4+ T cells (Figure 7.18E), CD8+ T cells (Figure
7.18F), macrophages (Figure 7.19G), M1 macrophages (Figure 7.18H), and MDSC
macrophages (Figure 7.18I).
Two of the mice (Mouse 1 and Mouse 2) were already exhibiting regression by
day 3 post-treatment initiation (which was their experimental endpoint for euthanasia and
tumor harvest). Mouse 1 (indicated as a red dot) demonstrated a 23% decrease in tumor
volume following treatment initiation, and the tumor exhibited high frequencies of innate
immune cells, particularly DCs (CD45+ cells: 35.5 %, NK cells: 2.98%, NKT cells: 5.81%,
DCs: 29.5%, CD4+ T cells: 0.33%, CD8+ T cells: 0.38%, macrophages: 14.5%, M1
macrophages: 4.07%, MDSC macrophages 2.89%). Similarly, Mouse 2 (indicated in blue)
had an 18% decrease in tumor volume following treatment initiation, and at day 3 innate
immune cell populations (predominantly DCs) were plentiful within the tumor (CD45+ cells:
34.2%, NK cells: 3.03 %, NKT cells: 4.26%, DCs: 25.2%, CD4+ T cells: 0.28%, CD8+ T
cells: 0.30%, macrophages: 11.2%, M1 macrophages: 1.34%, MDSC macrophages
2.11%). In contrast, Mouse 3 (indicated in purple) had a slowly growing tumor that
fluctuated between growth and regression, and at day 7 post-treatment initiation (the
experimental endpoint for this mouse), the tumor volume was almost identical to the initial
tumor volume. Mouse 3’s tumor had relatively few innate immune cells, with low levels of
DCs and an increased MDSC/M1 ratio (CD45+ cells: 4.83%, NK cells: 0.20%, NKT cells:
0.031%, DCs: 0.73%, CD4+ T cells: 0.19%, CD8+ T cells:
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Figure 7.18. Comparisons of immune cell subset frequencies across treatment groups
over time are shown, with the mice that underwent complete regression during this
experiment highlighted in color.
Frequency was calculated as % marker = (number of cells that were marker positive) /
(number of live cells) X 100. Graphical representation of the data depicts the mean
frequency overlaid with individual data points for each group. Statistical comparisons were
made via two-way ANOVA. The bars indicate standard deviation. Statistical significance
was defined as p < 0.05*, p < 0.01**, and p < 0.001***. Groups consisted of 5-10 mice per
treatment group per time point.
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0.11%, macrophages: 2.60%, M1 macrophages: 0.49%, and MDSC macrophages:
1.29%). Mouse 4 (indicated in green) had a tumor that increased in volume from day 0 to
day 2 but then steadily declined (19.5% decrease) from day 2 to day 7 post treatment
initiation, at which time its tumor was found to have higher innate immune cell frequencies
than Mouse 3 and also slight elevations in T cell frequencies (CD45+ cells: 17.7 %, NK
cells: 1.080%, NKT cells: 0.120%, DCs: 6.69%, CD4+ T cells: 2.21%, CD8+ T cells: 1.11%,
macrophages: 5.26%, M1 macrophages: 0.97%, and MDSC macrophages: 1.81%).

7.7 Intratumoral Cytokine Profiles Varied by Treatment

A multiplex approach was used to investigate the cytokine profiles of treated
neuroblastoma tumors derived from the same mice that were used for the aforementioned
immune cell infiltration experiments at days 2 and 7 post-treatment initiation. Treatment
with either nanoformulated CCL21 or free CCL21 resulted in varied changes in the level
of cytokines present within the samples derived from mice at day 2 and day 7 posttreatment initiation (Figure 7.19). The multiplex analysis revealed treatment-dependent
changes in anti-tumor cytokines (CXCL9, CXCL10, IFN- g, IL-12p70, CCL3, and CCL2;
Figure 7.20) as well as in pro-tumor cytokines (IL6, TIMP-1 and IL-16) (Figure 7.21).
7.7.1 Nanoformulated CCL21 Treatment Increased and Prolonged Levels of Anti-tumor
Cytokines
Overall, nanoformulated CCL21 was best able to successfully induce expression
levels of anti-tumor cytokines that were both increased and of longer duration. For
example, as displayed in Figure 7.21, while a decrease in CXCL9 levels over time was
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Figure 7.19. Cytokine levels were assessed in tumor supernatants derived from the
neuroblastoma tumors of mice euthanized at day 2 or at day 7 post-treatment initiation
with nanoformulated CCL21, CCL21 alone, or buffer alone.
The Proteome Profiler Mouse Cytokine Array Kit, Panel A (R&D Systems) was used for
the analysis. Graphical representation of the data depicts the mean pixel density overlaid
with individual data points for each group. Statistical comparisons were made via two-way
ANOVA. The bars indicate standard deviation. Statistical significance was defined as p <
0.05*, p < 0.01**, p < 0.001***, and p < 0.0001****. Groups consisted of 5 mice per
treatment group per time point.
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Figure 7.20. In total, the intratumoral cytokine profile induced by nanoformulated CCL21
treatment, as compared to CCL21 treatment, favored increased anti-tumor cytokine
expression.
Cytokine profiles from neuroblastoma tumor biopsy culture supernatants were assessed
via Proteome Profiler Cytokine Array. Mean pixel densities are shown for (A) CXCL9, (B)
CXCL10, (C) IFN-g, (D) IL-12 p70, (E) CCL3, and (F) CCL2. Statistical comparisons were
made via two-way ANOVA. The bars indicate standard deviation. Statistical significance
was defined as p < 0.05*, p < 0.01**, p < 0.001***, and p < 0.0001****. Groups consisted
of 5 mice per treatment group per time point.
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Figure 7.21. The intratumoral cytokine profile induced by nanoformulated CCL21
treatment, as compared to CCL21 treatment decreased the expression of pro-tumor
cytokines IL-6 and IL-16 but elevated the expression of TIMP-1.
Cytokine profiles from neuroblastoma tumor biopsy culture supernatants were assessed
via Proteome Profiler Cytokine Array. Mean pixel densities are shown for (A) IL-6, (B) IL16, (C) TIMP-1. Statistical comparisons were made via two-way ANOVA. The bars
indicate standard deviation. Statistical significance was defined as p < 0.05*, p < 0.01**,
p < 0.001***, and p < 0.0001****. Groups consisted of 5 mice per treatment group per
time point.
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observed across all 3 treatment groups, the nanoformulated CCL21 treatment caused a
much more enhanced and persistent presence of CXCL9 within the tumor at both days 2
and 7 post-treatment initiation in comparison with the other treatments (p < 0.0001).
Furthermore, at day 7, nanoformulated CCL21 treated resulted in significantly higher
CXCL10 expression compared to CCL21 (p = 0.0013) (Figure 7.21). At day 2, the level
of IFN-g in tumors of nanoformulated CCL21-treated mice was approximately 2-fold higher
than in tumors of CCL21-treated mice (p < 0.0001), although the IFN-g levels were similar
at day 7. Similarly, IL70 was ~2-fold higher in tumors of nanoformulated CCL21-treated
mice at day 2, compared to the level in tumors of CCL21-treated mice (p < 0.001), but was
not significantly higher than in tumors of CCL21-treated mice at day 7.

CCL3 was

significantly higher (p <0.0001) in samples from CCL21-treated tumors at day 2 posttreatment than in tumors treated with nanoformulated CCL21 (Figure 7.21). A steep
decline in CCL3 was observed in CCL21-treated tumors at day 7 whereas the
nanoformulated CCL21 treatment group showed a marginal increase. Nanoformulated
CCL21, but not CCL21, was capable of inducing significantly elevated (p < 0.0001) levels
of CCL2 that persisted over time (Figure 7.21).
7.7.2 Nanoformulated CCL21-Treated Tumors Exhibited Decreased Levels of Pro-Tumor
Cytokines
In addition to the enhanced antitumor effects exhibited by nanoformulated CCL21,
we also found that the level of pro-tumor cytokine IL-6 remained constant over time and
at a level significantly lower in the nanoformulated CCL21-treated tumors (p < 0.0001)
than in tumors treated with CCL21 (Figure 7.21). Nanoformulated CCL21 treatment was
also able to decrease the levels of the pro-tumor cytokine IL-16 significantly over time in
comparison to CCL21 alone (Figure 7.21).

In contrast to the positive effect of

nanoformulated CCL21 on reducing IL-6 and IL-16 in the tumors, the tumors treated with
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nanoformulated CCL21 had significantly greater levels of another pro-tumor cytokine,
TIMP-1, than those treated with CCL21 (Figure 7.21). Both nanoformulated CCL21
treatment and free CCL21 treatment resulted in proportional declines in the level of TIMP1 over time (Figure 7.21).
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8.1 Discussion and Summary of Research
The immunotherapeutic potential of CCL21, as a cancer treatment, has been
previously analyzed using various cancer models and methods of delivery, and
investigation of CCL21 therapy for tumors has advanced to clinical trials (Turnquist HR et
al., 2007; Ashour AE et al., 2007; Sharma S et al., 2001; Kirk CJ et al., 2001; Dubinett SM
et al., 2010; Liang CM, et al., 2007; Yousefieh N et al., 2009; Kar UK et al., 2011; Hu D et
al., 2012; Lin Y et al., 2014; Pellionisz PA et al., 2018; Semeraro M et al., 2015; Wang W
et al., 2015). CCL21, when administered intratumorally, has been found to result in tumor
growth inhibition, infiltration of DCs, CD4+ T cells, and CD8+ T cells, and demonstration of
systemic antitumor immunity in models of lung, breast, and pancreatic cancers,
melanoma, head and neck cancer, and other cancers, as reported in our studies and those
by other laboratories (Turnquist HR et al., 2007; Ashour AE et al., 2007; Sharma S et al.,
2001; Kirk CJ et al., 2001; Dubinett SM et al., 2010; Hu D et al., 2012; Lin Y et al., 2014;
Pellionisz PA et al., 2018) . Several modes of delivering CCL21 have been tested with
the objective of further increasing CCL21’s therapeutic impact (Dubinett et al., 2010; Kar
UK et al., 2011; Hu D et al., 2012; Lin Y et al., 2014; Pellionisz PA et al., 2018; Semeraro
M et al., 2015; Wang W et al., 2015; Rujkijyanont P et al., 2013; Oh KT et al., 2006). While
these modes of CCL21 delivery have shown potential, they have varied degrees of
limitations concerning the logistics of production and administration, loading capacity,
duration of therapeutic effect, injectability, and/or cost, thus presenting a need for
enchanced systems of delivery for CCL21 that are easily produced, biocompatible, and
injectable.
Applications of nanoparticles as drug delivery platforms have dramatically widened
over recent years, and nanoparticles have been adopted for numerous medical purposes
to provide well-controlled release of therapeutic agents. Many techniques have been
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developed for nanoparticle fabrication, and among the polymers tested, alginate is one
that has been used as a carrier for a variety of biological agents, such as genes, antigens,
and various proteins, allowing protection of these therapeutic agents during transit.
Alginates have emerged as one of the most extensively explored biomaterials owing to
their excellent biocompatibility, biodegradation, sol-gel transition properties, and chemical
versatility. Such characteristics make possible many modifications of alginate to shape
the properties of nanoparticles according to specific applications. As described in this
current report, we generated novel alginate nanoparticles to deliver CCL21 as an
injectable and biocompatible therapeutic nanoformulation for neuroblastoma treatment.
Our choice of alginate was based on its excellent safety record, ease of modification for
protein cargo delivery, and anionic polysaccharide chains that facilitate its interaction with
CCL21 (which has a net cationic charge). For materials such as proteins, avoiding harsh
conditions upon handling is crucial, and a natural polysaccharide like alginate is an
excellent candidate for encapsulation of CCL21. The nanoparticles were prepared by
ionotopic gelation, avoiding high temperatures and organic solvents that could potentially
compromise the biological activity of the protein. At the same time, this nanoformulation
allowed very high loading and the desired release profile.
The gelation rate and the temperature at which gelation occurs are critical in
establishing the mechanical integrity of the nanoparticles (Bronich TK et al., 2006).
However, temperature, pH, and time are also important for stimulating the protoncatalyzed hydrolysis of alginates within the particle, which leads to the release of the cargo
(Chander and Gangenahalli, 2020). Therefore, optimization of nanoparticle stability by
varying the alginate : CaCl2 ratio (Figure 7.1A) and the alginate : protamine sulfate ratio
(Figure 7.1B) was essential for producing small, uniform nanoparticles. The developed
set of alginate gelation parameters allowed achievement of a loading capacity for CCL21
of about 17%, which is substantially higher compared to reported protein loading in
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conventional PLGA micro- and nanoparticles and liposomes. Indeed, Giteau et al. used
protein precipitation to ensure stability upon encapsulation into PLGA microspheres and
were able to achieve about 0.5% loading with repect to lysozyme (Giteau A et al., 2008).
Modification of this methodology resulted in the production of lysozyme or cytochrome cloaded PLGA nanoparticles with loading capacity close to 5% (Moralez-Cruz M et al.,
2012). The modest protein loading capacity of an order of ~2-3% was also reported for
small size liposomes (50-150 nm) and was attributed to a low entrapment volume of
lipsosomes (Xu X et al., 2012). In the case of the alginate nanoparticles, it is likely that
the electrostatic interactions of CCL21 (a weakly cationic protein) with the negatively
charged alginate chains and porous structure of the formed gels are beneficial for higher
protein loading. An entrapment of relatively high content of protein (at a 6:1 ratio of
alginate to protein) did not appear to interfere with network formation. However, the further
attempts to increae the loading by decreasing the alginate to protein ratio resulted in
precipitation. The in vitro release rate was also shown to be governed by the ratio of
alginate to protein with unexpectedly slower release observed at relatively high protein
loading. It is likely that the high protein loading (6:1 ratio) may result in additional physical
crosslinking of alginate chains within the gel network compared to nanoparticles with low
protein loading (60:1 ratio), which correspondlingly might slow down diffusional mobility
and following release kinetics of protein. It is also possible that heterogeneities in protein
distribution throughout the gel network at higher loading can influence cargo release from
the gel matrix. Full elucidation of these complex mehanisms will require more detailed
investigation in future studies. The presense of Pluronic F127 contributes to the stability
of the alginate nanoparticle matrix, making it more compact and less leaky, therefore
leading to a further decrease in protein release rate. Thus, based on our pilot experiments
with cytochrome c, the remainder of our work utilized alginate nanoparticles formulated
with CCL21 at a 6:1 ratio of alginate to protein and incorporated Pluronic F127.
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Nanoformulated CCL21 treatment of the mouse neuroblastoma tumor resulted in
slower tumor growth and longer survival than treatment with CCL21 (Figure 7.6 and
Figure 7.8). A third of the mice treated with nanoformulated CCL21 underwent complete
tumor regression (Figure 7.6 and Figure 7.8).

Although only a minority of the

nanoformulated CCL21-treated mice experienced complete regression of their tumors,
this finding parallels the observations in cancer immunotherapy clinical trials that
commonly only a small portion of patients exhibit positive responses (Sambi M et al.,
2019).

To gain insight into the in vivo mechanisms for nanoformulated CCL21’s

therapeutic activity, we performed tracking studies and analysis of intratumoral immune
cell populations and cytokines.

From our tracking of fluorescently labeled CCL21

delivered in nanoparticles, we detected a higher level of fluorescence in the tumors at day
1 and day 2 following treatment, relative to fluorescently labeled free CCL21 administered
to the tumors (Figure 7.10).

In our investigation of immune cell populations in

nanoformulated CCL21- versus CCL21-treated tumors, the average frequency of NK cells
at day 3 was significantly higher in the tumors of mice that had been injected with
nanoformulated CCL21, suggesting a role for NK cells in the therapeutic effects. This
theory is further supported by the relatively high frequency of NK cells in the tumors of
mice whose tumors were undergoing regression by day 3 (Figure 7.18B). Observation of
the frequencies of immune cell subsets in mice whose tumors were regressing by day 3
also revealed increased levels of NKTs (Figure 7.18C), DCs (Figure 7.18D), and
macrophages (including MDSC macrophages) (Figure 7.18G, Figure 7.18H, and Figure
7.18I).
In our study, assessment of cytokine levels was also very informative, showing
heightened levels of CXCL9, CXCL10, IFN-g, IL-12 p70, CCL3, and CCL2 in the tumors
of nanoformulated CCL21-treated mice (as compared to CCL21-treated mice) at day 2 or
day 7 (or both) post-treatment (Figure 7.19 and Figure 7.20). These cytokines have all
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had anti-tumor effects ascribed to them. The anti-tumor effects of CXCL9, CXCL10, and
IFN-g have been reported for many cancer types, including serous ovarian and colorectal
cancers (Wang Y et al., 2018; Shriky B et al., 2020). CCL3-stimulated, IFN-g-mediated
recruitment of NK and CD103+ DCs was demonstrated to enhance tumor rejection and
CD8+ T cell infiltration in a colon cancer model (Wu B et al., 2018). Previous studies have
shown that the efficacy of CCL21 therapy in lung and breast cancers is linked to CXCL9,
CXCL10, and/or IFN-g. This trio of cytokines enhances immune reactivity against tumors,
in coordination with additional cytokines (Phan-Lai V et al., 2014; Sharma S et al., 2003;
Bronger H et al., 2016; Chen J et al., 2019). Our finding of elevated levels of IL-12 p70 in
nanoformulated CCL21-treated tumors corresponds with the previously reported antitumor effects of IL-12 in neuroblastoma (Lode HN et al., 1998; Croce M et al., 2005). In
addition, CCL3, in conjunction with IFN-g, is capable of augmenting anti-tumor immune
priming in the lymph node in a manner that is NK cell-dependent (Allen F et al., 2018). In
addition to up-regulating the presence of anti-tumor cytokines, nanoformulated CCL21
also down-regulated the expression of pro-tumor IL-6 and IL-16 in the tumor (Figure 7.19
and Figure 7.21). IL-6 is specifically recognized for promoting neuroblastoma growth
(Egler RA et al., 2008; Lagmay JP et al., 2009). However, unexpectedly, nanoformulated
CCL21 also increased the presence of TIMP-1, which has been reported to have protumor effects in the neuroblastoma setting (Paul P et al., 2017).
In patients, intratumoral injection of neuroblastomas with nanoformulated CCL21
would be feasible, since internal anatomical sites at which neuroblastoma tumors can be
present are identifiable and accessible in patients by the use of available imaging
techniques.

Most children at relapse have

131

I – or

123

I-meta-iodobenzylguanidine

scintiscan results that would identify a number of lesions that would be amenable to
nanoformulated CCL21 injection. Since the activity of nanoformulated CCL21 spurs a
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systemic immune response, rather than only a local one, it would only need to be
administered to a single metastasis, not to multiple sites. With other types of systemically
effective immunotherapy, reduction even in bone metastases has been demonstrated
(Rosner S et al., 2017; Reinstein ZZ et al., 2017), which supports the feasibility of
nanoformulated

CCL1’s

systemic

immune

influence

being

effective

against

neuroblastoma bone metastases as well as against soft tissue metastases.
In conclusion, we have designed an injectable, slow-release alginate-based
nanoformulation of CCL21 that has shown promise as an immunotherapeutic modality for
neuroblastoma treatment in our studies.

A great benefit of nanoformulated CCL21

intratumoral therapy is that it provides personalized immunotherapy by using the tumor
itself as the “vaccine,” while only requiring a single, non-personalized type of treatment
(i.e., the nanoformulated CCL21). In addition to nanoformulated CCL21’s usefulness in
neuroblastoma treatment, potentially other cancers for which CCL21 has previously been
shown to be effective may benefit even more from treatment with this alginate
nanoformulation of CCL21 than from treatment with CCL21 alone. In addition, alginate
nanoparticle versatility provides additional avenues, including the use of multiple cargoes,
which are options that we plan to pursue in the future. Taken together, our findings support
further development and characterization of nanoformulated CCL21 as an intratumoral
immunotherapy for cancer.
8.2 Future Directions
The aim of this section is to propose experiments for further investigation into the
efficacy and therapeutic mechanisms of nanoformulated CCL21 as an intratumoral
treatment for solid tumors. The findings from our studies have demonstrated the potential
of CCL21 as an intratumoral treatment agent. However, questions remain that pertain to
the immunological modifications, both within the tumor and systemically, that result from
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nanoformulated CCL21 treatment. The effects of nanoformulated CCL21 on metastatic
progression and other tumor types have yet to be determined.

8.2.1 Further Investigation into Nanoformulated CCL21-Mediated Immune Responses in
Neuroblastoma.
Studies from our laboratory and others have demonstrated significant influx of
DCs, effector T cells, NK cells, and NKT cells following intratumoral administration of
CCL21 (Turnquist HR et al., 2007; Ashour AE et al., 2007; Sharma S et al., 2001; Kirk CJ
et al., 2001; Dubinett SM et al., 2010; Hu D et al., 2012; Lin Y et al., 2014; Pellionisz PA
et al., 2018).

We confirmed that the nanoformulation process failed to alter the

chemotactic abilities of CCL21. Nanoformulated CCL21, as well as CCL21 alone, was
able to recruit anti-tumor immune cells into the neuroblastoma lesion as demonstrated by
flow cytometry analysis. However, significant differences were not observed between
nanoformulated CCL21 and CCL21 alone. The ability to induce tumor clearance was only
observed in nanoformulated CCL21-treated mice. Therefore, the mechanism behind
tumor clearance, as mediated by nanoformulated CCL21, remains unclear.
Immune cell visualization by multi-color fluorescent microscopy may reveal
differences in immune cell colocalization, changes in immunosuppressive cell subtypes,
or formations of tertiary lymphoid structures that distinguish nanoformulated CCL21 from
CCL21 alone. Nanoformulated CCL21 may be better equipped to induce larger quantities
or higher ordered tertiary lymphoid structures, which could result in more efficacious
processing and presentation of tumor-derived antigens, improve APC and T cell
interactions, and facilitate a more robust anti-tumor immune response. Nanoformulated
CCL21 may also modulate the immunosuppressive environment in a manner superior to
CCL21 alone, resulting in a more robust anti-tumor immune response. Additionally,
immunohistochemistry analysis could assist in the identification of immune cell foci and

241
locations of tertiary lymphoid structure formations. In this project, tumors treated with
nanoformulated CCL21 or with CCL21 alone have been collected at predetermined time
points (days 2, 3, and 7 post treatment initiation), formalin-fixed, and paraffin embedded.
Following sectioning, the tumor samples could be analyzed with markers for immune cell
subsets (DCs, memory T cells, effector T cells, etc.) as well as for markers corresponding
to proliferation and various cell death pathways.
We observed an increase in anti-tumor cytokines and chemokines collected from
tumor biopsy culture supernatants derived from nanoformulated CCL21-treated mice.
Differences in pro-tumor cytokines were noted as well. It would also be useful to assess
changes in cytokine and chemokine levels in the serum of mice treated with either CCL21
modality. Comparisons could be made in the cytokine levels between the serum and
tumor samples of the same treatment group over time as well as between treatment
groups. Further cytokine analysis utilizing qRT-PCR for cytokines and chemokines of
interest can be performed to confirm the multiplex results described above in addition to
identifying novel changes that are treatment dependent. These findings could identify
novel mechanisms of immune modulation induced by nanoformulated CCL21 that resulted
in delayed tumor growth, prolonged survival, and even tumor clearance in a mouse model
of neuroblastoma.
Investigation into the differences of nanoformulated CCL21 and CCL21 treatment
at the gene level could be performed by Nanostring technology, which can potentially
determine

predictive

signatures,

therapeutic

responders,

and

disease

biology

characteristics. Nanostring is compatible with a variety of sample types, including total
RNA, formalin-fixed paraffin-embedded tissues, and serum samples.

Use of the

Nanostring technology would allow for additional analysis to be performed on already
collected and stored samples or could be used on samples collected during future
experiments.

Oncology and immunology panels are available, providing detailed

242
information on gene expression patterns from the tumor to the microenvironment to the
immune system. The wealth of information that could be gained from this experiment is a
great benefit that may overcome the cost considerations.
As shown by our previous work, CCL21 is able to induce systemic anti-tumor
immune responses that are transferrable via splenocytes to naïve mice (Turnquist H et
al., 2007). We have also shown that nanoformulated CCL21 treatment is able to stimulate
tumor clearance and prevent recurrence in a neuroblastoma mouse model (Figure 7.9).
Additional studies are required to assess the role of nanoformulated CCL21 on systemic
anti-tumor immunity.

Adoptive transfer of splenocytes from nanoformulated CCL21-

treated mice to naïve mice may provide secondary confirmation that a successful, antitumor immune response was generated and could be transferred between individuals.
Assessment of cytotoxic T lymphocyte responses mediated by nanoformulated CCL21 or
CCL21 alone may elucidate differences in efficacy between the CCL21 treatment
modalities.

8.2.2 Determining the Therapeutic Efficacy of Nanoformulated CCL21 Utilizing Other
Mouse Models of Neuroblastoma.
Pilot studies have been performed which utilized ultrasound-guided implantation
of a neuroblastoma cell line into the adrenal gland/para-adrenal region of a syngeneic
mouse. Successful implantation and tumor development was observed. This model
would allow for investigation of stromal and tumor microenvironment involvement in tumor
development and response to treatment.

As the tumor cells were injected under

ultrasound guidance, delivery of nanoformulated CCL21 or other treatment modalities
could be performed in the same manner. Real time assessments could be made by
following tumor growth and progression longitudinally in mice over the course of the
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experiment, complementing or replacing studies involving numerous mice euthanized at
various time points.
CCL21 treatment was found to inhibit distant tumor growth in pancreatic tumor
models (Turnquist H et al., 2007). However, the effect of nanoformulated CCL21 on
metastases remains unclear. Metastatic spread was not observed in the subcutaneous
neuroblastoma model used in these studies. To determine the effect on metastases, mice
could be given tumor cell injections subcutaneously into either flank. Once palpable
tumors develop, one tumor would receive treatment. Tumor growth (on both sides) would
be monitored until an experimental endpoint is reached (study conclusion or a tumor
volume of 1000 mm3).
resected

and

Upon reaching the experimental endpoint, tumors would be

processed

for

downstream

analysis

such

as

flow

cytometry,

immunohistochemistry, or fluorescent microscopy. Another well studied option would be
to employ the Thy-MYC mouse model which spontaneously develops neuroblastoma
(Weiss WA et al., 1997). In this model, mice over express MYCN via a tyrosine hydroylase
promoter which drives development of neuroblastoma lesions and results in similar MYCN
protein levels and histopathology as human tumor samples (Chesler L et al., 2007, Weiss
WA et al., 1997, Burkhart CA et al., 2009; Waldeck K et al., 2016). Palpation or ultrasound
imaging could be used to administer nanoformulated CCL21 and other treatments (e.g.,
CCL21, nanoparticles only, or buffer) and to monitor tumor development and progression.
While the dosing schedule utilized throughout my dissertation work (Figure 6.2) was
successful in regard to inducing an immune response, inhibiting tumor growth, and
prolonging the survival of tumor-bearing mice, it is of interest to determine how alternative
dosing strategies would affect neuroblastoma growth and development. Combination
therapies are instrumental across all cancer types. Therefore, it would also be of value to
combine nanoformulated CCL21 with the standard of care therapies for neuroblastoma
(chemoradiation, surgical resection, etc).

Further collaboration with the Mohs laboratory
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could utilize guided surgical resection of neuroblastoma tumors to determine the efficacy
of nanoformulated CCL21 as a surgical neoadjuvant. The proposed studies could be
carried out in any of the mouse models mentioned.

8.2.2 Maximizing Nanoformulated CCL21 to its Fullest Potential.
CCL21, as an intratumoral therapy, has efficaciously inhibited tumor growth and
progression while augmenting the host’s anti-tumor immune responses in a variety of
cancer models. It would be of great value to determine the efficacy of nanoformulated
CCL21 in other solid tumors such as Ewing’s sarcoma or pancreatic cancer. Studies have
indicated that patients with higher expression of tumoral CCL21 have better prognoses,
greater responses to therapy, and fewer metastases (Sang LGL et al., 2016). In patients
with poor intratumoral expression of CCL21, administration of nanoformulated CCL21
could potentially induce a robust influx of APCs and immune effector cells into the tumor,
generating an anti-tumor immune response. Similar studies could also be performed in
pancreatic cancer models or other solid tumors that exhibit a predominantly cold and
suppressive immunophenoype.
Alginate nanoparticles are nontoxic, bio-available drug delivery molecules that can
be modified to carry therapeutic payloads. Slow release of the therapeutic agent inside,
whether it be CCL21 or a different treatment modality, could provide therapeutic
responses while mitigating toxicity through lack of systemic administration.

Studies

combining the nanoformulation of CCL21 and chemotherapeutic agents or small molecule
inhibitors (either alone or combined into one nanoparticle) could provide a broad array of
experimental avenues to undertake, yielding novel therapeutic targets and approaches.
Overall, our findings contribute to the growing body of literature demonstrating the
potential of CCL21 and the use of nanoparticles in cancer immunotherapy.
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